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Abstract 
 
 
 Chondroitin sulfate glycosaminoglycans are ubiquitously expressed linear, 
sulfated polysaccharides involved in cell growth, neuronal development and spinal cord 
injury. The different sulfation motifs presented by chondroitin sulfate may regulate its 
activity, but efforts to understand the precise biological roles of this glycosaminoglycan 
have been hampered by its complexity and heterogeneity. Here, we report the synthesis 
of well-defined chondroitin sulfate oligosaccharides through a convergent approach that 
permits installation of sulfate groups at precise positions along the carbohydrate 
backbone, biological evaluation of the synthetic molecules, and generation of antibodies 
that recognize the distinct sulfation motifs. 
Using the chondroitin sulfate oligosaccharide library, we demonstrate that specific 
sulfation patterns act as molecular recognition elements for growth factors, and modulate 
neuronal growth. We identified a chondroitin sulfate tetrasaccharide, CS-E, which 
stimulates the growth and differentiation of multiple neuron types. Through use of 
carbohydrate microarrays, we found that the CS-E tetrasaccharide binds to a variety of 
proteins involved in promoting neurite outgrowth. A CS-E disaccharide, an unsulfated 
tetrasaccharide, and three other sulfated tetrasaccharides, CS-A, CS-C, and CS-R, were 
also investigated, and showed little effect on neurite outgrowth and reduced growth factor 
binding compared to the CS-E tetrasaccharide. These studies represent the first, direct 
investigations into the structure-activity relationships of chondroitin sulfate using 
homogeneous synthetic molecules, define a tetrasaccharide as a minimal motif required 
for function, and reveal the importance of sulfation in chondroitin sulfate bioactivity.   
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Chapter 1: Chondroitin Sulfate Glycosaminoglycans 
 
The glycosaminoglycan family 
Glycosaminoglycans (GAGs) are linear, sulfated oligosaccharides that are 
involved in numerous biological functions, ranging from tissue structure and cell growth 
to protein activity regulation. Assembled from repeating disaccharide subunits, GAGs 
exhibit subtle variations in stereochemistry, length, and patterns of sulfation (Figure 1.1). 
Depending on the type of amino sugar found in the polymer, GAGs can be classified into 
two broad categories: the glucosaminoglycans, based on D-glucosamine (hyaluronan, 
keratan sulfate, heparin, and heparan sulfate), and the galactosaminoglycans, based on D-
galactosamine (chondroitin sulfate and dermatan sulfate). Chondroitin sulfate (CS) 
contains only glucuronic acid moieties, whereas, heparan sulfate (HS), heparin, and 
dermatan sulfate (DS) contain both iduronic (IdoA) and glucuronic acid (GlcA) units, 
adding another level of stereochemical complexity. Various sulfation motifs are created 
through modification of the carbohydrate backbone.1,2 For example, heparin and HS can 
be sulfated at the C-2 hydroxyl of IdoA and the C-3 and C-6 hydroxyls of glucosamine 
(GlcN). The C-2 amine can be sulfated acetylated or remain unmodified. Due to this 
complexity, an HS tetrasaccharide can present over 2000 sulfation motifs. CS also is 
diversely sulfated and can be modified at any of the free hydroxyls. Potentially, a simple 
CS tetrasaccharide can present 256 sulfation patterns. 
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Figure 1.1: The structures of GAG classes. 
 
In animals, GAGs can exist independently or are attached to core proteins, called 
proteoglycans, via a common GAG-protein linkage region tetrasaccharide on specific 
serine residues.3,4 Proteoglycans are major constituents of the extracellular matrix and 
cell membranes, and are important in a variety of functions, including cancer metastasis, 
embryonic development, viral entry and attachment, angiogenesis, and axonal guidance. 
They modulate cell-cell and cell-matrix interactions, contribute to the maintenance of 
normal tissue architecture and function, and participate in cell adhesion and growth 
control.3-7 Potentially, GAGs and their associated core proteins recruit protein ligands to 
the cell surface and act as templates to bring ligands and their corresponding receptors 
into the optimal alignment for productive binding (Figure 1.2).8,9 The number of GAGs 
attached to a proteoglycan can differ, as can the length, sugar composition, and sulfation 
pattern of the attached GAGs.5,6  These aspects are regulated depending on the location of 
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the proteoglycan, and the developmental and pathological state of the tissues where the 
proteoglycan exists. The sulfation patterns of GAGs are highly controlled and 
presumably dictate the ligands a proteoglycan can bind,10 but the difficulty in isolating 
GAG chains of  defined sulfation sequence for protein-binding analyses has hampered an 
understanding of the roles of specific sulfation sequences and the reasons exquisite 
pattern regulation is important. 
 
Figure 1.2: GAGs at the cell surface. 
 
In developing nervous tissue, proteoglycans have been implicated in various 
cellular processes such as cell proliferation, regulation of cell morphology, cell migration, 
cell differentiation, neurite formation, synapse stabilization and signal transduction. In 
central nervous tissues, the majority of the proteoglycans carry either CS or HS side 
chains. Some of them are constituents of the extracellular matrix, others are bound to the 
cell surface through a glycosylphosphatidylinositol (GPI) anchor and some are 
transmembrane proteins.4,6,8 Proteoglycans in the brain display affinity to a variety of 
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ligands, including growth factors, cell adhesion molecules, matrix components, enzymes, 
and enzyme inhibitors. During histogenesis of the central nervous system, proteoglycans 
and their putative binding partners frequently colocalize, so it is likely that proteoglycans 
mediate crucial events in brain development.3,4,8,9 
 
Heparan sulfate and heparin glycosaminoglycans 
 Understanding the importance and function of GAGs in vivo has been the focus of 
numerous investigations, and the majority of these studies concentrated on heparin and 
HS. Consisting of GlcN and either IdoA or GlcA, heparin and HS are joined by repeating 
α(1,4) and β(1,4) linkages. Heparin is usually localized to specialized granule cells but 
HS is present on multiple cell types and is more prevalent in vivo. HS displays a variety 
of sulfation patterns and has greater structural diversity than heparin.1,11 
Studies using NMR, X-ray crystallography and molecular modeling have shown 
that HS and heparin are helical molecules but the pitch of the helix can vary upon protein 
binding or with different counterions (Figure 1.3).11,12 The conformational flexibility of 
the IdoA subunit provides an additional level of 3-dimensional complexity, and is 
proposed to enhance heparin/HS-protein interactions.11,13  
 The biosynthesis of heparin and HS begins in the Golgi apparatus, and starts with 
generation of the tetrasaccharide linkage region, GlcA β(1,3)-galactose β(1,3)-galactose 
β(1,4)-xylose β- 1-O-Ser, common to heparan sulfate, heparin and CS GAGs (Figure 1.4). 
Xylose, from uridine diphosphate-xylose, is linked to select proteoglycan core protein 
serines followed by the addition of two galactose units and a GlcA moiety through three 
distinct transferases.14,15 This region can be sulfated or phosphorylated.16 The addition of 
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N-acetylglucosamine (GlcNAc) to the linker determines the chain will be HS or heparin 
and is followed by alternating addition of GlcA and GlcNAc by EXT1 and EXT2, the HS 
and heparin polymerases.15 
Figure 1.3: NMR structure of a heparin dodecasaccharide. The top structure shows the view parallel to the 
helical axis and the bottom structure the view perpendicular to the helical axis.12 
 
Sulfation of HS or heparin GAGs also takes place in the Golgi apparatus and 
sulfotransferases add sulfate groups from 3’ phosphoadenosine-5’ phosphosulfate (PAPS) 
to the growing oligosaccharides. How the resulting sulfation pattern is determined and 
the organization of the sulfotransferases in the Golgi apparatus are unknown, but the 
enzymes are believed to form complexes with other enzymes in the pathway. Fifteen 
HS/heparin sulfotransferases have been identified in mice and humans. The first 
sulfotransferase to modify the HS/heparin chain is NDST (N-
deacetylase/sulfotransferase), a bifunctional enzyme that deacetylates and subsequently 
sulfates the GlcNAc C-2 amines.2,17,18 
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 After N-sulfation, some of the GlcA moieties are converted to IdoA by a C-5 
epimerase. This is followed by sulfation of the C-2 positions of IdoA and GlcA,19,20 C-6 
sulfation of GlcN21,22 and C-3 sulfation of GlcN, the rarest form of HS/heparin 
sulfation.23,24,25 
Figure 1.4: The biosynthesis of heparin, heparan sulfate and chondroitin sulfate. SQV enzymes are from 
Caenorhabditis elegans. 
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HS and heparin have been linked to Alzheimer’s disease,26 cancer metastasis,27 
entry of herpes simplex virus type I24 and malaria,28 embryonic development,29,30 nerve 
cell communication, and axonal guidance.30-33 Genetic investigations have shown that 
deletion of the HS and heparin polymerase EXT1 leads to severe defects in mammalian 
brain morphogenesis, irregular midline axon guidance, and embryonic death in mice, 
demonstrating the importance of HS and heparin in central nervous system formation.31  
The fine structures of HS and heparin have been implicated in dictating their 
protein binding partners and functions in vivo.11,14 Knockout studies of the HS-modifying 
enzymes C-5 epimerase, 2-O-sulfotransferase and 6-O-sulfotransferase in Caenorhabditis 
elegans suggest that some neuron types have a dependence on certain HS motifs and that 
specific sulfation patterns are necessary for normal growth.34 The chemorepellent protein 
Slit is involved in axonal guidance, and is dependent on HS to bind to its receptor, Robo, 
at the tip of axons to repel axonal growth.33 The specific sulfation sequence needed for 
the HS to interact with Slit is unknown, but O-sulfation is required.35  
Two important developmental pathways are regulated by differentially sulfated 
HS GAGs, Wnt and Hedgehog (Hh) signaling. Disruptions in a Drosophila NDST 
displayed a complete loss of activity in the Wingless (Wg), a Wnt family member, and 
Hh pathways.36 Mutation of the gene tout velu, a gene encoding an HS polymerase, had 
defective Hh signaling.37,38 Recently, an extracellular sulfatase, QSulf1, has been found 
to remove the 6-O sulfates from HS to form a low affinity HS-Wnt complex and promote 
the interaction of Wnt with its receptor, Frizzled.39,40 Interestingly, this suggests that 
sulfation of HS and heparin is dynamic and remodeling of sulfate groups can occur at the 
cell surface, not only in the Golgi. The generation of a low affinity HS-Wnt complex 
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upon sulfate group cleavage and the effects on Wnt signaling in Drosophila after the loss 
of NDST suggest a sulfation pattern dependence for HS-Wnt binding.  
The mechanisms through which HS and heparin modulate the events described 
earlier are not well understood but it has been suggested that HS and heparin form 
complexes with growth factors and their receptors in a sulfation-dependent manner. The 
best-studied examples of the importance of sulfation on HS bioactivity and in ligand-
receptor complex formation are the fibroblast growth factors (FGFs). The FGFs are a 
family of proteins involved in morphogenesis, angiogenesis, and development,41 and 
crystal structures of HS oligosaccharides with FGF1-FGF receptor 2 (FGFR2)42 or FGF2-
FGFR143 demonstrate that HS forms a complex with FGFs and FGFRs to promote 
signaling. Binding of FGF-1 to its receptor requires both 2-O-sulfation and 6-O-sulfation, 
and FGF-2 requires 2-O-sulfation but not 6-O-sulfation.44 As mentioned earlier, isolation 
of GAGs with defined sulfation is extremely difficult, and the heterogeneous nature of 
biochemical HS and heparin preparations has hampered attempts to determine the precise 
sulfation motifs necessary for FGF binding. Without access to defined HS sequences, 
understanding the roles of sulfation in HS-protein binding is not possible. 
 Chemical approaches enable synthesis of sulfated oligosaccharides with distinct 
structures, and thus, systematic investigation of HS-protein binding and bioactivity. The 
structural requirements for HS recognition of both antithrombin III (ATIII) and FGF-1 
have been determined through use of synthetic small molecules. A sulfated HS 
pentasaccharide synthesized by Choay et al. interacted with ATIII to prevent blood 
coagulation, and led to an understanding of the mechanism of heparin anticoagulant 
activity (Figure 1.5).45  
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Figure 1.5: Structure of a synthetic HS pentasaccharide with ATIII binding. 
 
Angulo et al. performed investigation of FGF-1 binding to HS with a library of 
synthetic HS hexa- and octasaccharides (Figure 1.6).46 Oligosaccharides 1 and 2 display 
the major sulfation motif found in heparin, and the distribution of the negatively-charged 
groups is on both sides of the helix adopted by these two molecules. Hexasaccharide 3 
has a lower overall charge than 1 or 2 and the sulfate groups are presented on only one 
face of the helix. The anionic charge of hexasaccharides 4 and 5 is similar to 3, but the 
distributions of the sulfate groups are altered. Octasaccharide 2 and hexasaccharide 3 
promoted FGF-1-mediated cell proliferation, whereas the other oligosaccharides had poor 
mitogenic activity. The precise arrangement of sulfate groups appears to be important for 
the HS-FGF-1 interaction and subtle changes can lead to dramatic effects in the 
biological properties of HS. These studies with HS small molecules are remarkable as 
GAG chains are typically hundreds of monosaccharides long, but synthetically accessible 
pentasaccharide, hexasaccharide, and octasaccharide motifs captured the activities of 
these long polysaccharides. The ability to understand HS-protein binding and the 
biological functions of HS with defined, synthetic molecules enables investigation into 
GAG structure-activity relationships. 
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Figure 1.6: Synthetic HS library for FGF-1 binding studies. 
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Chondroitin sulfate glycosaminoglycans 
Historically, research on GAGs has focused on heparin and HS, despite the 
ubiquitous expression of CS oligosaccharides. CS consists of repeating disaccharide units 
of GlcA and N-acetylgalactosamine (GalNAc) linked through β-(1,3) and (1,4) glycosidic 
bonds. As described earlier, CS displays a variety of sulfation patterns, and CS 
polysaccharides can range from 10 to 100 disaccharide units in length.1 
CS GAGs have a non-rigid, helical structure, like HS and heparin, and the 
presence of different counterions changes the shape of the helix. For example, X-ray 
crystallographic analysis of a CS-A [GlcA-GalNAc(4-O-SO3-)] hexasaccharide in the 
presence of sodium ions47 (Figure 1.7) afforded a tighter helix than a crystal structure of a 
tetrasaccharide with bulkier calcium ions coordinated (Figure 1.8).48 The flexibility of CS 
allows for multiple protein binding conformations and different sulfate group 
orientations. 
Similar to HS, the biosynthesis of CS begins in the Golgi apparatus and with the 
placement of the tetrasaccharide linker on specific serine residues (Figure 1.4). GalNAc 
is the next monomer added and then CS synthases add alternating units of GlcA and 
GalNAc.49,50 Sulfotransferases use PAPS to add sulfate groups to the chains, and there are 
three major families of CS sulfotransferases: one transfers sulfate groups to the C-4 
hydroxyl of GalNAc residues, the second to the C-6 hydroxyls of GalNAc and the last to 
the C-2 hydroxyls of GlcA units. In total, seven CS sulfotransferases have recently been 
identified and cloned.2 Sulfation of the C-4 GalNAc hydroxyl to afford the pattern called 
CS-A or the C-6 GalNAc hydroxyl to yield CS-C happens first and these motifs are the 
most commonly displayed. Additional sulfation of the C-4 sulfated product usually 
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occurs at the C-6 hydroxyl to generate CS-E, and the C-6 sulfated product is normally 
modified at the C-2 hydroxyl of GlcA to generate CS-D (Figure 1.9).2 The variety of 
sulfotransferases leads to the generation of multiple sulfation motifs and creates the 
structural complexity observed in CS GAGs.  
Figure 1.7: X-ray crystal structure of a CS-A hexasaccharide coordinated to sodium ions. The top structure 
shows the view parallel to the helical axis and the bottom structure the view perpendicular to the helical 
axis.47 
 
 
 
Figure 1.8: X-ray crystal structure of a CS-A tetrasaccharide coordinated to calcium ions. The top structure 
shows the view parallel to the helical axis and the bottom structure the view perpendicular to the helical 
axis.48 
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Figure 1.9: The most prevalent chondroitin sulfate sulfation motifs in vivo. 
 
CS is important in proper embryonic development and the sulfation motifs 
presented are carefully regulated during this crucial time. Proper development of the 
brain is dependent on the regulation of CS chains by chondroitin-4-sulfotransferase and 
chondroitin-6-sulfotransferase enzymes.10 RNA-mediated interference of the CS synthase 
gene of Caenorhabditis elegans led to defects in vulval morphogenesis and 
embryogenesis.51 Despite the lack of sulfation present on Caenorhabditis elegans CS, 
these studies still show the importance of CS in the embryo. Mice with a mutant form of 
chondroitin-4-sulfotransferase 1 had severe chondrodysplasia and a disorganized 
cartilage growth plate resulting in osteoarthritis, demonstrating the necessity of C-4 
sulfation and the importance of CS structure in proper cartilage formation.52 Knockout 
mice lacking one of the chondroitin-6-sulfotransferase genes were generated to 
understand the importance of CS-D sulfation on development but the mice displayed 
normal growth, yet had decreased numbers of lymphocytes in the spleen.53 Compensation 
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E) or by other sulfotransferases may be why a dramatic effect was not observed. In 
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understand the significance of CS and the impact of specific sulfation patterns in the 
embryo, but these models provide only limited amounts of information. Multiple motifs 
may be affected by the loss of the sulfotransferase and distinct sulfation types cannot be 
targeted. 
Differentially sulfated CS structures have been implicated in a variety of 
processes related to disease and injury. For example, Plasmodium falciparum, the 
malarial parasite, has evolved to use CS as a method for cell attachment. Erythrocytes 
infected by malarial parasites bind to the placenta through a CS-A dodecasaccharide and 
adversely affect both mother and child. Interestingly, binding is inhibited by the CS-E 
motif, thus preventing adhesion to the placenta.55-57 In cancer, melanoma chondroitin 
sulfate proteoglycan is an early cell surface melanoma progression marker that stimulates 
cancer cell proliferation, migration, and invasion.58 The structure of the attached CS 
chain has not been elucidated but its activity appears to be regulated by sulfation.59 CS is 
the most common component in wound fluid, and binds several factors involved in 
leukocyte adhesion, including L-selectin, P-selectin, and CD44.60,61 The binding appears 
to be sulfation dependent as L-selectin and P-selectin bind only to motifs enriched in CS-
E and CS-B [IdoA-GalNAc(4-O-SO3-)], but CD44 is capable of binding all CS sulfation 
motifs. Versican, a CS proteoglycan (CSPG) containing high amounts of CS-E and CS-B, 
has been shown to bind to the inflammatory chemokines SLC, IP-10, and SDF-1β.61,62 
CS is essential in the development of the central nervous system by regulating 
axonal growth and pathfinding,63,64 and, paradoxically, CS has been described as both 
growth promoting and inhibitory to neurons. CSPGs can repel migrating neurons or 
extending axons in brain development or following injury, but tissues that strongly 
 15 
express CS do not always exclude the entry of axons.65,66 During the migration of neural 
crest cells, the temporal and spatial changes of CSPG expression patterns are inversely 
correlated with the pathways of the cells, suggesting an inhibitory role.67 In contrast, CS 
has been found in the tracts of developing axons and the CS-E-enriched chains of the 
proteoglycan phosphacan promote neurite outgrowth of both embryonic rat mesecephalic 
and hippocampal neurons.68,69 A CSPG cannot be simply classified as neurite outgrowth 
supportive or inhibitory as its spatial and temporal regulation, its interactions with protein 
ligands, like growth factors, and potentially its sulfation pattern define its properties on 
neurite outgrowth.  
Numerous proteins have been identified as CS binders, and CS fine structure is 
believed to regulate these recognition events. Through assays with CSPGs and 
heterogeneous preparations of CS polysaccharides, the neuronal growth factors 
pleiotrophin, midkine, FGF-2, and FGF-16 were found to interact with CS.70-72 It is 
unknown if CS molecules form complexes with ligands and their receptors to promote 
signaling in a manner similar to HS, FGF, and FGFR, and no crystal structures have been 
reported. Pleiotrophin and midkine are related proteins involved in the promotion of 
neurite outgrowth, and they both bind to the CS-E-enriched proteoglycan phosphacan and 
polysaccharides concentrated in CS-E.70-72 Intriguingly, CS-E polysaccharides have been 
shown to promote the outgrowth of neurons, perhaps through pathways regulated by 
midkine and pleiotrophin.73 Unfortunately, as with HS and heparin, the heterogeneity of 
the CS molecules used in the studies described does not allow an understanding of the 
roles of precise sulfation patterns, making a chemical approach that provides defined 
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oligosaccharides necessary to determine the biological relevance of different CS sulfation 
motifs.  
Our knowledge of the physiological importance of CS oligosaccharides would be 
significantly enhanced by an ability to correlate structure with function. As demonstrated 
with HS, synthetic small molecules can recapitulate the activity of large polysaccharides 
and bind proteins like ATIII and FGF-1 in a sulfation pattern dependent manner. 
Synthesis of a library of CS oligosaccharides with differential sulfation would provide 
access to defined structures not obtainable from natural sources, and allow us to elucidate 
what impact precise motifs have on ligand binding and the development and function of 
neurons. It would also enable evaluation of the somewhat contradictory nature of CS 
GAGs, as they are both neuronal growth inhibitory and stimulatory. Such detailed 
structure-function analyses have not yet been performed for CS and are needed to fully 
understand its activities. This thesis describes our approach to a synthetic library of CSs, 
identification of the biologically relevant motifs, and determination of the roles of 
specific CS motifs in neuronal development and function.  
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Chapter 2: Chemical Synthesis of Chondroitin Sulfate Oligosaccharides 
 
Chondroitin sulfate glycosaminoglycans 
Chondroitin sulfate (CS) glycosaminoglycans (GAGs) are highly sulfated sugars 
composed of the repeating β-linked disaccharide unit N-acetylgalactosamine (GalNAc) 
and glucuronic acid (GlcA, Figure 2.1).  On the cell surface and in the extracellular 
matrix, CS chains can be hundreds of monosaccharide units long, display multiple 
sulfation patterns, and are attached to proteoglycan core proteins via serine residues. 
Together, CS chains and their associated core proteins have been proposed to recruit 
protein ligands, such as growth factors and cytokines, to the cell surface and may act as 
templates to bring ligands and their corresponding receptors into the optimal alignment 
for productive binding.1,2,3  CS proteoglycans (CSPGs) modulate cell-cell and cell-matrix 
interactions, contribute to the maintenance of normal tissue architecture and function, and 
                               Figure 2.1: Known chondroitin sulfate disaccharides. Ac = acetyl.   
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participate in cell adhesion and growth control.4-8 The sulfation patterns of CSPGs are 
highly regulated, differentially expressed in distinct tissues9 and they potentially dictate 
the proteins a proteoglycan can bind. 
While CS binds growth factors and potentially regulates cell surface 
interactions,10 the importance of specific sulfation motifs in modulating binding and the 
impact of distinct patterns on chondroitin sulfate bioactivity are unclear. Interest has 
grown in elucidating how sulfation directs recognition events and affects the functions of 
CS in vivo. An understanding of the physiological role of chondroitin sulfate (CS) 
oligosaccharides would be significantly enhanced by an ability to correlate structure with 
function. Although several strategies have been developed, there are currently no 
methods to systematically explore the role of specific sulfation sequences. For instance, 
genetic approaches that target a sulfotransferase gene perturb multiple sulfation patterns 
throughout the polysaccharide chain and cannot be used to study the impact of a single 
structural motif.11,12 Biochemical methods afford a mixture of heterogeneously sulfated 
compounds of poorly defined linear sequence,13 thereby complicating efforts to relate a 
biological function to a specific sulfation sequence.  
Chemical synthesis and chemoenzymatic synthesis of GAGs provide access to 
well-defined structures for biological evaluation. While investigations into the 
chemoenzymatic synthesis of CS have not been pursued until recently as not all of the 
enzymes involved are fully characterized,14 carbohydrate chemists have used chemical 
synthesis to generate CS disaccharides,15-20 trisaccharides,20,21 tetrasaccharides,20,22,23 
pentasaccharides,24 and hexasaccharides,22,25 but the bioactivities of these molecules have 
not yet been described. 
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 We reasoned that the combination of chemical synthesis and systematic 
biological studies would advance an understanding of the physiological roles of CS. As 
shown with synthetic heparan sulfate small molecules (see Chapter 1), slight changes in 
sulfation can have dramatic affects on protein interactions and the cellular response to 
HS.26,27 A library of synthetic CS oligosaccharides with precise sulfation motifs should 
provide crucial information regarding the possible existence of a “sulfation code” for CS, 
where distinct sulfation sequences have specific protein-binding and neurobiological 
properties. Our studies would be the first reported to use defined CS small molecules for 
biological evaluation. 
 
Chemical synthesis of chondroitin sulfate oligosaccharides 
Unlike for DNA and peptides, no general synthetic method exists for the synthesis 
of carbohydrates. Selective protection and deprotection of hydroxyl protecting groups 
and generation of glycosidic linkages at different positions along the carbohydrate ring 
makes development of a general method for carbohydrate synthesis difficult.28 Due to 
their high degree of functionality, the synthesis of CS glycosaminoglycans is challenging 
and lengthy, with more than 40 chemical steps required for a single oligosaccharide.29 To 
be practical for biological studies, a modular, efficient approach must be designed to 
minimize the number of steps and afford sufficient quantities of oligosaccharides for 
analysis. Construction of CS necessitates stereospecific formation of β-glycosidic 
linkages, the use of uronic acid donors or acceptors of low reactivity, and regiospecific 
functionalization of hydroxyl groups of comparable reactivity to install distinct sulfation 
sequences. Protecting group strategies must be carefully selected as they determine not 
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only the pattern of sulfation, but also the reactivities of the glycosyl donor and acceptor. 
Slight changes in protecting groups have been reported to lead to dramatic changes in the 
stereochemistry and yield of the glycosidic bond formed.30  
CS is composed of two types of glycosidic linkages, the β(1,4)-linkage between 
the C-4 hydroxyl of GlcA and GalNAc, and the β(1,3)-linkage between the C-3 hydroxyl 
of GalNAc and GlcA (Figure 2.2). As the β(1,4)-linkage is the more hindered and 
difficult to form a glycosidic bond, it is usually generated at the disaccharide formation 
stage of the synthesis and then the β(1,3)-linkage is formed to make larger 
oligosaccharides. The C-4 hydroxyl also can have reduced nucleophilicity during 
coupling due to the electron-withdrawing nature of the C-5 ester present on the GlcA 
monomer. As a result, oxidation of the C-6 hydroxyl group is often performed after the 
coupling reaction, though oxidation can be difficult on larger substrates. For the synthesis 
of CS oligosaccharides, Koenigs-Knorr glycosylation using glycosyl bromides15 and 
Schmidt’s trichloroacetimidate method26,27 (Figure 2.3) have been the conventional 
methods for generating glycosidic linkages. Trichloroacetamides are very active and 
these donors compensate for the less reactive oxidized GlcA monomer. 
 
 
 Figure 2.2: Structure of a CS-E tetrasaccharide. 
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Figure 2.3: The structures of donors used in CS synthesis. 
 
All of the linkages in CS are β-glycosidic linkages, so a neighboring participating 
group at the C-2 position is commonly used to direct the stereochemistry during the 
coupling reaction (Scheme 2.1).22 The C-2 position of the GlcA monomer is usually 
protected with an ester protecting group, such as a benzoyl or an acetyl. Unfortunately, 
the N-acetyl group present on the C-2 position of the GalNAc residues in the final 
molecules is a poor participating group during coupling reactions, so the amine of the 
GalNAc donor is typically masked as an azide or with a protecing group like 
trichloroacetyl. While azides are not participating groups, β-linkages have been 
successfully generated using α-trichloroacetimidate donors containing C-2 azides.20 C-2 
azides are quite common at some stage of most CS syntheses and they are readily 
accessed through an azidonitration reaction of tri-O-acetylgalactal (Scheme 2.2).15,19,20,31 
The expense of galactosamine inhibits its ability to be an accessible starting material for 
the synthesis of CS. 
 
                 Scheme 2.1: Activation of donors with C-2 participating groups. 
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Scheme 2.2: Azidonitration of tri-O-acetylgalactal with cerium ammonium nitrate and sodium azide. 
 
One of the most challenging tasks in the synthesis of CS glycosaminoglycans is 
the development of an orthogonal protecting group strategy. Protecting groups chosen for 
the synthesis must withstand acidic coupling conditions and harsh, sometimes acidic 
sulfation reactions. Early CS syntheses utilized benzyl and acetate protecting groups,15 
because these groups do not tend to negatively affect the reactivities of the donor and 
acceptor. Ester protecting groups larger than acetates, such as benzoyl, are electron 
withdrawing and can decrease coupling reaction yields when present on either the donor 
or acceptor. One problem with acetyl groups is that they can readily migrate around the 
carbohydrate ring under basic conditions.30 For this reason, the repertory of protecting 
groups for CS synthesis has been expanded. Benzylidene rings, benzoyl esters, p-
methoxybenzyl groups, silyl ethers, pivolate esters, and levulinoyl esters are some of the 
protecting groups successfully used in CS syntheses.16-25 The deactivating nature of the 
larger ester groups is compensated by their stability. The protecting group present at the 
reducing end sugar must also be carefully chosen, as this group has to mimic the native 
carbohydrate. CS oligosaccharides lacking a protecting group at this position are difficult 
to characterize because anomerization complicates NMR analysis. The methyl group is a 
commonly used group at the reducing end due to its small size, but it can only be cleaved 
with acid hydrolysis, and therefore cannot be readily removed from the 
oligosaccharide.15,16 
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The presence of sulfate esters on the final CS product adds complexity to the 
synthesis since sulfate groups are both acid and base sensitive, and decrease the solubility 
of the CS oligosaccharide in organic solvents. For these reasons, sulfation generally 
occurs at the end of the synthesis. 
  
Sinäy’s approach to a CS-A disaccharide 
The first synthesis of a CS disaccharide was reported in 1989 by Marra et al.15 
(Scheme 2.3). Glycosyl bromide 6, synthesized in 3 steps from D-glucurono-6,3-lactone, 
was coupled to glycosyl acceptor 7, synthesized in 3 steps from tri-O-acetylgalactal, in 
the presence of silver triflate to provide the desired β-disaccharide in 85% yield. The 
disaccharide was further elaborated by a regioselective benzylidene ring opening to 
provide the free C-4 hydroxyl group in 78% yield, which was then sulfonated with sulfur 
trioxide-trimethylamine. Deprotection of the benzyl ethers and reduction of the azide to 
the amine was performed using H2 and palladium on carbon. The resulting amine was 
acetylated to yield the final CS-A disaccharide 10. While this route could provide access 
to other CS sulfation patterns such as CS-E and potentially CS-C, the presence of a 
methyl group at the reducing end prevents further elongation of the oligosaccharide 
because acid cleavage of this group would also lead to removal of the benzylidene ring. 
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Scheme 2.3: The first synthesis of a CS-A disaccharide by Marra and Sinäy. Ph = phenyl, Ac = acetyl, Me 
= methyl, TMA = trimethylamine, Tf = trifluoromethanesulfonate, Bn = benzyl. 
 
Jacquinet’s approach to CS-A and CS-C disaccharides 
 In 1990, the Jacquinet group developed syntheses of β(1,4)-linked CS 
disaccharides (Scheme 2.4).19 This more sterically hindered linkage can be difficult to 
generate and the reactive α-glycosyl trichloroacetimidate group was exploited to 
construct it. With non-participating groups at C-2 and treatment with BF3•OEt2 at low 
temperature, α-glycosyl trichloroacetimidates undergo inversion at the anomeric center to 
give β-linked products.32 Glycosyl imidates 11 and 12 were synthesized from galactal (6 
steps for 11 and 5 steps for 12) and reacted with 13 in the presence of BF3•OEt2 followed 
by tetrabutylammonium fluoride (TBAF) cleavage of the 6-O-silyl ether to afford 14 and 
15 in 62% and 55% yields, respectively. The modest yields demonstrate the challenge 
associated with formation of the β(1,4)-linkage and generation of the α-disaccharide 
when using a non-participating group at the C-2 position. Elaboration of 14 and 15 led to 
formation of CS-A disaccharide 18 and CS-C disaccharide 19. As with the previous 
synthesis, production of longer oligosaccharides would be difficult due to the methyl 
protecting group at the reducing end position. In addition, multiple sulfation patterns 
cannot be generated from one disaccharide. Two disaccharides must be synthesized and 
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two GalNAc monomers, making synthesis of large amounts of the CS oligosaccharides 
tedious and more challenging. 
 
 
Scheme 2.4: Jacquinet’s synthesis of CS-A and CS-C disaccharides. Bn = benzyl, Bz = benzoyl, Ac = 
acetyl, TBS = t-butyldimethylsilyl, TBAF = tetrabutylammonium fluoride, PDC = pyridinium dichromate, 
TMA = trimethylamine, Me = methyl. 
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Ogawa’s synthesis of CS-A, CS-C, and CS-E tetrasaccharides 
In 1995, Tamura et al.23 reported the synthesis of the first CS-A tetrasaccharide 
and in 1997, the syntheses of CS-C and CS-E tetrasaccharides (Schemes 2.5 and 2.6).20 
As in the previous example, glycosyl imidates were used to generate the β(1,3)- and 
β(1,4)-glycosidic linkages. Glycosyl imidate 20 was synthesized from galactose in 11 
steps and acceptor 21 from known compound p-methoxyphenyl β-D-glucopyranoside in 4 
steps.33 Coupling of these two compounds with subsequent 6-O-silyl ether deprotection 
gave the key disaccharide 22 in 70% yield. Opting to form the less hindered 1,3-linkage 
during tetrasaccharide construction, disaccharide 22 was converted into donor 23 or 
acceptor 24. Reaction of these molecules with BF3•OEt2 afforded tetrasaccharide 25 in 
50% yield.  
 
Scheme 2.5: Synthesis of Tamura and Ogawa’s fully protected tetrasaccharide. Ph = phenyl, TBS  = t-
butyldimethylsilyl, TBAF = tetrabutylammonium fluoride, PMB = p-methoxybenzyl, pMP = p-
methoxyphenyl, Lev = levulinoyl, Me = methyl. 
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Tetrasaccharide 25 was converted to 26 in 4 steps. Since the levulinoyl group can 
be cleaved during benzylidene acetal removal, it was replaced with the more stable and 
less migratable pivolate group. The azides were reduced to amines and acetylated. 26 was 
subsequently reacted in two ways. First, it was converted to CS-E tetrasaccharide 27 by 
cleavage of the benzylidene acetal, followed by sulfonation with sulfur trioxide-
trimethylamine and saponification of the esters. The authors had planned to use this 
approach to synthesize 29, but selective C-6 sulfonation was not observed. Others have 
reported difficulty with this type of simultaneous sulfation of the C-4 and C-6 
hydroxyls.34 To access 29, a more stepwise approach was required. 26 was converted to 
23 by regioselective ring opening of the benzylidene ring using sodium 
cyanoborohydride and HCl-ether. Protection of the C-4 hydroxyl group as an acetate, 
benzyl deprotection, sulfonation, and ester cleavage gave CS-C tetrasaccharide 29 in 
good yield. CS-A tetrasaccharide 30 was synthesized in a similar manner by sulfonation, 
debenzylation, and ester hydrolysis. All three CS molecules were made from key 
disaccharide 22, making this an efficient synthesis of CS. The relatively low-yielding 
regioselective ring-opening is one disadvantage of this method, and the multiple products 
of this reaction are difficult to separate. Methods to selectively sulfate or benzoylate the 
C-6 positions would provide access to all of the sulfation patterns from the tetraol 
generated through removal of the benzylidene rings of 26. Another weakness of this 
method is the protection of the anomeric positions of the reducing end sugars with p-
methoxyphenyl groups. This group does provide a UV active moiety to simplify 
purification of the oligosaccharides, but it is bulky and does not mimic the native 
oligosaccharide structure.  Biological evaluation of these oligosaccharides would most 
 39 
likely require replacement of the anomeric p-methoxyphenyl with a smaller, less intrusive 
protecting group. 
 
Scheme 2.6: Synthesis of Tamura and Ogawa’s CS-A, CS-C, and CS-E tetrasaccharides. Ph = phenyl, Piv  
= pivolate, Ac = acetate, PMB = p-methoxybenzyl, pMP = p-methoxyphenyl, TMA = trimethylamine, Me 
= methyl, CSA = (±)-DL-camphor-10-sulfonic acid, DMAP = 4-dimethylaminopyridine.  
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Karst and Jacquinet’s synthesis of a CS-D hexasaccharide 
In 2002, Karst et al. reported the first synthesis of a CS hexasaccharide, CS-D    
(Schemes 2.7 and 2.8).22 Disaccharide imidate 31 was synthesized in 14 steps from 
known starting materials.26,34 31 was converted to acceptor 32 by treatment with 
methanol and TMSOTf followed by reaction with thiourea to remove the C-4 
chloroacetate group. Glycosyl imidate 31 and acceptor 32 were coupled in the presence 
of TMSOTf, and the product was immediately reacted with thiourea to afford 
tetrasaccharide 33 in 44% yield. Even though the more hindered 1,4-linkage was formed, 
the yield was similar to that of Ogawa et al.20,23 This demonstrates the influence of 
protecting groups in activating or deactivating the glycosidic bond forming reaction, and 
the presence of a C-2 trichloroacetamide on the donor promotes formation of the β-
glycosidic linkage. Acceptor 33 was treated with TMSOTf and 32 to afford the 
hexasaccharide in good yield. The chloroacetate group was removed with thiourea and 
exchanged for a p-methoxybenzyl group to afford 34. Exchange was necessary because  
 
Scheme 2.7: Synthesis of Karst and Jacquinet’s fully protected hexasaccharide. Me = methyl, MCA = 
monochloroacetyl, Bn = benzyl, Bz = benzoyl, TCA = trichloroacetyl, TMSOTf = trimethylsilyl 
trifluoromethane sulfonate, PMB = p-methoxybenzyl. 
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the chloroacetate group would be cleaved under the basic conditions needed to remove 
the benzoyl groups at sites of sulfation. 
Hexasaccharide 34 was transformed to 35 by conversion of the N-trichloroacetyl 
groups to N-acetyl groups using tributyltin hydride and AIBN,35 followed by treatment of 
this product with base to cleave the esters.36 Sulfonation with sulfur trioxide-
trimethylamine proceeded rapidly at the C-6 position, but sluggishly at C-2. A large 
excess of reagent was required to drive the reaction to completion. The final CS-D 
hexasaccharide 36 was obtained by hydrogenolysis of the benzyl ethers using H2 and 
palladium on carbon.  
 
 
Scheme 2.8: Karst and Jacquinet’s CS-D hexasaccharide. Me = methyl, Bn = benzyl, Bz = benzoyl, PMB = 
p-methoxybenzyl, Ac = acetyl, AIBN = 2,2′-azobis(2-methylpropionitrile), TMA = trimethylamine, Bu = 
butyl. 
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Conclusion 
 The chemical synthesis of CS GAGs is a formidable challenge. In the past two 
decades, much progress has been made to generate oligosaccharides of different lengths 
and sulfation patterns. New, modular syntheses are needed for rapid formation of focused 
libraries of sulfated CS compounds, and defined saccharides should provide a means to 
dissect systematically the structure-function relationships of CS GAGs. Notably, the 
biological activities of the oligosaccharides constructed in the previous studies described 
in this chapter have not been reported in the literature.  Access to these sugars should 
enable an understanding of their roles in a biological context, and we began our studies 
with this goal in mind. 
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Chapter 3: Synthesis and Neurobiological Evaluation of Chondroitin Sulfate 
Oligosaccharides Bearing the CS-E Sulfation Pattern∗† 
Background  
Glycosaminoglycans (GAGs) have an inherent capacity to encode functional 
information that rivals DNA, RNA and proteins. On the cell surface and in the 
extracellular matrix, chondroitin sulfate (CS) GAGs are hundreds of monosaccharide 
units in length, and they display a variety of sulfation patterns that are tightly regulated in 
vivo (see Figure 2.1 of Chapter 2).1,2 Over the past several decades, genetic and 
biochemical studies have established the importance of GAGs in regulating many 
physiological processes, including morphogenesis and development, viral invasion, 
cancer metastasis and spinal cord injury.3-6 However, a key unresolved question is 
whether and how glycosaminoglycans utilize specific sulfation sequences to modulate 
biological processes.  
In the central nervous system, CS and their associated proteoglycans have been 
shown to prevent axonal growth and inhibit neural regeneration in areas of injury, but 
tissues that strongly express CS do not always exclude the entry of axons.6,7 Several 
methods have been employed to understand this paradox, but none of these strategies can 
determine the importance of specific sulfation sequences. For example, mutations of 
sulfotransferase genes disrupt multiple sulfation patterns on the GAG chain and cannot be 
                                                
∗ Syntheses of chondroitin sulfate oligosaccharides were done in collaboration with Ross Mabon, a former 
postdoctoral scholar in the Hsieh-Wilson laboratory, Sherry M. Tsai, a former graduate student in the 
Hsieh-Wilson laboratory, and Manish Rawat, a postdoctoral scholar in the Hsieh-Wilson laboratory. 
Neurobiological studies were done in collaboration with Cristal I. Gama, a graduate student in the Hsieh-
Wilson laboratory. 
 
† Portions of this chapter were taken from S.E. Tully et al. (2004) J. Am. Chem. Soc. 126, 7736-7737 and 
C.I. Gama et al. (2006) Nat. Chem. Biol. accepted.   
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used to elucidate the impact of a single motif.3,8 Biochemical preparations of CS 
polysaccharides have been shown both to stimulate and attenuate the growth of cultured 
neurons,9-11 and the contradictory observations may be due to the difficulty in isolating 
defined CS molecules from natural sources such as shark cartilage. The heterogeneity of 
CS polysaccharides obtained through such methods has hampered efforts to relate precise 
CS structure with function.12  
Among the sulfation patterns implicated in the modulation of cell growth is the 
disulfated CS-E motif, a sulfation pattern enriched in the developing central nervous 
system (Figure 3.1).13,14 Heterogeneous polysaccharides enriched in CS-E have been 
shown to promote neurite outgrowth in hippocampal neurons,15 and they bind numerous 
growth factors active in the brain such as midkine, pleiotrophin, and fibroblast growth 
factor-2 (FGF-2).16 CS-E represented only 65% of the overall sulfation pattern of the 
molecules used in these studies, raising some doubt as to whether other motifs might be 
contributing to the observed effects.  
To investigate the biological properties of CS-E and establish the minimal 
structural determinants for activity, we sought to develop a modular and efficient 
synthesis of di- and tetrasaccharides bearing this sulfation pattern. Many heparan sulfate 
glycoaminoglycan binding proteins recognize tetra- or pentasaccharide motifs,17,18 but 
literature reports of CS proteoglycan-protein interactions suggest CS motifs of 
octasaccharides or larger are necessary for recognition.19 We wanted to determine if 
synthetic CS-E di- or tetrasaccharides could recapitulate the activities of the CS-E 
enriched polysaccharides. We also decided to generate a tetrasaccharide lacking sulfation 
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for comparison in our studies in order to understand the importance of sulfation in CS 
activity (Figure 3.1).  
To evaluate the biological activities of the synthetic molecules, we planned to 
analyze their abilities to promote neurite outgrowth of hippocampal neurons. The 
hippocampus is a region of the brain important in learning and memory20 and it is also 
one of the first regions affected during Alzheimer’s disease.21 Synthetic, neurite 
outgrowth promoting CS small molecules could prove to be quite powerful in curing the 
dementia caused by Alzheimer’s and in understanding the importance of CS GAGs in 
learning and memory. 
 
 
    Figure 3.1: Structures of the initial library of synthetic CS oligosaccharides. All = allyl, Ac = acetyl. 
 
Development of a synthetic route to chondroitin sulfate oligosaccharides 
As described in Chapter 2, the synthesis of CS oligosaccharides is challenging 
and requires stereospecific formation of glycosidic linkages and regiospecific 
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functionalization of hydroxyl groups of comparable reactivity to install distinct sulfation 
sequences. While we first wanted to create di- and tetrasaccharides bearing the CS-E 
sulfation motif, we sought to design a modular synthetic approach that would allow us to 
rapidly generate multiple sulfation patterns from a single disaccharide intermediate. 
Retrosynthetic analysis of CS di- and tetrasaccharides afforded two possible routes and 
led to glucuronic acid (GlcA) monomers 39 and 44 and N-acetylgalactosamine (GalNAc) 
monomers 40 and 43 (Scheme 3.1). Coupling 39 and 40 places the GalNAc subunit at the 
reducing end, whereas, coupling of 43 to 44 places the GlcA moiety at the reducing end. 
In retrosynthesis 1, the hindered β(1,4)-glycosidic linkage is constructed when coupling 
disaccharides, but for retrosynthesis 2, this linkage is generated during monomer 
coupling. We pursued the two syntheses in parallel to determine the highest yielding 
method. This is possible as both the GlcA monomers can be generated through one 
synthetic pathway and both the GalNAc monomers through another pathway. 
We decided to oxidize the C-6 position of the glucuronic acid monomer at the 
monomer stage as oxidation is easier to perform on monosaccharides than on 
oligosaccharides. The methyl ester is deactivating, but there is precedent for high yielding 
and stereoselective coupling reactions with glucuronic methyl ester monomers.22,23  
To direct the β-stereochemistry of the glycosidic bond forming reaction, we 
planned to exploit C-2 N-trichloroacetyl (TCA) or O-benzoyl (Bz) participating groups in 
a manner comparable to previous syntheses (see Chapter 2).24 α-Trichloroacetimidates 
and thioglycosides are more activated leaving groups than glycosyl bromides and thus 
were chosen as donors. The versatility of thioglycosides enables conversion to the more 
activated α-trichloroacetimidate, if necessary. Additionally, for retrosyntthesis 1, an α- 
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Scheme 3.1: Retrosynthetic analysis 1 (left) and retrosynthetic analysis 2 (right) of CS tetrasaccharides. Me 
= methyl, All = allyl, Ac = acetyl, pMP = p-methoxyphenyl, TBS = t-butyldimethylsilyl, Bz = benzoyl, 
TCA = trichloroacetyl, PhMe = tolyl, TIPS = triisopropylsilyl. 
 
trichloroacetimidate was chosen as the donor in the formation of the disaccharide because 
it should be selectively activated in the presence of a thioglycoside, allowing for 
orthogonal coupling reactions.25 The thioglycoside present at the reducing end allows for 
extension to tetrasaccharides and longer oligosaccharides.  
An orthogonal protecting group strategy was designed to install specific sulfation 
sequences. We chose the p-methoxybenzylidene group to mask positions that are exposed 
at late stages of the synthesis for sulfation.  Unlike a benzylidene ring, this group is 
readily cleaved through oxidative cleavage with DDQ, eliminating the need to perform an 
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acidic cleavage and minimizing side reactions such as loss of other protecting groups and 
destruction of glycosidic linkages. In addition, it is more amenable to cleavage on solid 
support, which would be valuable for future extension of the synthesis to solid-phase. To 
elongate the carbohydrate chain, a silyl ether (TIPS or TBS) is used to protect the C-4 
position of GlcA or C-3 position of GalNAc and liberate a hydroxyl group nucleophile 
for reaction with a glycosylating agent. In addition to their abilities as participating 
groups, the N-TCA group is also readily converted to the acetamide during late stages of 
the synthesis and the Bz groups are easily cleaved. Finally and unique to our synthesis, 
we utilize the allyl moiety at the reducing end of the oligosaccharides as a convenient 
chemical handle for conjugation to proteins, small molecules and surfaces.  
 
Monomer synthesis for retrosynthesis 1 
Glucuronic acid monomer 39 was synthesized in 11 steps and 21% overall yield 
from β-D-glucose pentaacetate, and importantly, this synthesis was readily performed on 
a multigram scale to obtain pure monomer (Scheme 3.2). β-D-Glucose pentaacetate was 
converted to thioglycoside 45 in 92% yield using tin (IV) tetrachloride and p-
toluenethiol, and the thioglycoside was then transformed to 46 through a methanolysis 
reaction in 99% yield. Tetraol 46 generated p-methoxybenzylidene 47 in 70% yield using 
p-methoxybenzylidene dimethyl acetal and a catalytic amount of DL-camphor-10-sulfonic 
acid. A small amount of DMF was added to the reaction to enhance the solubility of 46, 
but running the reaction in DMF instead of acetonitrile led to prolonged reaction times. 
Dibenzoylation of the diol using benzoyl chloride and DMAP afforded 48, and 
regioselective ring opening of the acetal using TFA and NaBH3CN26 followed by silyl 
protection of the C-4 hydroxyl yielded 49 in 69% yield. Next, the PMB group was 
 54 
removed by oxidative cleavage with DDQ and the resulting primary alcohol 50 was 
oxidized with pyridinium dichromate in DMF to afford the acid over the aldehyde and 
leave the thiol unoxidized.27,28 The acid was then esterified under standard conditions 
using diazomethane, and conversion of thioglycoside 51 to the corresponding imidate 
furnished the monomer 39 in 80% yield over the two steps. The imidate was chosen over 
the thioglycoside for the final monomer as it should be more reactive in the coupling 
reaction to the GalNAc monomer.29  
 
Scheme 3.2: Synthesis of the glucuronic acid monomer 39. Ac = acetyl, Me = methyl, All = allyl, pMP = 
p-methoxyphenyl, TBS = t-butyldimethylsilyl, Bz = benzoyl, PhMe = tolyl, p-MeOC6H4CH(OMe)2 = p-
methoxybenzaldehyde dimethyl acetal, CSA = (±)-DL-camphor-10-sulfonic acid, TFA = trifluoroacetic 
acid, TBSOTf = t-butyldimethylsilyl trifluoromethane sulfonate, TEA = triethylamine, PMB = p-
methoxybenzyl, DDQ = 2,3-dichloro-5,6-dicyano-p-benzoquinone, PDC = pyridinium dichromate, NIS = 
N-iodosuccinimide. 
 
Synthesis of the galactosamine monomer 40 was accomplished on a multigram 
scale in eleven steps from D-galactose and an 11% overall yield (Scheme 3.3). D-
Galactose was converted to tri-O-acetylgalactal 53 in a three-step reaction sequence for a 
yield of 51%.30 D-Galactose was first acetylated using acetic anhydride and catalytic 
perchloric acid. The peracetylated galactose was converted to the glycosyl bromide using 
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hydrogen bromide in acetic acid, and the bromide was reduced to tri-O-acetylgalactal 53 
using elemental zinc and aqueous acetic acid. Azidonitration using cerium ammonium 
nitrate and sodium azide afforded nitrate 54 as a mixture of α- and β-anomers in 48% 
yield.31 Acetate 55 was prepared from 54 in 95% yield utilizing sodium acetate and acetic 
acid, and subsequently, the azide was reduced and converted to the trichloroacetamide 
56. Formation of thioglycoside 57 using boron trifluoride diethyl etherate and p-
toluenethiol followed by deacetylation under Zemplén conditions afforded 58 in 78% 
yield from 56. Monomer 40 was completed through installation of a p-
methoxybenzylidene ring on the C-4 and C-6 hydroxyls utilizing p-methoxybenzylidene 
dimethyl acetal and a catalytic amount of DL-camphor-10-sulfonic acid. 
 
 
Scheme 3.3: Synthesis of the galactosamine monomer 40. Ac = acetyl, CAN = cerium ammonium nitrate, 
TCACl = trichloroacetyl chloride, TEA = triethylamine, PhMe = tolyl, pMP = p-methoxyphenyl, p-
MeOC6H4CH(OMe)2 = p-methoxybenzaldehyde dimethyl acetal, CSA = (±)-DL-camphor-10-sulfonic acid 
. 
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Generation of the disaccharide for retrosynthesis 1 
 With the protected donor and acceptors in hand, Ross Mabon and I undertook 
construction of disaccharide building block 38 (Scheme 3.4 and Table 3.1). 
Unexpectedly, the yields for this coupling were quite low even though it generates the 
less hindered β(1,3)-linkage. While some of the α(1,3)-linked disaccharide was observed, 
the major by-product was monosaccharide 51 (Scheme 3.2) in yields ranging from 20% – 
60%. This product was presumably formed through an intermolecular aglycon transfer 
reaction (Scheme 3.5) and demonstrates one of the difficulties in coupling to 
thioglycoside acceptors.32 
Scheme 3.4: Formation of disaccharide 38. Me = methyl, TBS = t-butyldimethylsilyl, Bz = benzoyl, PhMe 
= tolyl, pMP = p-methoxyphenyl, TCA = trichloroacetyl. 
          
 
 
Table 3.1: Conditions attempted for generation of disaccharide 38. NIS = N-iodosuccinimide, TMSOTf = 
trimethylsilyl trifluoromethanesulfonate, Et = ethyl. 
 
     
O
HO
NHTCA
SPhMe
O
O
pMP
O
MeO2C
TBSO
BzO
O
Cl3C
NH
BzO
+ OO
NHTCA
SPhMe
O
O
pMP
O
MeO2C
TBSO
BzO
BzO
39 40 38
Donor (eq) Acceptor (eq) Activator (eq)* Solvent Temp (
oC) Time (h) !-di
1.2 1.0 BF3!OEt2 (0.1) Toluene/CH2Cl2 0 1 21%
1.8 1.0 BF3!OEt2 (0.3) CH2Cl2 -15 2 18%
1.2 1.0 BF3!OEt2 (0.3) CH2Cl2 -45 2 32%
1.0 1.7 BF3!OEt2 (0.3) CH2Cl2 -45 to rt 3 46%
1.1 1.0 TMSOTf (0.2) Toluene/CH2Cl2 rt 1 16%
1.8 1.0 TMSOTf (0.4) Toluene/CH2Cl2 -15 3 17%
1.2 1.0 TMSOTf (0.2) CH2Cl2 -15 1 21%
1.2 1.0 TMSOTf (0.2) CH2Cl2 -78 to rt 3 28%
1.2 1.0 TMSOTf (1.1) CH2Cl2 -78 to rt 18 32%
*NIS also used in each condition (1.4 eq)
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Scheme 3.5: Intermolecular aglycon transfer. Me = methyl, TBS = t-butyldimethylsilyl, Bz = benzoyl, 
PhMe = tolyl, pMP = p-methoxyphenyl, TCA = trichloroacetyl, TMS = trimethylsilyl. 
 
 
To avoid this transfer, we placed the allyl group on the reducing end of GalNAc at 
an earlier stage in the synthesis. The allyl group should be stable to all coupling 
conditions and not sensitive to aglycon transfer. We envisioned that for generation of 
larger oligosaccharides, the allyl group could be cleaved to afford an anomeric mixture of 
alcohols and the imidate generated for coupling reactions.33 The new GalNAc monomer 
60 was made in three steps from 40 (Scheme 3.6). First, a TIPS group was added to the 
C-3 hydroxyl using triisopropylsilyl chloride and imidazole. This was followed by 
allylation though activation of the thioglycoside with triflic acid and N-iodosuccinimide 
and coupling to allyl alcohol to afford 59 in 75% yield. The silyl group was then cleaved 
to afford GalNAc acceptor 60.  
O
MeO2C
BzO
TBSO
O CCl3
NH
BzO
O
HO SPhMe
TCAHN
O
O
pMP
O
MeO2C
BzO
TBSO
BzO
SPhMe
O
MeO2C
BzO
TBSO
O CCl3
NH
BzO
TMS OTf
Cl3C N
H
O
TMS
O
MeO2C
BzO
TBSO
O
O
Ph
+
TfO-
O
OHMePhS
NHTCA
O
O
pMP
O
MeO2C
BzO
TBSO
BzO
SPhMe
39 40 51
 58 
 
Scheme 3.6: Synthesis of the galactosamine monomer 60. All = allyl, pMP = p-methoxyphenyl, PhMe = 
tolyl, NIS = N-iodosuccinimide, TIPSCl = triisopropylsilyl chloride, TfOH = triflic acid, TCA = 
trichloroacetyl, TBAF = tetrabutylammonium fluoride, DMAP = 4-dimethylaminopyridine. 
 
 Imidate 39 was coupled to allyl glycoside acceptor 60 using TMSOTf in CH2Cl2 
at -40 °C to afford disaccharide 61 in 75% yield (Scheme 3.7). As anticipated, formation 
of the β(1,3)-glycosidic linkage was exclusively observed at low temperature due to the 
presence of a C-2 participating group and an α-trichloroacetimidate in the glycosyl 
donor. Upon generating the key disaccharide for retrosynthesis 1, we were then able to 
explore generation of larger oligosaccharides and the remaining sulfation and 
deprotection steps for the synthesis of the CS-E disaccharide. 
  
Scheme 3.7: Formation of disaccharide 61. Me = methyl, All = allyl, pMP = p-methoxyphenyl, TBS = t-
butyldimethylsilyl, Bz = benzoyl, TCA = trichloroacetyl, PhMe = tolyl, TMSOTf = trimethylsilyl 
trifluoromethane sulfonate. 
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Monomer synthesis for retrosynthesis 2 
 In parallel to retrosynthesis 1, we investigated the generation of CS 
oligosaccharides through retrosynthesis 2. The GlcA monomer for retrosynthesis 2 was 
readily generated using monomer 39 from retrosynthesis 1 (Scheme 3.8). Coupling 
imidate 39 to allyl alcohol through activation with TMSOTf proceeded in 85% yield to 
afford 62. GlcA acceptor 44 was then formed by HF•pyridine cleavage of the TBS group. 
HF•pyridine was chosen over TBAF as β-elimination of the C-4 hydroxyl was observed 
when TBAF was employed.  
 
Scheme 3.8: Synthesis of the glucuronic acid monomer 44. Me = methyl, All = allyl, TBS = t-
butyldimethylsilyl, Bz = benzoyl, TMSOTf = trimethylsilyl trifluoromethane sulfonate, pyr = pyridine. 
 
The GalNAc monomer for retrosynthesis 2 is intermediate 43 from Scheme 3.6 
for the monomers of revised retrosynthesis 1.  
 
Generation of the disaccharide for retrosynthesis 2  
Sherry M. Tsai investigated coupling of donor 43 to acceptor 44 to form the key 
disaccharide in retrosynthesis 2. In the presence of N-iodosuccinimide and triflic acid, the 
coupling afforded the β-disaccharide 42 in 58% yield and the corresponding α-
disaccharide in 32% yield (Scheme 3.9). Separation of the anomeric mixture was tedious 
and only possible by preparative thin layer chromatography, making generation of 
multiple grams of this disaccharide difficult. In contrast, key disaccharide 61 of 
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retrosynthesis 1 is easily purified through standard large-scale silica gel chromatographic 
methods and can be readily synthesized on a multigram scale necessary to complete the 
synthesis of CS oligosaccharides.  For this reason, and the reduced yield compared to the 
previous coupling, we decided to continue the remaining synthesis utilizing 
retrosynthesis 1 in order to obtain multigram amounts of the disaccharide building block.  
 
 
Scheme 3.9: Formation of disaccharide 42. Me = methyl, All = allyl, pMP = p-methoxyphenyl, Bz = 
benzoyl, TCA = trichloroacetyl, PhMe = tolyl, TMSOTf = trimethylsilyl trifluoromethane sulfonate, NIS = 
N-iodosuccinimide, TfOH = triflic acid, TIPS = triisopropylsilyl. 
 
 
Tetrasaccharide 37 and Hexasaccharide 68 Formation   
To synthesize the fully-protected tetrasaccharide, both a disaccharide acceptor and 
donor were generated from 61. Activation of the disaccharide was envisioned to proceed 
through conversion of the C-1 allyl group to the lactol followed by formation of the 
trichloroacetimidate. Ross Mabon used GalNAc monomer 59 as a model system to test 
the isomerization of the olefin (Scheme 3.10). As summarized in Table 3.2, conventional 
methods such as Pd(PPh3)4,34 PdCl2,35 Wilkinson’s catalyst,36-38 NiCl2(dppp)2 in the 
presence of Et3Al,39 palladium on carbon,40 sodium borohydride in the presence of 
iodine,41 and [Ir(COD)(PMePh2)2]PF6,42 did not yield the desired isomerization. This is 
presumably due to interference by the C-2 trichloroacetamide, as the 2-acetamido 
derivative readily isomerized upon treatment with [Ir(COD)(PMePh2)2]PF6. Fortunately, 
treatment with Grubbs’ second-generation catalyst43 led to the desired product likely 
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through either hydride addition-elimination or π-allyl metal coordination and a 1,3-
hydride shift.44 Running the reaction in H2 accelerated the reaction time, but the reaction 
proceeded smoothly in the presence or absence of H2. 
 
Scheme 3.10: Isomerization of the GalNAc anomeric allyl group. pMP = p-methoxyphenyl, TCA = 
trichloroacetyl, TIPS = triisopropylsilyl. 
 
Table 3.2: Allyl isomerization conditions. dppp = 1,3-bis(diphenylphosphino)propane, COD = cis,cis-1,5-
cyclooctadiene, Ph = phenyl, AcOH = acetic acid, Et = ethyl, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, 
DABCO = 1,4-diazabicyclo[2.2.2]octane, DIPEA = N,N-diisopropylethylamine. 
 
Reaction of disaccharide 61 with Grubbs’ second-generation catalyst was 
followed by hydrolysis of the enol ether and conversion to the imidate under standard 
conditions to afford donor 64 (Scheme 3.11). Disaccharide 61 also provided access to 
glycosyl acceptor 65 via desilylation with HF•pyridine. Sherry M. Tsai attempted a 
similar olefin isomerization strategy with disaccharide 42 in order to advance the 
Catalyst Additives Solvent Yield
Pd(PPh3)4 AcOH MeOH no reaction
PdCl2 none MeOH no reaction
(Ph3P)3RhCl DBU EtOH/toluene/H2O no reaction
(Ph3P)3RhCl DABCO EtOH/benzene/H2O no reaction
(Ph3P)3RhCl DIPEA toluene no reaction
NiCl2(dppp)2 Et3Al, then H2O MeOH no reaction
10% Pd/C none MeOH no reaction
NaBH4  I2 MeOH no reaction
[Ir(COD)(PMePh2)2]PF6 H2 THF no reaction
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synthetic route of retrosynthesis 2, but the reaction was low-yielding, and further 
confirmed our decision to proceed forward with retrosynthesis 1. 
 
Scheme 3.11: Generation of the disaccharide donor 64 and acceptor 65. Me = methyl, All = allyl, pMP = 
p-methoxyphenyl, TBS = t-butyldimethylsilyl, Bz = benzoyl, TCA = trichloroacetyl, pyr = pyridine, DBU 
= 1,8-diazabicyclo[5.4.0]undec-7-ene, Ph = phenyl, Cy = cyclohexyl. 
 
Ross Mabon and Manish Rawat screened numerous conditions for the coupling of 
64 and 65 (Scheme 3.12 and Table 3.3) and ultimately, activation of the imidate with 
TMSOTf at low temperature provided the highest yield and excellent β-stereoselectivity. 
The lower yields for the glycosylation reaction compared to those observed for 
disaccharide generation were due to the ability of the imidate donor to readily hydrolyze 
(10 – 20%) and also to rearrange and generate an unreactive amide by-product 66 (20 – 
30%) (Scheme 3.13). Katie Saliba and Manish Rawat are currently investigating 
alternative coupling reactions. By increasing the bulk of the C-2 amine-protecting group, 
it should be possible to eliminate rearrangement of the imidate donor to an amide such as 
66. Replacement of the TCA group with phthaloyl (Phth) or a trichloroethoxycarbonyl 
(Troc) should increase yields and prevent formation of the unreactive amide species. 
Also, donors containing 4,6-benzylidene rings can have unexpected stereochemical 
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results during coupling reactions.45 While formation of the α-linked product was not a 
problem in our case, replacement of the p-methoxybenzylidene ring with two protecting 
groups might increase the reaction yield in future syntheses. With the current method, we 
were able to generate gram quantities of the key tetrasaccharide intermediate and proceed 
with the synthesis of CS tetrasaccharides. 
 
Scheme 3.12: Formation of tetrasaccharide 37. Me = methyl, All = allyl, pMP = p-methoxyphenyl, TBS = 
t-butyldimethylsilyl, Bz = benzoyl, TCA = trichloroacetyl. 
 
 
 
Table 3.3: Conditions attempted for generation of tetrasaccharide 37. TBSOTf = t-butyldimethylsilyl 
trifluoromethane sulfonate, TMSOTf = trimethylsilyl trifluoromethane sulfonate, Et =ethyl, Me =methyl. 
Scheme 3.13: Rearrangement of disaccharide donor 64. Me = methyl, pMP = p-methoxyphenyl, TBS = t-
butyldimethylsilyl, Bz = benzoyl, TCA = trichloroacetyl. 
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Activator (eq) Solvent Temp (oC) !-tetra
TMSOTf (0.2) CH2Cl2 -15 35%
TMSOTf (0.4) CH2Cl2 -15 22%
BF3!Et2O (0.2) CH2Cl2 -15 18%
ZnCl2!Et2O (0.6) CH2Cl2 -15 trace
TBSOTf (0.2) CH2Cl2 -15 40%
MeOTf (0.6) CH2Cl2 -15 trace
BF3!Et2O (0.4) CH2Cl2/toluene (1:1) -10 25%
TMSOTf (0.2) CH2Cl2/toluene (1:1) -10 28%
TMSOTf (0.2) THF -15 trace
TMSOTf (0.2) MeCN -15 trace
TBSOTf (0.3) CH2Cl2 0 34%
TMSOTf (0.2) CH2Cl2 -78 to -20 44%
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Hexasaccharide 68 was made in a manner similar to tetrasaccharide 37. First, 
acceptor 67 was formed through silyl deprotection of the TBS group of tetrasaccharide 37 
(Scheme 3.14), followed by coupling to donor 64 in an unoptimized yield of 25%. While 
we could generate fully-protected hexasaccharides, we decided to focus the synthesis on 
CS-E di- and tetrasaccharides first elucidate their neurobiological activities. In addition, 
we thought optimization of the final deprotection and sulfation steps and the purification 
of these highly-charged molecules would be more straightforward on the smaller 
carbohydrates. 
 
 
Scheme 3.14: Formation of tetrasaccharide acceptor 67 and hexasaccharide 68. Me = methyl, All = allyl, 
pMP = p-methoxyphenyl, TBS = t-butyldimethylsilyl, Bz = benzoyl, TCA = trichloroacetyl, pyr = pyridine, 
TMSOTf = trimethylsilyl trifluoromethane sulfonate. 
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Elaboration of protected di- and tetrasaccharides to form CS-E oligosaccharides 
 With fully-protected di- and tetrasaccharides, we embarked on the final 
deprotection and sulfation steps necessary to create CS-E oligosaccharides. Due to the 
relative ease of obtaining large amounts of disaccharide versus tetrasaccharide, we 
decided to optimize the end game on disaccharide 61. Two routes were designed due to 
an earlier report suggesting that simultaneous sulfation of the C-4 and C-6 hydroxyls 
might be challenging.9 One method involved regioselective ring-opening of the p-
methoxybenzylidene ring and sequential sulfation of the two hydroxyl groups (Scheme 
3.15), and the other concurrent sulfation of the C-4 and C-6 hydroxyls (Scheme 3.16). 
Both methods began with radical-mediated conversion of the N-trichloroacetyl group to 
N-acetyl with tributyltin hydride and AIBN provided disaccharide 69 in 85% yield.46 For 
the more stepwise approach, several conditions were attempted for the regioselective ring 
opening of 69, such as, TFA and sodium cyanoborohydride in DMF,26 HCl in ether and 
sodium cyanoborohydride in THF,47 and triethylsilane and triflic acid in CH2Cl2,48 and 
these conditions mostly led to hydrolysis of the p-methoxybenzylidene ring and only a 
small amount of the desired product. Ultimately, treatment with TFA and sodium 
cyanoborohydride in CH2Cl2 afforded the product in 82% yield. Sulfation of the C-4 
hydroxyl proceeded rapidly, and was followed by cleavage of the PMB group and C-6 
sulfation to afford the disulfated product 72. The target CS-E disaccharide 73 was 
obtained after silyl deprotection, saponification, and gel filtration chromatography using 
Sephadex G-10 resin and sodium ion-exchange chromatography with Sephadex C-25. In 
addition to generating the CS-E motif, this approach can also produce the CS-A 
disaccharide, a motif with only C-4 sulfation, if the second sulfation is not performed.  
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 The shorter, less stepwise approach also readily yielded the CS-E tetrasaccharide. 
Oxidative cleavage of the p-methoxybenzylidene ring of 69 was performed with DDQ,49 
as the anomeric allyl group, unlike primary allyl protecting groups, is not sensitive to 
DDQ cleavage.50 A small amount of TBS group loss was observed, most likely due to the 
acidity of the reaction. This was followed by sulfation of the resulting diol 74 with a large 
excess of sulfur trioxide-trimethylamine and cleavage of the silyl group and esters to 
afford 45 milligrams of 73. Biological studies require nanogram to microgram amounts 
of material to perform, so the route afforded more than enough material to study the 
activity of the carbohydrate. Since this method is shorter, we decided to proceed with it 
for the synthesis of the CS-E tetrasaccharide. 
 
 
 
Scheme 3.15: Stepwise synthesis of the CS-E disaccharide 73. Me = methyl, All = allyl, pMP = p-
methoxyphenyl, TBS = t-butyldimethylsilyl, Bz = benzoyl, TCA = trichloroacetyl, pyr = pyridine, TFA = 
trifluoroacetic acid, TMA = trimethylamine, Bu = butyl, PMB = p-methoxylbenzyl, DDQ = 2,3-dichloro-
5,6-dicyano-p-benzoquinone, AIBN = 2,2′-azobis(2-methylpropionitrile). 
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Scheme 3.16: Streamlined synthesis of the CS-E disaccharide 73. Me = methyl, All = allyl, pMP = p-
methoxyphenyl, TBS = t-butyldimethylsilyl, Bz = benzoyl, TCA = trichloroacetyl, pyr = pyridine, TMA = 
trimethylamine, Bu = butyl, DDQ = 2,3-dichloro-5,6-dicyano-p-benzoquinone, AIBN = 2,2′-azobis(2-
methylpropionitrile). 
 
The 1H NMR spectrum of the pure CS-E disaccharide is shown in Figure 3.2. The 
doublet for the anomeric GlcA proton is located at 4.46 ppm and has a J value of 7.8 Hz. 
The anomeric GalNAc proton is at 4.54 ppm and, due to a long-range splitting with an 
allyl group proton, it is not the expected doublet, but a multiplet. The C-4 and C-6 
protons of the GalNAc moiety are at 4.80 ppm and 4.05 – 4.02 ppm, respectively. The C-
4 proton can appear as a singlet or have an extremely small splitting value. 
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The synthesis of CS-E tetrasaccharide 79 began with generation of tetraol 76 
through radical mediated formation of the acetamide followed by DDQ cleavage of the p-
methoxybenzylidene acetal (Scheme 3.17). Unlike the reaction sequence for the 
formation of the CS-E disaccharide, the DDQ cleavage was performed in acetonitrile 
instead of methylene chloride. The change of solvents resulted in a shorter reaction time 
and eliminated loss of the TBS group. This tetraol is a key intermediate in the synthesis, 
as it can be used to generate several CS sulfation patterns (see Chapter 4). Elaboration of 
tetraol 76 through sulfation with sulfur trioxide-trimethylamine followed by deprotection 
of the silyl group and ester hydrolysis provided the desired CS-E tetrasaccharide 79 in 
54% yield over three steps (Scheme 3.18). Sequential LiOOH-NaOH treatment was used 
during the saponification reaction to minimize β-elimination at the GlcA C-4 position,51 
and the sulfation reaction was carefully monitored to ensure that the pH did not drop 
below pH 5.0.  The unsulfated tetrasaccharide 81 was generated from tetraol 76 through 
cleavage of the TBS group and the ester protecting groups in a three-step reaction series 
to yield the final product (Scheme 3.19). Both products were purified by Sephadex G-25 
gel filtration chromatography and the 1H NMR spectra of the pure products are shown in 
Figures 3.3 and 3.4. Complete assignments were done with proton decoupling 
experiments, and the C-4 GalNAc protons of 79 were located at 4.85 and 4.79 ppm, 
indicating the presence of C-4 sulfation. The doublets of doublets ranging from 3.77 – 
3.34 Hz are characteristic for the C-2, C-3 and C-4 protons of the GlcA monomers. With 
the three desired CS oligosaccharides synthesized, we began to investigate the biological 
activities of these molecules. 
 
 70 
 
Scheme 3.17: Generation of key tetrasaccharide tetraol 76. Me = methyl, All = allyl, pMP = p-
methoxyphenyl, TBS = t-butyldimethylsilyl, Bz = benzoyl, TCA = trichloroacetyl, Bu = butyl, DDQ = 2,3-
dichloro-5,6-dicyano-p-benzoquinone, AIBN = 2,2′-azobis(2-methylpropionitrile), DMA = N,N-
dimethylacetamide. 
 
Scheme 3.18: Generation of the CS-E tetrasaccharide 79. Me = methyl, All = allyl, TBS = t-
butyldimethylsilyl, Bz = benzoyl, pyr = pyridine, TMA = trimethylamine. 
 
 
 
 
Scheme 3.19: Generation of the unsulfated CS tetrasaccharide 81. Me = methyl, All = allyl, TBS = t-
butyldimethylsilyl, Bz = benzoyl, pyr = pyridine, TMA = trimethylamine. 
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Neurobiological evaluation of synthetic CS oligosaccharides 
To explore the abilities of 73, 79, and 81 to modulate neuronal growth, Cristal 
Gama cultured primary hippocampal neurons on poly-DL-ornithine-coated coverslips 
with or without each compound. After 48 h, the neurons were fixed, immunostained with 
anti-tau antibodies, and examined by confocal microscopy.52 Sulfated tetrasaccharide 79 
exhibited striking effects on neuronal morphology and growth (Figure 3.5). The number 
of neurites emanating from the cell body was enhanced, and the growth of the major 
extension was dramatically stimulated by 39.3 ± 3.6% relative to the poly-DL-ornithine 
control. In contrast, sulfated disaccharide 73 and unsulfated tetrasaccharide 81 had no 
significant effects on neuronal outgrowth. Notably, these studies are the first biological  
Figure 3.5: CS-E tetrasaccharide 79 stimulates the outgrowth of hippocampal neurons. Top: 
Immunofluorescence images of neurons 48 h after treatment with the indicated compound. Bottom: 
Statistical analysis of neurite length. *p<0.0001. 
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investigation using well-defined CS structures. We find that a specific sulfation motif, 
CS-E, promotes the outgrowth of neurons, and a tetrasaccharide was identified as a 
minimum structural motif with biological activity. Sulfation was a prerequisite for 
function, as the unsulfated tetrasaccharide failed to promote neurite outgrowth. 
 
Discussion 
 One of the primary goals of this work was to develop an efficient, modular 
synthesis of CS oligosaccharides. Starting from β-D-glucose pentaacetate and D-
galactose, we generated gram quantities of key disaccharide intermediate 61 and key 
tetrasaccharide intermediate 37. From these compounds, we were able to synthesize CS-E 
di- and tetrasaccharides and an unsulfated tetrasaccharide in milligram amounts, more 
than enough needed for biological studies that usually require nanogram to microgram 
amounts of material. The synthesis is versatile enough to create a library of CS 
oligosaccharides with differing sulfation patterns, as will be demonstrated in Chapter 4.  
The ability of the CS-E tetrasaccharide to stimulate the outgrowth of hippocampal 
neurons suggests that CS GAGs may be important in directing neuronal growth during 
the formation of the central nervous system. The observed effects of CS-E tetrasaccharide 
79 support previous studies implicating the CS-E motif in the growth and development of 
neurons. For example, CS-E is found on the protein appican, an isoform of the amyloid 
precursor protein that exhibits neurotrophic activity.53 CS-E is also associated with the 
proteoglycans syndecan-1 and -4, neuroglycan C and phosphacan.13,54 It is a motif 
enriched in the developing brain13,14 and may line axonal growth tracts to guide neurons 
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to their proper targets. Moreover, polysaccharides enriched in the CS-E motif have been 
shown to promote the outgrowth of neurons.10  
The discovery that CS small molecules can recapitulate the activities of larger 
polysaccharides was significant. As mentioned earlier, heparan sulfate 
glycosaminoglycan protein-binding motifs are generally tetra- and pentasaccharides,17,18 
but previous studies with CS-protein interactions have suggested binding motifs of 
octasaccharides or larger.19 The ability of the CS-E tetrasaccharide to stimulate growth 
indicates that CS binding proteins can recognize this small, synthetically accessible unit. 
It also validates our approach to use CS small molecules to understand the structural 
determinants and mechanisms of CS activity. 
Since the unsulfated CS tetrasaccharide had no activity with hippocampal 
neurons, sulfation must be crucial for the growth-promoting effects observed. It is 
unknown whether a specific orientation of the sulfate groups is necessary for activity, 
perhaps by engaging growth factors or other proteins. Through synthesis of a variety of 
sulfation patterns (see Chapter 4) and discovery of new CS protein binding partners with 
biochemical assays (see Chapter 4) and microarrays (see Chapter 5), we plan to elucidate 
the molecular determinants necessary for CS activity and establish whether CS acts 
through a “sulfation code” where proteins recognize distinct sulfation sequences. 
 
 
 
 
 
 76 
Conclusion 
In summary, we have developed a modular synthesis of CS oligosaccharides with 
defined sulfation patterns, synthesized di- and tetrasaccharides bearing the CS-E motif, 
and discovered that the CS-E tetrasaccharide stimulates the growth and differentiation of 
neurons. Our studies provide the first, direct investigations into the structure-activity 
relationships of CS using homogeneous, synthetic molecules.52 The findings indicate that 
the CS-E sulfation motif is likely an important structural determinant for CS activity in 
vivo, endowing CS polysaccharides with the ability to induce neuronal growth. CS small 
molecules should provide new chemical approaches to understand and manipulate 
neuronal growth and regeneration. 
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Experimental Procedures for Chapter 3 
 
General methods 
 
Unless stated otherwise, reactions were performed in flame-dried glassware under 
a nitrogen or an argon environment, using freshly-distilled solvents. Acetonitrile used for 
LC/MS was HPLC grade, and all aqueous solutions were made from nanopure water. All 
other commercially obtained reagents were used as received. Thin-layer chromatography 
(TLC) was performed using E. Merck silica gel 60 F254 precoated plates (0.25 mm). 
Visualization of the developed chromatogram was performed by fluorescence quenching, 
cerium ammonium molybdate stain, or ninhydrin stain, as necessary. ICN silica gel 
(particle size 0.032 - 0.063 mm) was used for flash chromatography. Gel filtration 
chromatography (Sephadex LH-20, G-10 and G-25 ultrafine) and ion exchange 
chromatography [Sephadex C-25 (Na+)] were used in order to achieve purification of 
the final products. 
1H NMR and proton decoupling spectra were recorded on Varian Mercury 300 
(300 MHz) and Varian Mercury 600 (600 MHz) spectrometers and the 1H NMR spectra 
are reported in parts per million (δ) relative to the residual solvent peak. Data for 1H are 
reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet), coupling constant in Hz, and integration. 13C NMR 
spectra were obtained on a Varian Mercury 300 (75 MHz) spectrometer and are reported 
in parts per million (δ) relative to the residual solvent peak. IR spectra were recorded on a 
Perkin Elmer Paragon 1000 spectrometer and are reported in terms of frequency of 
absorption (cm-1). A JASCO P-1010 was used to measure optical rotation. Mass spectra 
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were obtained from the Protein/Peptide MicroAnalytical Laboratory on a Perkin 
Elmer/Sciex API 365 triple quadrupole/electrospray tandem mass spectrometer and the 
Mass Spectrometry Facility at the California Institute of Technology on a JEOL JMS-
600H High Resolution Mass Spectrometer.  
 
Synthetic methods 
 
p-Methylphenyl 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-glucopyranoside (45).55 β-D-
Glucose pentaacetate (2.0 g, 5.1 mmol) was dissolved in CH2Cl2 (20 mL). p-Toluenethiol 
(0.7 g, 5.6 mmol) was added and the solution was cooled to -20 °C. SnCl4 in CH2Cl2 (1 
M in CH2Cl2, 3.6 mL, 3.6 mmol) was added dropwise over a period of 5 min, and the 
reaction was stirred at -20 °C for 3 h. The reaction was quenched with saturated aqueous 
NaHCO3 (10 mL) and warmed to rt. The organic layer was extracted, dried (MgSO4), 
filtered, and concentrated to afford a yellow-white solid. Purification by flash 
chromatography (25% → 30% EtOAc:hexanes) yielded 45 (2.14 g, 92%) as a white 
solid. The spectral data agreed with published data. Rf 0.57 (50% EtOAc:hexanes). 1H 
NMR (300 MHz, CDCl3): δ = 7.41 (d, J = 8.4 Hz, 2H, SC6H4Me), 7.12 (d, J = 8.1 Hz, 
2H, SC6H4Me), 5.20 (t, J = 9.45 Hz, 1H), 5.01 (t, J = 9.8 Hz, 1H), 4.92 (t, J = 9.6 Hz, 
1H), 4.63 (d, J = 10.2 Hz, 1H), 4.20 – 4.15 (m, 2H), 3.69 (dq, J = 3.0, 2.1 Hz, 1H), 2.34 
(s, 3H, SPhCH3), 2.08 (s, 3H, OC(O)CH3), 2.08 (s, 3H, OC(O)CH3), 2.01 (s, 3H, 
O
OAc
SPhMeAcO
AcO
OAc
45
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OC(O)CH3), 1.98 (s, 3H, OC(O)CH3). ESI MS: m/z: calcd for C21H26NaO9S: 477.12; 
found: 477.0 [M + Na]+. 
 
 
p-Methylphenyl-1-thio-β-D-glucopyranoside (46).55 45 (9.1 g, 20 mmol) was dissolved 
in MeOH (80 mL) and CH2Cl2 (40 mL). To this solution was added K2CO3 (2.8 g, 20 
mmol), and the reaction was stirred at rt until all of the starting material had been 
converted to the lowest Rf product. The reaction was acidified to pH 6 with Dowex 
50X8-200, filtered, and concentrated to afford 46 (5.6 g, 99%) as a white solid. The 
spectral data agreed with published data. Rf 0.11 (75% EtOAc:hexanes). 1H NMR (300 
MHz, CD3OD): δ = 7.26 (d, J = 8.4 Hz, 2H, SC6H4Me), 7.12 (d, J = 8.4 Hz, 2H, 
SC6H4Me), 4.57 (d, J = 9.6 Hz, 1H), 3.73 (dd, J = 11.9, 1.5 Hz, 1H), 3.58 (dd, J = 12.0, 
4.8 Hz, 1H), 3.34 – 3.21 (m, 3H), 3.11 (t, J = 9.5 Hz, 1H), 2.28 (s, 3H, SPhCH3). ESI 
MS: m/z: calcd for C13H18NaO5S: 309.08; found: 309.0 [M + Na]+. 
 
 
p-Methylphenyl 4,6-O-p-methoxybenzylidene-1-thio-β-D-glucopyranoside (47).  The 
procedure for the preparation of 47 was adapted from Ye et. al.56 p-Methylphenyl-1-thio-
β-D-glucopyranoside 46 (36.7 g, 128 mmol) was dissolved in DMF (30.0 mL) and 
CH3CN (300 mL).  p-Anisaldehyde dimethyl acetal (44.0 mL, 256 mmol) and DL-10-
 
O
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SPhMe
HO
HO
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HO
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camphorsulfonic acid (6.00 g, 25.6 mmol) were added.  The reaction was stirred at rt for 
12 h.  The reaction was quenched with TEA and concentrated to afford an orange syrup.  
The product was purified by flash chromatography (50% → 70% EtOAc:hexanes) to 
afford 47 (36 g, 70%) as a white crystalline solid.  Rf 0.26 (50% EtOAc:hexanes).  [α]D21 
= -38 (c = 1.0, CH2Cl2); IR (thin film on NaCl):  υ = 3447, 2869, 1614, 1518, 1250, 
1104, 1084, 1033 cm-1; 1H NMR (300 MHz, CDCl3):  δ = 7.43 (d, J = 8.1 Hz, 2H, 
SC6H4Me), 7.39 (d, J = 9.0 Hz, 2H, C6H4OMe), 7.15 (d, J = 7.5 Hz, 2H, SC6H4Me), 6.88 
(d, J = 9.0 Hz, 2H, C6H4OMe), 5.48 (s, 1H, MeOPhCH), 4.56 (d, J = 9.9 Hz, 1H, H-1), 
4.35 (dd, J = 3.9, 10.5 Hz, 1H), 3.85 – 3.72 (m, 5H), 3.50 – 3.39 (m, 3H), 2.80 (br s, 1H, 
OH), 2.67 (br s, 1H, OH), 2.36 (s, 3H, SPhCH3); 13C NMR (75 MHz, CDCl3):  δ = 138.8, 
138.2, 133.6, 132.1, 129.9, 129.4, 127.7, 113.7, 101.8, 88.7, 80.2, 74.5, 72.5, 70.5, 68.6, 
55.3, 21.2; HR-FAB MS:  m/z:  calcd for C21H25O6S:  405.1372; found:  405.1359 [M + 
H]+. 
 
p-Methylphenyl 2,3-di-O-benzoyl-4,6-O-p-methoxybenzylidene-1-thio-β-D-
glucopyranoside (48).  47  (23.7 g, 58.6 mmol) was dissolved in CH2Cl2 (670 mL).  In a 
separate flask, benzoyl chloride (17.0 mL, 146 mmol) was added dropwise to a solution 
of 4-(dimethylamino)pyridine (25.1 g, 205 mmol) in CH2Cl2 (225 mL).  The benzoyl 
chloride/4-(dimethylamino)pyridine solution was then slowly added to the solution of 47.  
An additional volume of CH2Cl2 (19.0 mL) was used to complete the transfer of solution.  
The reaction was allowed to stir at rt for 25 min and then quenched with saturated 
O
BzO
SPhMe
O
O
BzO
pMP
48
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aqueous NaHCO3.  The aqueous layer was extracted with CH2Cl2 (2x).  The combined 
organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to 
yield a pale yellow solid.  This crude material was washed with MeOH and 
crystallization from EtOAc afforded 48 as a white solid (31 g, 86%).  Rf 0.43 (30% 
EtOAc:hexanes).  [α]D22 = +25 (c = 0.42, CH2Cl2); IR (thin film on NaCl):  υ = 2934, 
1740, 1735, 1730, 1715, 1700, 1617, 1614, 1517, 1272, 1251, 1095 cm-1; 1H NMR (300 
MHz, CDCl3):  δ = 7.98 – 7.90 (m, 4H, ArH), 7.56 – 7.30 (m, 10H, ArH), 7.12 (d, J = 8.1 
Hz, 2H, SC6H4Me), 6.82 (d, J = 8.7 Hz, 2H, C6H4OMe), 5.76 (dd, J = 9.3, 9.3 Hz, 1H, H-
3), 5.49 (s, 1H, MeOPhCH), 5.43 (dd, J = 9.3, 9.3 Hz, 1H, H-2), 4.95 (d, J = 10.5 Hz, 
1H, H-1), 4.43 (dd, J = 4.5, 10.8 Hz, 1H), 3.90 – 3.82 (m, 2H), 3.76 – 3.67 (m, 4H), 2.35 
(s, 3H, SPhCH3); 13C NMR (75 MHz, CDCl3):  δ = 165.6, 165.2, 160.1, 138.8, 133.8, 
133.3, 133.1, 129.9, 129.8, 129.8, 129.4, 129.3, 129.2, 128.4, 128.3, 127.9, 127.5, 113.6, 
101.5, 87.3, 78.5, 73.4, 71.1, 71.0, 68.5, 55.3, 21.3; HR-FAB MS:  m/z:  calcd for 
C35H33O8S:  613.1896; found:  613.1879 [M + H]+.  
 
 
p-Methylphenyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-6-O-p-methoxybenzyl-
1-thio-β-D-glucopyranoside (49). The procedure for the regioselective ring opening of 
48 was adapted from Johansson et al.26 Typically, 48 (12.0 g, 19.6 mmol) was dissolved 
in DMF (261 mL) and sodium cyanoborohydride (6.15 g, 97.9 mmol), and activated 3Å 
powdered molecular sieves (12.0 g) were added to the solution. The reaction was cooled 
to 0 °C, and trifluoroacetic acid (15.3 mL, 196 mmol) was added dropwise to the 
O
OBz
SPhMeTBSO
BzO
OPMB
49
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reaction.  The reaction was stirred at 0 °C for 1 h, and then allowed to warm to rt.  After 
stirring at rt for 1 d, the reaction was filtered, diluted with CH2Cl2, and quenched with 
cold saturated aqueous NaHCO3.  The aqueous layer was separated and extracted with 
CH2Cl2 (2x).  The combined organic layers were washed with saturated aqueous NaHCO3 
(1x) and brine (1x), dried over Na2SO4, filtered, and concentrated.  To remove the 
remaining sodium cyanoborohydride, the crude material was re-dissolved in CH2Cl2 (250 
mL) and washed with brine (3x).  The organic layer was dried over Na2SO4, filtered, and 
concentrated to afford a white solid containing the desired alcohol. Rf 0.23 (30% 
EtOAc:hexanes). 
 
The crude alcohol was dissolved in CH2Cl2 (476 mL), TEA (8.20 mL, 58.6 mmol) was 
added, and the reaction cooled to 0 °C.  tert-Butyldimethylsilyl trifluoromethanesulfonate 
(11.2 mL, 48.8 mmol) was added dropwise to the reaction.  The reaction was allowed to 
warm to rt and stirred for 3 h.  It was then quenched with saturated aqueous NaHCO3 and 
diluted with CH2Cl2.  The aqueous layer was separated and extracted with CH2Cl2 (3x).  
The combined organic layers were washed with brine, dried over Na2SO4, filtered, and 
concentrated to afford an orange syrup.  The product was purified by flash 
chromatography (10% → 12% EtOAc:hexanes) to afford 49 (13 g, 94%) as a white foam.  
Rf 0.64 (30% EtOAc:hexanes).  [α]D22 = +36 (c = 1.0, CH2Cl2); IR (thin film on NaCl):  υ 
= 2953, 2928, 2856, 1734, 1612, 1602, 1513, 1451, 1272, 1251, 1106, 1089, 1069 cm-1; 
1H NMR (300 MHz, CDCl3):  δ = 7.92 – 7.87 (m, 4H, ArH), 7.51 – 7.27 (m, 10H, ArH), 
7.03 (d, J = 7.8 Hz, 2H, SC6H4Me), 6.94 – 6.91 (m, 2H, ArH), 5.59 (dd, J = 9.2, 9.2 Hz, 
1H, H-3), 5.30 (dd, J = 9.6, 9.6 Hz, 1H, H-2), 4.88 (d, J = 9.6 Hz, 1H, H-1), 4.60 (d, J = 
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11.4 Hz, 1H, CH2PhOMe), 4.51 (d, J = 11.7 Hz, 1H, CH2PhOMe), 4.01 (dd, J = 9.0, 9.0 
Hz, 1H, H-4), 3.84 – 3.64 (m, 6H, H-5, H-6, H-6, PhOCH3), 2.32 (s, 3H, SPhCH3), 0.74 
(s, 9H, (CH3)3CSi), 0.02 (s, 3H, CH3Si), -0.22 (s, 3H, CH3Si); 13C NMR (75 MHz, 
CDCl3):  δ = 165.9, 165.3, 159.2, 138.2, 133.4, 133.1, 133.0, 130.5, 129.9, 129.9, 129.8, 
129.7, 129.5, 129.3, 128.6, 128.4, 128.3, 113.9, 86.1, 81.0, 77.5, 73.3, 71.3, 69.4, 68.7, 
55.5, 25.9, 21.5, 18.1, -3.9, -4.4; HR-FAB MS:  m/z:  calcd for C41H47O8SSi:  727.2785; 
found:  727.2761 [M]+. 
 
p-Methylphenyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-1-thio-β-D-
glucopyranoside (50).  The preparation of 50 was performed by using a modified 
procedure from Zhang et al.49 In a flask covered with aluminum foil, 49 (13.2 g, 18.1 
mmol) was dissolved in CH2Cl2 (440 mL).  Water (23.0 mL) and 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (4.93 g, 21.7 mmol) were added.  The reaction was stirred at rt 
for 13 h.  The reaction was then quenched with aqueous NaHCO3, and water was added 
to dissolve all solids.  The aqueous layer was separated and extracted with CH2Cl2 (3x).  
The combined organic layers were washed with brine, dried over Na2SO4, filtered, and 
concentrated to yield a peach solid.  The product was purified by flash chromatography 
(40% CH2Cl2:hexanes → 100% CH2Cl2 → 10% EtOAc: CH2Cl2) to afford 50 (9.4 g, 
86%) as a white foam.  Rf 0.41 (20% EtOAc:hexanes).  [α]D22 = +62 (c = 1.0, CH2Cl2); 
IR (thin film on NaCl):  υ = 3442, 2951, 2928, 2856, 1733, 1602, 1493, 1451, 1273, 
1088, 1070, 1027 cm-1; 1H NMR (300 MHz, CDCl3):  δ = 7.92 – 7.88 (m, 4H, ArH), 7.52 
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– 7.45 (m, 2H, ArH), 7.38 – 7.32 (m, 6H, ArH), 7.12 (d, J = 8.1 Hz, 2H, SC6H4Me), 5.62 
(dd, J = 9.3, 9.3 Hz, 1H, H-3), 5.29 (dd, J = 9.6, 9.6 Hz, 1H, H-2), 4.93 (d, J = 9.9 Hz, 
1H, H-1), 4.02 – 3.92 (m, 2H), 3.81 – 3.73 (m, 1H), 3.60 – 3.55 (d, J = 11.4 Hz, 1H), 
2.35 (s, 3H, SPhCH3), 1.95 (br s, 1H, OH), 0.76 (s, 9H, (CH3)3CSi), 0.07 (s, 3H, CH3Si), 
-0.20 (s, 3H, CH3Si); 13C NMR (75 MHz, CDCl3):  δ = 165.9, 165.4, 138.7, 133.5, 133.3, 
133.2, 130.0, 130.0, 129.9, 129.8, 129.4, 128.5, 128.5, 128.4, 86.4, 81.1, 77.2, 71.3, 69.0, 
62.0, 25.9, 21.6, 18.2, -3.9, -4.3; HR-FAB MS:  m/z:  calcd for C33H41O7SSi:  609.2342; 
found:  609.2321 [M + H]+. 
 
p-Methylphenyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-1-thio-β-D-
glucopyranosyluronate (51). 50 (9.42 g, 15.5 mmol) was dissolved in DMF (115 mL).  
Pyridinium dichromate (34.9 g, 92.8 mmol) was added, and the reaction was stirred at rt 
for 3 d.  To precipitate and remove the chromium salts, EtOAc was added, and the 
reaction was filtered and concentrated (3x).  The remaining salts were removed by flash 
chromatography (100% EtOAc) to yield a white foam containing the desired carboxylic 
acid. Rf 0.17 (30% EtOAc:hexanes). 
 
The crude acid was placed in a round bottom flask that had no scratches, dissolved in 
CH2Cl2 (187 mL), put behind a blast shield, and cooled to 0 °C.  Using a glass pipet with 
a rounded tip, diazomethane57 (93.0 mL, 0.2 M in diethyl ether, 18.6 mmol) was slowly 
added.  After stirring at 0 °C for 1 h, a few drops of glacial acetic acid were added until 
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the reaction turned colorless.  The reaction mixture was then concentrated and purified by 
flash chromatography (10% → 15% EtOAc:hexanes) to yield 51 (6.0 g, 61%) as a white 
solid.  Rf 0.67 (30% EtOAc:hexanes).  [α]D22 = +54 (c = 1.0, CH2Cl2); IR (thin film on 
NaCl):  υ = 3443, 2953, 2928, 2857, 1732, 1601, 1493, 1451, 1437, 1269, 1085, 1069 
cm-1; 1H NMR (300 MHz, CDCl3):  δ = 7.90 – 7.86 (m, 4H, ArH), 7.52 – 7.46 (m, 2H, 
ArH), 7.38 – 7.31 (m, 6H, ArH), 7.10 (d, J = 8.1 Hz, 2H, SC6H4Me), 5.59 (dd, J = 9.3, 
9.3 Hz, 1H, H-3), 5.30 (dd, J = 9.6, 9.6 Hz, 1H, H-2), 4.90 (d, J = 9.9 Hz, 1H, H-1), 4.26 
(dd, J = 9.2, 9.2 Hz, 1H, H-4), 4.08 (d, J = 8.7 Hz, 1H, H-5), 3.82 (s, 3H, CO2CH3), 2.33 
(s, 3H, SPhCH3), 0.71 (s, 9H, (CH3)3CSi), -0.05 (s, 3H, CH3Si), -0.22 (s, 3H, CH3Si); 13C 
NMR (75 MHz, CDCl3):  δ = 168.3, 168.3, 165.9, 165.3, 138.8, 133.7, 133.4, 133.4, 
130.0, 130.0, 130.0, 129.7, 129.5, 128.5, 128.2, 87.2, 80.4, 76.6, 70.9, 70.7, 52.8, 25.6, 
21.4, 18.0, -4.2, -4.9; HR-FAB MS:  m/z:  calcd for C34H41O8SSi:  637.2291; found:  
637.2284 [M + H]+. 
 
Methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-α /β-D-glucopyranosyluronate 
(52). 51  (6.09 g, 9.56 mmol) was dissolved in CH2Cl2 (67.0 mL) and water (0.70 mL) 
was added.  A solution was prepared containing 2.93 g N-iodosuccinimide, 127 mL 
CH2Cl2, 3.10 mL THF, and 78.0 µL triflic acid.  130 mL of this solution was slowly 
added to the reaction mixture via an additional funnel.  The reaction stirred at rt for 5.5 h.  
It was then quenched with 1 M Na2S2O3 and diluted with CH2Cl2.  The aqueous layer was 
separated and extracted with CH2Cl2 (3x).  The combined organic layers were washed 
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with brine, dried over Na2SO4, filtered, and concentrated.  The product was purified by 
flash chromatography (15% → 30% EtOAc:hexanes) to afford 52 (4.3 g, 84%, 6.2β:1α) 
as a white foam.  Rf 0.30, 0.36 (30% EtOAc:hexanes).  [α]D22 = +99 (c = 1.0, CH2Cl2); IR 
(thin film on NaCl):  υ = 3455, 2954, 2930, 2857, 1732, 1602, 1451, 1275, 1110, 1070 
cm-1; 1H NMR (300 MHz, CDCl3):  δ = 8.18 – 8.07 (m, 4H, ArH), 7.99 – 7.90 (m, 4H, 
ArH), 7.69 – 7.31 (m, 12H, ArH), 6.55 (d, J = 3.3 Hz, 1H, H-1, α), 5.94 (dd, J = 9.0, 9.9 
Hz, 1H), 5.72 – 5.58 (m, 3H), 5.22 – 5.14 (m, 2H), 4.62 (d, J = 9.3 Hz, 1H, H-1, β), 4.40 
– 4.27 (m, 2H), 4.13 (d, J = 9.3 Hz, 1H), 3.81 (s, 3H, CO2CH3), 3.80 (s, 3H, CO2CH3), 
3.46 (d, J = 3.6 Hz, 1H), 0.76 (s, 9H, (CH3)3CSi), 0.75 (s, 9H, (CH3)3CSi), -0.01 (s, 6H, 
CH3Si), -0.15 (s, 6H, CH3Si); 13C NMR (75 MHz, CDCl3):  δ = 169.8, 169.0, 168.7, 
167.4, 167.3, 166.1, 165.9, 165.0, 134.2, 133.9, 133.8, 133.6, 133.4, 130.3, 130.2, 130.1, 
129.9, 129.1, 129.0, 128.8, 128.6, 128.6, 92.2, 90.9, 75.8, 74.8, 74.6, 74.6, 72.5, 72.4, 
72.3, 71.1, 70.5, 70.2, 52.9, 25.7, 25.6, 18.0, -4.2, -4.9; HR-FAB MS:  m/z:  calcd for 
C27H35O9Si:  531.2050; found:  531.2041 [M + H]+. 
 
  
Methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-α-D-glucopyranosyluronate 
trichloroacetimidate (39). The preparation of 39 was performed by using a procedure 
modified from Driguez et al.58 52 (3.32 g, 6.26 mmol) was azeotroped by co-evaporated 
with toluene (2 x 20 mL) and dried under vacuum overnight.  It was then dissolved in 
CH2Cl2 (49.0 mL).  Trichloroacetonitrile (3.80 mL, 37.5 mmol) and Cs2CO3 (0.820 g, 
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2.50 mmol) were added.  After stirring at rt for 4 h, additional trichloroacetonitrile (0.950 
mL, 9.50 mmol) and Cs2CO3 (0.200 g, 0.600 mmol) were added.  The reaction was 
allowed to stir an additional 4 h and then concentrated.  The product was purified by flash 
chromatography (10% EtOAc:hexanes + 0.1% TEA) to afford 39 (3.8 g, 89%), with a 
trace amount of the β anomer, as a white foam.  The compound was stored at –20 °C and 
under Ar to prevent hydrolysis and rearrangement of the imidate to an amide by-product, 
and was stable under these conditions. Rf 0.57 (30% EtOAc:hexanes).  [α]D22 = +99 (c = 
1.0, CH2Cl2); IR (thin film on NaCl):  υ = 3343, 2954, 2930, 2858, 1757, 1735, 1676, 
1602, 1451, 1315, 1267, 1111, 1095 cm-1; 1H NMR (300 MHz, CDCl3):  δ = 8.60 (s, 1H, 
C=NH), 7.96 – 7.87 (m, 4H, ArH), 7.53 – 7.29 (m, 6H, ArH), 6.74 (d, J = 3.9 Hz, 1H, H-
1), 5.99 (dd, J = 9.0, 10.2 Hz, 1H, H-3), 5.43 (dd, J = 3.9, 10.5 Hz, 1H, H-2), 4.51 (d, J = 
9.3 Hz, 1H, H-5), 4.38 (dd, J = 9.3, 9.3 Hz, 1H, H-4), 3.81 (s, 3H, CO2CH3), 0.74 (s, 9H, 
(CH3)3CSi), -0.01 (s, 3H, CH3Si), -0.15 (s, 3H, CH3Si); 13C NMR (75 MHz, CDCl3):  δ = 
168.7, 165.7, 165.7, 160.8, 133.7, 133.5, 130.1, 129.9, 129.7, 128.7, 128.6, 128.6, 93.4, 
74.6, 72.5, 70.9, 70.8, 53.0, 53.0, 25.7, 18.0, -4.1, -4.9; ESI MS:  m/z:  calcd for 
C29H34Cl3NNaO9Si:  696.1; found:  696.2 [M +  Na]+. 
 
Allyl methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate (62). 39 (100 mg, 0.15 mmol) was azeotroped by co-evaporation 
with toluene (3x) and placed under high vacuum to dry for 3 h. CH2Cl2 (1.2 mL) and 4Å 
powdered molecular sieves were then added and stirred. To this solution were added allyl 
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alcohol (100 µL, 1.48 mmol) and trimethylsilyl trifluoromethanesulfonate (1 N in 
toluene, 30 µL, 0.03 mmol). After stirring at rt for 12 h, the reaction was quenched with 
TEA, filtered through Celite, and concentrated to afford a yellow syrup. Purification of 
this oil by flash chromatography (30% EtOAc:hexanes) afforded 62 (72 mg, 85%) as a 
white solid. Rf 0.78 (4.5:4.5:1 CH2Cl2:hexanes:EtOAc). 1H NMR (300 MHz, CDCl3): δ = 
7.92 – 7.87 (m, 4H, ArH), 7.51 – 7.45 (m, 2H, ArH), 7.37 – 7.31 (m, 4H, ArH), 5.81 – 
5.68 (m, 1H, OCH2CH=CH2), 5.59 (dd, J = 9.3, 9.3 Hz, 1H, H-2), 5.38 (dd, J = 8.6, 8.6 
Hz, 1H, H-3), 5.21 (dd, J = 1.5, 17.4 Hz, 1H, OCH2CH=CH2), 5.11 (dd, J = 1.6, 10.4 Hz, 
1H, OCH2CH=CH2), 4.80 (d, J = 7.8 Hz, 1H, H-1), 4.38 – 4.29 (m, 2H, H-4, 
OCH2CH=CH2), 4.13 – 4.06 (m, 2H, H-5, OCH2CH=CH2), 3.81 (s, 3H, CO2CH3), 0.73 
(s, 9H, (CH3)3CSi), -0.03 (s, 3H, CH3Si), -0.20 (s, 3H, CH3Si). ESI MS: m/z: calcd for 
C30H39O9Si: 571.7; found 571.7 [M + H]+. 
 
Allyl methyl 2,3-di-O-benzoyl-β-D-glucopyranosyluronate (44). To a solution of 62 
(72 mg, 0.13 mmol) in dry THF (01.8 mL) and pyridine (1.8 mL) cooled to 0 ˚C was 
added HF•pyridine (0.64 mL). The reaction mixture was warmed to rt and stirred for 12 
h. The mixture was then diluted with EtOAc and washed with 10% aqueous CuSO4. The 
aqueous phase was extracted with EtOAc (3x) and the combined organics washed with 
saturated aqueous NaHCO3 and dried over MgSO4. The solvent was removed in vacuo to 
afford a white solid. Purification of this solid by flash chromatography (40 
EtOAc:hexanes) afforded 44 (42 mg, 73%) as a white solid. Rf  0.25 (30% 
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EtOAc:hexanes). 1H NMR (300 MHz, CDCl3): δ = 7.98 – 7.94 (m, 4H, ArH), 7.53 – 7.48 
(m, 2H, ArH), 7.40 – 7.34 (m, 4H, ArH), 5.84 – 5.71 (m, 1H, OCH2CH=CH2), 5.54 (dd, J 
= 8.7, 9.9 Hz, 1H, H-2), 5.47 (dd, J = 7.8, 9.3 Hz, 1H, H-3), 5.24 (dd, J = 1.6, 17.6 Hz, 
1H, OCH2CH=CH2), 5.14 (dd, J = 0.9, 10.5 Hz, 1H, OCH2CH=CH2), 4.81 (d, J = 7.2 Hz, 
1H, H-1), 4.38 (dd, J = 4.5, 13.2 Hz, 1H, OCH2CH=CH2), 4.25 – 4.07 (m, 3H, H-4, H-5, 
OCH2CH=CH2), 3.86 (s, 3H, CO2CH3), 3.38 (d, J = 3.6 Hz, 1H, OH). ESI MS: m/z: calcd 
for C30H39O9Si: 457.4; found 457.5 [M + H]+. 
 
Tri-O-acetylgalactal (53).30 Tri-O-acetylgalactal was prepared in the manner of 
Kozikowski et al.30 A stirred suspension of D-galactose (0.071 g, 0.39 mmol) in acetic 
anhydride (40 mL) was treated dropwise with 70% perchloric acid (0.250 mL). 
Additional D-galactose (9.97 g, 55.3 mmol) was added in small portions over a period of 
45 min. The reaction mixture was maintained at 40 °C during the addition by periodic 
cooling in an ice bath. When the addition of D-galactose was complete, the solution was 
cooled to 23 oC and 30% HBr in acetic acid (44 mL) was added. The reaction was stirred 
for 1.5 h. The reaction mixture was then diluted with CH2Cl2 (93 mL), washed with cold 
water (2 x 30 mL), and washed with cold 5% aqueous NaHCO3 (2 x 30 mL). The organic 
layer was dried (Na2SO4), filtered, and concentrated to afford a yellow syrup that was 
immediately used in the next step. The syrup was added over a period of 1 h to Zn° (25.2 
g, 386 mmol) in 50 % aqueous acetic acid (160 mL) with mechanical stirring while 
keeping the temperature at –15 °C to –20 °C. After the addition, the reaction was stirred 
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at 0 °C for 1 h. The reaction mixture was then filtered through celite and diluted with 
CH2Cl2 (100 mL). It was extracted with ice water (3 x 35 mL), and the organic extract 
was washed with cold saturated aqueous NaHCO3 (2 x 30 mL) and with brine (30 mL). 
The solution was dried (Na2SO4), filtered, and concentrated to afford a white syrup. This 
was purified by flash chromatography (30% EtOAc:hexanes) to afford tri-O-
acetylgalactal 53 (7.6 g, 51%) as a white syrup. The work-up procedures for this reaction 
series must be carefully followed and the ratios of organic layer to water layer exactly 
measured. The spectral data agreed with published data. Rf 0.59 (50% EtOAc:hexanes). 
1HNMR (300 MHz, CDCl3): δ = 6.45 (dd, J = 6.3, 1.8 Hz, 1H), 5.55 – 5.54 (m, 1H), 5.43 
– 5.41 (m, 1H), 4.72 (dq, J = 2.1, 1.5 Hz, 1H), 4.29 – 4.21 (m, 3H), 2.12 (s, 3H, 
OC(O)CH3), 2.08 (s, 3H, OC(O)CH3), 2.02 (s, 3H, OC(O)CH3). ESI MS: m/z: calcd for 
C12H16NaO7: 295.08; found: 295.2 [M + Na]+.  
 
 
Nitro 2-deoxy-2-azido-3,4,6-tri-O-acetyl-α ,β-D-galactopyranoside (54).31 
Azidonitration was performed in the manner of Lemieux et al.31 Tri-O-acetylgalactal 53 
(1.5 g, 5.5 mmol) was dissolved in CH3CN (20 mL) and this was added to a dry mix of 
NaN3 (0.54 g, 8.27 mmol) and cerium ammonium nitrate (9.1 g, 16.5 mmol) under N2 at 
–15 °C (dry ice/ethylene glycol). The reaction was stirred at –15 °C for 20 h. After that, 
cold diethyl ether (25 mL) and water (25 mL) were added. The organic layer was 
separated and washed with ice-cold water (3 x 25 mL), dried (Na2SO4), filtered, and 
concentrated to afford a white-yellow syrup. The product was purified by flash 
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chromatography (40% EtOAc:hexanes) to afford nitrate 54 (1.0 g, 48%, 1:1 α/β) as a 
white syrup. The work-up procedures for this reaction series must be carefully followed 
and the ratios of organic layer to water layer exactly measured. The spectral data agreed 
with published data. Rf 0.80 (50% EtOAc:hexanes). IR (thin film on NaCl) νmax: 2124 
(N3), 1753 (OAc), 1668 (ONO2) cm-1; 1H NMR (300 MHz, CDCl3): δ = 6.34 (d, J = 3.9 
Hz, 1H, α-isomer), 5.57 (d, J = 9.0 Hz, 1H, β-isomer), 5.50 (dd, J = 3.3, 1.5 Hz, 1H, α-
isomer), 5.39 (dd, J = 3.3, 0.9 Hz, 1H, β-isomer), 5.25 (dd, J = 11.3, 3.3 Hz, 1H, α-
isomer), 4.95 (dd, J = 10.2, 3.3 Hz, 1H, β-isomer), 4.15 – 4.04 (m, 4H, α-isomer), 4.15 – 
4.04 (m, 3H, β-isomer), 3.82 (q, J = 9.6, 8.7 Hz, 1H, β-isomer), 2.17 (s, 3H, OC(O)CH3, 
α-isomer), 2.17 (s, 3H, OC(O)CH3, β-isomer), 2.08 (s, 3H, OC(O)CH3, β-isomer), 2.07 
(s, 3H, OC(O)CH3, α-isomer), 2.04 (s, 3H, OC(O)CH3, β-isomer), 2.03 (s, 3H,  
OC(O)CH3, α-isomer). ESI MS: m/z: calcd for C12H16N4NaO10: 399.08; found: 399.0 [M 
+ Na]+. 
 
Acetyl 2-Deoxy-2-azido-3,4,6-tri-O-acetyl-α ,β-D-galactopyranoside (55).31 Nitrate 54 
(1.5 g, 4 mmol) was dissolved in acetic acid (9.4 mL) and to this mixture was added 
anhydrous sodium acetate (0.65 g). The reaction was heated to 100 °C for 1.5 h. It was 
then cooled to rt and diluted with CH2Cl2 (50 mL). The organic layer was treated with ice 
water (40 mL), saturated aqueous NaHCO3 (2 x 20 mL), and water (25 mL). The organic 
layer was dried (Na2SO4), filtered, and concentrated to afford a yellow syrup that later 
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crystallized to afford white, crystalline acetate 55 (1.41 g, 95%, 1:1 α/β). The spectral 
data agreed with published data. Rf 0.70 (50% EtOAc:hexanes). 1H NMR (300 MHz, 
CDCl3): δ = 6.32 (d, J = 3.9 Hz, 1H, α-isomer), 5.54 (d, J = 8.7 Hz, 1H, β-isomer), 5.47 
(dd, J = 3.0, 1.2 Hz, 1H, α-isomer), 5.40 (dd, J = 3.45, 1.2 Hz, 1H, β-isomer), 5.31 (dd, J 
= 10.8, 3.3 Hz, 1H, α-isomer), 4.89 (dd, J = 10.8, 3.3 Hz, 1H, β-isomer), 4.15 – 4.04 (m, 
3H, α-isomer), 4.15 – 4.04 (m, 3H, β-isomer), 3.93 (q, J = 11.1, 3.6 Hz, 1H, α-isomer), 
3.84 (q, J = 9.8, 8.7 Hz, 1H, β-isomer), 2.20 (s, 3H,  OC(O)CH3, α-isomer), 2.17 (s, 3H,  
OC(O)CH3, β-isomer), 2.16 (s, 3H, OC(O)CH3, β-isomer), 2.09 (s, 3H, OC(O)CH3, α-
isomer), 2.07 (s, 3H, OC(O)CH3, β-isomer), 2.06 (s, 3H, OC(O)CH3, α-isomer), 2.04 (s, 
3H,  OC(O)CH3, α-isomer), 2.03 (s, 3H, OC(O)CH3, β-isomer). ESI MS: m/z: calcd for 
C14H19N3O9: 396.10; found: 396.0 [M + Na]+. 
 
1,3,4,6-tetra-O-acetyl-2-deoxy-2-trichloroacetamido-α /β-D-galactopyranoside (56). 
To 1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-D-galactopyranoside 55 (0.100 g, 0.268 mmol) 
in THF (5.00 mL) was added p-tosic acid monohydrate (0.051 g, 0.27 mmol) followed by 
Pd/C (0.017 g, 6 mol%). The reaction was placed under an atmosphere of H2 and stirred 
at rt for 18 h. The Pd/C was removed by filtration through Celite and the solvent 
concentrated to afford an anomeric mixture of crude amines as a pale yellow foam. The 
crude mixture was used for the next step without purification.  
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To a solution of crude amines in THF (5 mL) cooled to 0 °C, was added 
trichloroacetylchloride (0.22 g, 0.13 mL, 1.2 mmol) followed by TEA (0.25 mL, 1.8 
mmol). After stirring at 0 °C for 15 min, the reaction mixture was quenched with 
saturated aqueous NaHCO3. The water layer was separated and extracted with CH2Cl2 
(2x), the combined organics dried over Na2SO4, and the solvent removed in vacuo to 
afford a yellow oil. Purification of this oil by flash chromatography (30% → 40% 
EtOAc:hexanes) afforded 56 (0.099 g, 75%, 3.1β:1α) as a white solid Rf 0.61 and 0.53 
(60% EtOAc:hexanes). 1H NMR (300 MHz, CDCl3): δ = 6.73 (d, J = 9.0 Hz, 2H, 
NHTCA), 6.30 (d, J = 3.9 Hz, 1H, H-1, α), 5.45 (d, J = 3.3 Hz, 3H), 5.32 (dd, J = 3.5 Hz 
and 11.3 Hz, 2H), 4.58 (m, 2H), 4.26 (dd, J = 6.6 Hz, 6.6 Hz, 2H), 4.20 – 4.03 (m, 4H), 
2.17 (s, 6H, OC(O)CH3), 2.15 (s, 6H, OC(O)CH3), 2.02 (s, 6H, OC(O)CH3), 2.00 (s, 6H, 
OC(O)CH3); 13C NMR (75 MHz, CDCl3): δ = 171.2, 170.5, 170.2, 168.7, 162.2, 90.5, 
69.0, 67.8, 66.8, 61.5, 49.6, 21.2, 21.0; HR-FAB MS: m/z: calcd for C16H19Cl3NO10: 
490.0075; found: 490.0073 [M - H]-. 
 
p-Methylphenyl 2-deoxy-2-trichloroacetamido-3,4,6-tri-O-acetyl-1-thio-β-D-
galactopyranoside (57). To a solution of 56 (0.050 g, 0.10 mmol) in dry CH2Cl2 (0.35 
mL) was added p-toluenethiol (0.042 g, 0.34 mmol) followed by BF3•OEt2 (0.043 g, 
38 µL, 0.30 mmol) and the reaction mixture stirred at rt. After 2 h, a further addition of p-
toluenethiol (0.012 g, 0.10 mmol) and BF3•OEt2 (0.014 g, 13 µL, 0.10 mmol) was made, 
O
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followed by stirring at rt for 1 h. The reaction mixture was quenched with saturated 
aqueous NaHCO3 and the organic phase washed twice with saturated aqueous NaHCO3 
and water. The aqueous layers were back-extracted with CH2Cl2 (3x), and the combined 
organics washed with brine and dried over Na2SO4 to afford an amber oil. Purification of 
this oil by flash chromatography (20% → 25% EtOAc:hexanes) afforded 57 (0.044 g, 
80%) as a white solid. Rf 0.51 (50% EtOAc:hexanes). [α]D23 = -2.4 (c = 0.5, CH2Cl2); IR 
(thin film on NaCl):  υ = 3450, 1752, 1655, 1529, 1493, 1370, 1230, 1082, 1045 cm-1; 1H 
NMR (300 MHz, CDCl3): δ = 7.42 (d, J = 8.3 Hz, 2H, SC6H4Me), 7.12 (d, J = 8.3 Hz, 
2H, SC6H4Me), 6.77 (d, J = 8.7 Hz, 1H, NHTCA), 5.39 (d, J = 3.3 Hz, 1H, H-4), 5.29 
(dd, J = 3.3, 11.1 Hz, 1H, H-3), 4.89 (d, J = 10.5 Hz, 1H, H-1), 4.22 – 4.09 (m, 3H, H-2, 
H-6), 3.94 (dd, J = 6.6, 6.6 Hz, 1H, H-5), 2.34 (s, 3H, SPhCH3), 2.13 (s, 3H, OC(O)CH3), 
2.04 (s, 3H, OC(O)CH3), 1.97 (s, 3H, OC(O)CH3); 13C NMR (75 MHz, CDCl3): δ = 
170.6, 170.5, 170.2, 161.9, 138.8, 133.5, 129.9, 128.5, 92.5, 87.2, 74.9, 70.9, 67.1, 62.0, 
51.7, 21.6, 21.1, 21.0, 20.9; HR-FAB MS: m/z: calcd for C21H25Cl3NO8S: 556.0367; 
found: 556.0369 [M + H]+. 
 
 p-Methylphenyl 2-deoxy-2-trichloroacetamido-3-O-triisopropylsilyl-4,6-O-p-
methoxybenzylidene-1-thio-β-D-galactopyranoside (58).  A solution of 57 (17.9 g, 
0.0320 mol) in dry CH2Cl2 (85 mL) and MeOH (435 mL) was stirred at rt for 30 min and 
NaOMe (25 wt% solution in MeOH, 0.52 g, 2.1 mL, 9.6 mmol) was then added. After 
stirring for 2 h, Dowex 50X8-200 was added and stirring continued for an additional 30 
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min. The Dowex beads were removed by filtration and the solvent removed in vacuo to 
afford 58 (13.5 g, 98%) as a yellow solid. This compound was suitable for the next step 
without purification. Rf 0.11 (75% EtOAc:hexanes). 1H NMR (300 MHz, CD3OD): δ = 
7.42 (d, J = 8.3 Hz, 2H, SC6H4Me), 7.09 (d, J = 8.3 Hz, 2H, SC6H4Me), 4.91 (d, J = 10.5 
Hz, 1H, H-1), 4.05 (dd, J = 8.7, 9.1 Hz, 1H, H-2), 3.87 (d, J = 1.8 Hz, 1H, H-6), 3.81 – 
3.68 (m, 3H, H-3, H-4, H-6), 3.55 (dd, J = 6.6, 6.6 Hz, 1H, H-5), 2.34 (s, 3H, SPhCH3). 
 
p-Methylphenyl 2-deoxy-2-trichloroacetamido-4,6-O-p-methoxybenzylidene-1-thio-
β-D-galactopyranoside (40). To a solution of 58 (13.5 g, 0.0310 mol) in acetonitrile 
(800 mL, minimum amount) was added p-anisaldehyde dimethyl acetal (11 g, 12 mL, 
0.063 mol) and DL-10-camphorsulfonic acid (10 mol%) and the mixture stirred at rt for 
12 h. The reaction mixture was quenched with TEA and the solvent concentrated to 
afford a yellow solid. Purification of this solid by flash chromatography (40% → 80% 
EtOAc:hexanes) afforded 40 (13 g, 76%) as a white solid. Rf 0.25 (50% EtOAc:hexanes). 
[α]D24 = -14.6 (c = 0.5, CH2Cl2); IR (thin film on NaCl):  υ = 3333, 1687, 1615, 1519, 
1492, 1403, 1364, 1301, 1248, 1167, 1095, 1055 cm-1; 1H NMR (300 MHz, CDCl3): δ = 
7.55 (d, J = 8.4 Hz, 2H, SC6H4Me), 7.34 (d, J = 8.7 Hz, 2H, C6H4OMe), 7.12 (d, J =  8.4 
Hz, 2H, SC6H4Me), 6.88 (d, J = 8.7 Hz, 2H, C6H4OMe), 6.81 (d, J = 7.5 Hz, 1H, 
NHTCA), 5.48 (s, 1H, MeOPhCH), 5.03 (d, J = 9.9 Hz, 1H, H-1), 4.37 (dd, J = 1.5, 12.6 
Hz, 1H, H-6), 4.20 – 4.10 (m, 2H, H-3, H-4), 4.01 (dd, J = 1.5, 12.6 Hz, 1H, H-6), 3.83 
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(s, 3H, PhOCH3), 3.69 (m, 1H, H-2), 3.57 (s, 1H, H-5), 2.58 (d, J = 10.5 Hz, 1H, OH), 
2.37 (s, 3H, SPhCH3);  13C NMR, (75 MHz, CDCl3): δ = 162.1, 160.5, 139.0, 134.7, 
130.2, 130.0, 128.1, 126.9, 113.8, 101.4, 84.0, 75.2, 70.7, 70.3, 69.5, 55.7, 54.4, 21.7; 
HR-FAB MS: m/z: calcd for C23H25Cl3NO6S: 548.0469; found: 548.0448 [M + H]+. 
 
  
p-Methylphenyl 2-deoxy-2-trichloroacetamido-3-O-triisopropylsilyl-4,6-O-p-
methoxybenzylidene-β-D-galactopyranoside (43). To a solution of 40 (5.6 g, 0.010 
mol) in dry DMF (50 mL) at rt was added triisopropylsilyl chloride (6.3 g, 0.033 mol, 7.0 
mL), imidazole (2.7 g, 0.040 mol) and 4-(dimethylamino)pyridine (0.49 g, 40 mol%). 
The reaction mixture was stirred for 4 h, whereupon further addition of triisopropylsilyl 
chloride (3.2 g, 3.5 mL, 0.016 mol), imidazole (1.4 g, 0.020 mol) and 4-
(dimethylamino)pyridine (0.25 g, 20 mol%) were added. The reaction mixture was stirred 
for 12 h and quenched with saturated aqueous NaHCO3. The aqueous layer was extracted 
with EtOAc (3x) and the combined organics washed with brine and dried over MgSO4 to 
afford a pale yellow oil. Purification of this oil by flash chromatography (10% → 15% 
EtOAc:hexanes) afforded 43 (5.3 g, 75%) as a white solid. Rf 0.57 (30% 
EtOAc:hexanes). [α]D23 = +5.9 (c = 0.5, CH2Cl2); IR (thin film on NaCl):  υ = 2943, 
2866, 1705, 1616, 1519, 1493, 1464, 1365, 1249, 1170, 1139, 1083, 1051 cm-1; 1H NMR 
(300 MHz, CDCl3): δ = 7.57 (d, J = 8.1 Hz, 2H, SC6H4Me), 7.38 (d, J = 8.7 Hz, 2H, 
C6H4OMe), 7.07 (d, J = 8.1 Hz, 2H, SC6H4Me), 6.87 (d, J = 8.7 Hz, 2H, C6H4OMe), 
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6.85 (m, 1H, NHTCA), 5.45 (s, 1H, MeOPhCH), 5.39 (d, J = 9.9 Hz, 1H, H-1), 4.62 (dd, 
J = 3.2, 10.2 Hz, 1H, H-3), 4.37 (dd, J = 1.7, 12.5 Hz, 1H, H-6), 4.13 (d, J = 3.2 Hz, 1H, 
H-4), 4.01 (dd, J = 1.7, 12.5 Hz, 1H, H-6), 3.83 (s, 3H, PhOCH3), 3.71 (m, 1H, H-2), 
3.55 (s, 1H, H-5), 2.34 (s, 3H, SPhCH3), 1.01 (s, 21H, [(CH3)2CH]3),  13C NMR (75 
MHz, CDCl3): δ = 161.3, 160.1, 138.5, 134.1, 130.7, 130.0, 128.0, 127.9, 113.5, 101.1, 
83.4, 76.7, 71.0, 70.3, 69.7, 55.6, 54.8, 21.7, 18.5, 18.4, 13.1; HR-FAB MS: m/z: calcd 
for C32H45Cl3NO6SSi: 704.1621; found: 704.1623 [M + H]+. 
 
Allyl 2-deoxy-2-trichloroacetamido-3-O-triisopropylsilyl-4,6-O-p-
methoxybenzylidene-β-D-galactopyranoside (59). To a solution of 43 (11 g, 0.016 mol) 
in dry CH2Cl2 (675 mL) were added 4Å powdered molecular sieves. After stirring for 1 h 
at rt, allyl alcohol (9.3 g, 11 mL, 0.16 mol) and N-iodosuccinimide (5.3 g, 0.023 mol) 
were added, and the mixture was cooled to 0 °C. Triflic acid (0.5 N solution in CH2Cl2, 
1.44 g, 9.60 mmol, 19.2 mL) was added and the reaction stirred at 0 °C for 10 min. The 
mixture was quenched with TEA, washed with brine, and dried over MgSO4. The solvent 
was removed in vacuo to afford a yellow oil. Purification of this oil by flash 
chromatography (5% → 15% EtOAc:hexanes) afforded 59 (8.1 g, 79%) as a white solid. 
Rf 0.41 (30% EtOAc:hexanes). [α]D24 = +38.1 (c = 0.5, CH2Cl2); IR (thin film on NaCl):  
υ = 3445, 1644, 1520, 1463, 1368, 1249, 1171, 1123, 1060 cm-1; 1H NMR (300 MHz, 
CDCl3): δ =  7.45 (d, J = 8.9 Hz, 2H, C6H4OMe), 6.97 (d, J = 7.2 Hz, 1H, NHTCA), 6.87 
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(d, J = 8.9 Hz, 2H, C6H4OMe), 5.96 – 5.83 (m, 1H, OCH2CH=CH2), 5.49 (s, 1H,  
MeOPhCH), 5.26 (dd, J = 1.4, 17.3 Hz, 1H, OCH2CH=CH2), 5.17 (dd, J = 1.4, 10.5 Hz, 
1H, OCH2CH=CH2), 5.16 (d, J = 8.1 Hz, 1H, H-1), 4.65 (dd, J = 3.3, 10.5 Hz, 1H, H-3), 
4.37 (m, 2H, OCH2CH=CH2, H-6), 4.13 – 4.05 (m, 3H, OCH2CH=CH2, H-4, H-6), 3.81 
(s, 3H, PhOCH3), 3.75 (m, 1H, H-2), 3.48 (s, 1H, H-5), 1.05 (s, 21H, [(CH3)2CH]3); 13C 
NMR (75 MHz, CDCl3): δ = 161.7, 160.1, 134.0, 130.5, 127.8, 118.2, 113.6, 101.2, 97.8, 
76.6, 70.6, 69.9, 69.5, 66.7, 64.2, 57.6, 55.6, 18.5, 18.4, 13.1; HR-FAB MS: m/z: calcd 
for C25H37Cl3NO6Si: 580.1456; found: 580.1474 [M+ - OAll]. 
 
Allyl 2-deoxy-2-trichloroacetamido-4,6-O-p-methoxybenzylidene-β-D-
galactopyranoside (60). To a solution of 59  (8.00 g, 12.5 mmol) in THF (290 mL) was 
added tetrabutylammonium fluoride (1 N solution in THF, 4.91 g, 18.8 mL, 18.8 mmol) 
and the mixture stirred at rt for 8 h. At this time, a second addition of 
tetrabutylammonium fluoride (2.5 g, 9.4 mmol, 9.4 mL) was made and the reaction 
stirred for an additional 12 h. The solvent was removed in vacuo to afford a yellow oil. 
Purification of this oil by flash chromatography (40% → 80% EtOAc:hexanes) yielded 
60 (5.14 g, 85%) as a white solid. Rf 0.17 (50% EtOAc:hexanes). [α]D24 = +0.62 (c = 0.5, 
CH2Cl2); IR (thin film on NaCl):  υ = 3423, 1686, 1616, 1531, 1402, 1366, 1303, 1249, 
1170, 1097, 1060 cm-1; 1H NMR (300 MHz, CDCl3): δ = 7.43 (d, J = 8.7 Hz, 2H, 
C6H4OMe), 6.89 (d, J = 8.7 Hz, 2H, C6H4OMe), 6.87 (m, 1H, NHTCA), 5.95 – 5.82 (m, 
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1H, OCH2CH=CH2), 5.54 (s, 1H, MeOPhCH), 5.29 (dd, J = 1.4, 17.7 Hz, 1H, 
OCH2CH=CH2), 5.19 (dd, J = 1.4, 10.5 Hz, 1H, OCH2CH=CH2), 4.84 (d, J = 8.4 Hz, 
1H, H-1), 4.44 – 4.32 (m, 2H, H-3, H-6), 4.26 – 4.07 (m, 4H, OCH2CH=CH2, H-4, H-6), 
3.81 (m, 1H, H-2), 3.81 (s, 3H, PhOCH3), 3.53 (s, 1H, H-5), 2.71 (d, J = 9.9 Hz, 1H, 
OH); 13C NMR (75 MHz, CDCl3): δ = 162.5, 160.4, 153.6, 133.7, 130.0, 127.9, 118.3, 
113.8, 101.6, 98.7, 75.2, 70.4, 69.4, 69.3, 67.0, 57.2, 55.7; HR-FAB MS: m/z: calcd for 
C19H23Cl3NO7: 482.0540; found: 482.0531 [M + H]+. 
 
Methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-glucopyranosyluronate)-(1 
→ 3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-trichloroacetamido-1-thio-β-D-
galactopyranoside (38). 39 (20 mg, 0.030 mmol) and 40 (17 mg, 0.026 mmol) were 
combined, azeotroped by co-evaporation with toluene (3x), and placed under high 
vacuum overnight to dry. The mixture was dissolved in CH2Cl2 (0.6 mL) and 4Å 
powdered molecular sieves added. The mixture was stirred for 1 h at rt , cooled to –78 
°C, and N-iodosuccinimide (9.7 mg, 0.042 mmol) was added. Trimethylsilyl 
trifluoromethanesulfonate (0.1 N solution in CH2Cl2, 62 µL, 0.005 mmol) was cooled to –
78 °C and added dropwise to the reaction mixture. After 45 min, the reaction mixture was 
warmed to rt, stirred for 30 min and then quenched with TEA. The mixture was filtered 
and concentrated to afford a yellow oil. Purification of this oil by preparative thin layer 
chromatography (30% EtOAc:hexanes) afforded 38 (7.5 mg, 28%) as a white solid. Rf 
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0.53 (40% EtOAc:hexanes).1H NMR (300 MHz, CDCl3): δ = 7.83 – 7.77 (m, 4H, ArH), 
7.50 – 7.43 (m, 4H, ArH), 7.33 – 7.27 (m, 6H, ArH), 6.99 (d, J = 8.4 Hz, 2H, C6H4OMe), 
6.86 (d, J = 8.7 Hz, 1H, SC6H4Me), 6.75 (d, J = 6.6 Hz, 1H, NHTCA), 5.46 – 5.29 (m, 
4H, H-1 GalNAc, H-2 GlcA, H-3 GlcA, MeOPhCH), 5.02 (d, J = 7.2 Hz, 1H, H-1 GlcA), 
4.69 (dd, J = 3.3, 10.5 Hz, 1H, H-3 GalNAc), 4.39 – 4.27 (m, 3H, H-4 GalNAc, H-4 
GlcA, H-6 GalNAc), 4.05 (d, J = 9.3 Hz, 1H, H-5 GlcA), 4.00 (dd, J = 0.9, 10.8 Hz, 1H, 
H-6 GalNAc), 3.83 (s, 3H, CO2CH3), 3.80 (s, 3H, PhOCH3), 3.69 – 3.60 (m, 1H, H-2 
GalNAc), 3.57 (s, 1H, H-5 GalNAc), 0.71 (s, 9H, (CH3)3CSi), -0.09 (s, 3H, CH3Si), -0.25 
(s, 3H, CH3Si). ESI MS:  m/z:  calcd for C50H57Cl3NO14SSi:  1062.5; found:  1062.5 [M + 
H]+. 
 
 Allyl (4,6-O-p-methoxybenzylidene-3-O-triisopropylsilyl-2-deoxy-2-
trichloroacetamido-β-D-galactopyranosyl)-(1 → 4)-methyl 2,3-di-O-benzoyl-β-D-
glucopyranosyluronate (42). 43 (0.044 g, 0.063 mmol) and 44 (0.016 g, 0.035 mmol) 
were combined, azeotroped by co-evaporated with toluene (3x), and put under high 
vacuum overnight to dry. The mixture was dissolved in CH2Cl2 (0.5 mL) and 4Å 
powdered molecular sieves added. The mixture was stirred for 1 h at rt and then cooled to 
–15 ˚C. N-iodosuccinimide (16 mg, 0.07 mmol) and triflic acid (0.25 N solution in 
CH2Cl2, 15 µL, 0.004 mmol) were added, and the reaction was stirred at –15 ˚C for 30 
min and quenched with TEA. The mixture was filtered and the solvent removed in vacuo 
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to afford a yellow oil. Purification of this oil by preparative thin layer chromatography 
(25% EtOAc:hexanes) afforded 42 (21 mg, 58%) as a white solid. The α-linked product 
was observed in 32% yield. Rf 0.50 (30% EtOAc:hexanes). 1H NMR (300 MHz, CDCl3): 
δ = 7.97 – 7.93 (m, 4H, ArH), 7.53 – 7.48 (m, 1H, ArH), 7.39 – 7.31 (m, 3H, ArH), 7.23 
– 7.18 (m, 2H, ArH), 7.07 (d, J = 9.0 Hz, 2H, C6H4OMe), 6.82 (d, J = 7.8 Hz, 1H, 
NHTCA), 6.74 (d, J = 8.1 Hz, 2H, C6H4OMe), 5.84 – 5.71 (m, 1H, OCH2CH=CH2), 5.71 
(dd, J = 8.7, 9.0 Hz, 1H, H-2 GlcA), 5.38 (dd, J = 8.7, 9.3 Hz, 1H, H-3 GlcA), 5.28 – 
5.20 (m, 3H, H-1 GalNAc, MeOPhCH, OCH2CH=CH2), 5.14 (dd, J = 1.5, 11.2 Hz, 1H, 
OCH2CH=CH2), 4.83 (d, J = 7.2 Hz, 1H, H-1 GlcA), 4.60 (dd, J = 8.7, 8.7 Hz, 1H, H-4 
GlcA), 4.38 – 4.32 (m, 2H, H-3 GalNAc, OCH2CH=CH2), 4.18 – 4.09 (m, 2H, H-5 GlcA, 
OCH2CH=CH2), 3.96 – 3.67 (m, 4H, H-6 GalNAc, H-6 GalNAc, H-2 GalNAc, H-4 
GalNAc) 3.86 (s, 3H, CO2CH3), 3.80 (s, 3H, PhOCH3), 3.31 (s, 1H, H-5 GalNAc), 0.99 
(s, 21H, [(CH3)2CH]3); ESI MS: m/z: calcd for C49H61Cl3NO15Si: 1038.4; found 1038.5 
[M + H]+. 
 
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1 →  3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-
trichloroacetamido-β-D-galactopyranoside (61).  A mixture of donor 39 (0.50 g, 0.74 
mmol) and acceptor 60 (0.30 g, 0.62 mmol) was azeotroped by co-evaporated with 
toluene (3 x 3 mL) and dried under vacuum overnight.  The mixture was dissolved in 
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CH2Cl2 (16 mL), and activated 4Å powdered molecular sieves were added.  The reaction 
was stirred at rt for 1.5 h.  The reaction was then cooled to -40 °C and stirred for an 
additional 30 min.  Trimethylsilyl trifluoromethanesulfonate (1 N in CH2Cl2, 125 µL, 
0.123 mmol) at -40 °C was added to the reaction dropwise.  The reaction was allowed to 
stir an additional 30 min. A carefully controlled temperature gradient was essential to 
avoid formation of the inseparable ortho ester. It was then warmed to -10 °C over a 
period of 30 min, quenched with TEA, and allowed to warm to rt. The reaction was 
filtered and concentrated to afford a yellow syrup.  The product was purified by flash 
chromatography (30% EtOAc:hexanes) to afford 61 (0.46 g, 74%) as a white solid.  Rf 
0.12 (30% EtOAc:hexanes).  1H NMR (300 MHz, CDCl3): δ = 7.87 – 7.82 (m, 4H, ArH), 
7.48 – 7.39 (m, 4H, ArH), 7.35 – 7.26 (m, 4H, ArH), 6.86 (d, J = 8.7 Hz, 2H, C6H4OMe), 
6.82 (d, J = 7.2 Hz, 1H, NHTCA), 5.89 – 5.76 (m, 1H, OCH2CH=CH2), 5.45 (s, 1H, 
MeOPhCH), 5.52 – 5.39 (m, 2H, H-2 GlcA, H-3 GlcA), 5.22 (dd, J = 1.6, 17.6 Hz, 1H, 
OCH2CH=CH2), 5.13 (dd, J = 1.0, 10.4 Hz, 1H, OCH2CH=CH2), 5.08 (d, J = 7.5 Hz, 1H, 
H-1 GlcA), 5.05 (d, J = 8.1 Hz, 1H, H-1 GalNAc), 4.67 (dd, J = 3.3, 10.8 Hz, 1H, H-3 
GalNAc), 4.36 – 4.27 (m, 4H, OCH2CH=CH2, H-4 GalNAc, H-4 GlcA, H-6 GalNAc), 
4.10 (d, J = 9.3 Hz, 1H, H-5 GlcA), 4.07 – 4.01 (m, 2H, OCH2CH=CH2, H-6 GalNAc), 
3.79 (s, 6H, CO2CH3, PhOCH3), 3.77 – 3.68 (m, 1H, H-2 GalNAc), 3.48 (s, 1H, H-5 
GalNAc), 0.72 (s, 9H, (CH3)3CSi), -0.08 (s, 3H, CH3Si), -0.23 (s, 3H, CH3Si); 13C NMR 
(75 MHz, CDCl3):  δ = 168.7, 165.7, 165.2, 162.3, 160.0, 133.8, 133.4, 133.4, 130.5, 
130.0, 129.9, 129.5, 129.2, 128.5, 127.7, 118.2, 113.6, 100.7, 100.6, 97.8, 92.3, 76.4, 
75.8, 75.6, 73.6, 72.0, 70.9, 70.6, 69.2, 66.8, 55.6, 55.4, 52.9, 25.7, 18.1, -4.0, -4.7; HR-
FAB MS:  m/z:  calcd for C46H53Cl3NO15Si:  992.2250; found:  992.2255 [M]+. 
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Methyl (2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-glucopyranosyluronate)-(1 
→  3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-trichloroacetamido-α-D-
galactopyranoside trichloroacetimidate (64). To a solution of 61 (2.5 g, 2.5 mmol) in 
dry CH2Cl2 (40 mL) was added Grubbs’ second-generation catalyst (0.43 g, 20 mol%) 
and the mixture stirred at rt for 2 h. The solvent was removed in vacuo to afford a brown 
oil. Purification of this oil by flash chromatography (15% → 20% EtOAc:hexanes) 
afforded E/Z-prop-2-enyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1 → 3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-
trichloroacetamido-β-D-galactopyranoside (1.92 g, 77%) as a white solid. Rf (E and Z) 
0.68 (60% EtOAc:hexanes). [α]D25 = +29.1 (c = 1.0, CH2Cl2); IR (thin film on NaCl):  υ 
= 3308, 2954, 2858, 1755, 1734, 1717, 1694, 1617, 1602, 1540, 1520, 1452, 1371, 1268, 
1221, 1176, 1147, 1089, 1069, 1040, 1026, 1001 cm-1; 1H NMR (300 MHz, CDCl3): δ = 
7.85 (m, 3H, ArH), 7.48 – 7.28 (m, 10H, ArH, OCH=CHCH3), 6.87 (d, J = 8.7 Hz, 2H, 
C6H4OMe), 6.82 (d, J = 6.6 Hz, 1H, NHTCA), 6.17 (m, 1H, CH=CHCH3), 5.52 – 5.40 
(m, 3H,  MeOPhCH, H-2 GlcA, H-3 GlcA), 5.19 (d, J = 8.1 Hz, 1H, H-1 GalNAc), 5.08 
(d, J = 7.2 Hz, 1H, H-1 GlcA), 4.68 (dd, J = 3.8, 11.0 Hz, 1H, H-3 GalNAc), 4.39 – 4.28 
(m, 3H, H-4 GalNAc, H-4 GlcA, H-6 GalNAc), 4.16 – 4.02 (m, 2H, H-5 GlcA, H-6 
GalNAc), 3.87 (m, 1H, H-2 GalNAc), 3.81 (s, 3H, PhOCH3), 3.80 (s, 3H, CO2CH3), 3.54 
(s, 1H, H-5), 1.51 (m, 3H, OCH=CHCH3), 0.72 (s, 9H, (CH3)3CSi), -0.07 (s, 3H, CH3Si), 
O
pMP
O
BzO
BzO
TBSO
MeO2C
O
TCAHN
O
O
O
Cl3C
NH64
 104 
-0.22 (s, 3H, CH3Si); 13C NMR (75 MHz, CDCl3): δ = 168.7, 165.7, 165.3, 162.4, 162.3, 
160.0, 143.5, 142.1, 133.5, 133.4, 130.4, 130.1, 129.9, 129.5, 129.1, 128.5, 127.7, 113.6, 
105.7, 104.8, 100.8, 100.6, 100.5, 98.4, 98.0, 76.5, 75.6, 75.5, 73.5, 73.4, 72.0, 70.9, 69.0, 
67.2, 67.1, 55.6, 55.1, 55.0, 52.9, 25.7, 18.1, 12.6, 9.7, -4.0, -4.7. 
 
To a solution of E/Z-prop-2-enyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-
β-D-glucopyranosyluronate)-(1 → 3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-
trichloroacetamido-β-D-galactopyranoside (6.2 g, 6.3 mmol) in dry THF (118 mL), water 
(24 mL) and pyridine (1.9 mL), was added iodine (3.1 g) and the mixture stirred at 
ambient temperature for 30 min. The solvent was removed in vacuo to afford a yellow 
oil. The oil was taken up in EtOAc and washed with 5% aqueous Na2SO3, saturated 
aqueous NaHCO3, brine and dried over MgSO4. The solvent was removed in vacuo to 
afford a pale yellow oil. Purification of this oil by flash chromatography (40% → 60% 
EtOAc:hexanes) afforded an anomeric mixture of methyl (2,3-di-O-benzoyl-4-O-tert-
butyldimethylsilyl-β-D-glucopyranosyluronate)-(1 → 3)-4,6-O-p-methoxybenzylidene-2-
deoxy-2-trichloroacetamido-α/β-D-galactopyranoside (4.8 g, 81%) as a pale yellow solid. 
Rf 0.28 and 0.18 (50% EtOAc:hexanes). [α]D25 = +79.0 (c = 1.0, CH2Cl2); IR (thin film 
on NaCl):  υ = 3521, 2930, 1738, 1682, 1615, 1519, 1452, 1394, 1251, 1172, 1093, 1069, 
1031 cm-1; 1H NMR (300 MHz, CDCl3): δ = 7.92 – 7.85 (m, 3H, ArH), 7.54 – 7.45 (m, 
3H, ArH), 7.40 – 7.27 (m, 4H, ArH), 7.12 (d, J = 9.0 Hz, 2H, C6H4OMe), 6.96 (d, J = 
6.3Hz, 1H,  NHTCA), 6.72 (d, J = 9.0 Hz, 2H, C6H4OMe), 5.60 (m, 1H, H-1 GalNAc), 
5.50 (dd, J = 8.2, 8.2 Hz, 1H, H-3 GlcA), 5.42 (dd, J = 8.2, 8.2 Hz, 1H, H-2 GlcA), 5.24 
(s, 1H, MeOPhCH), 5.21 (d, J = 7.5 Hz, 1H, H-1 GlcA), 4.39 – 4.35 (m, 4H, H-3 
 105 
GalNAc, H-4 GalNAc, H-4 GlcA), 4.23 – 4.02 (m, 3H, H-2 GalNAc, H-5 GlcA, H-6 
GalNAc), 3.96 (s, 1H, H-5 GalNAc), 3.79 (s, 3H, PhOCH3), 3.75 (s, 3H, CO2CH3), 3.03 
(d, J = 3.3 Hz, 1H, OH), 0.73 (s, 9H, (CH3)3CSi), -0.08 (s, 3H, CH3Si), -0.22 (s, 3H, 
CH3Si); ESI MS: m/z: calcd for C43H50Cl3NO15Si: 954.2914; found: 954.2910 [M - H]-.       
   
To a solution of methyl (2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1 → 3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-
trichloroacetamido-α/β-D-galactopyranoside (4.6 g, 4.8 mmol) in dry CH2Cl2 (190 mL) 
cooled to 0 °C, was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.29 g, 0.29 mL, 1.9 
mmol) and trichloroacetonitrile (10 g, 7.2 mL, 71 mmol). After stirring for 15 min, the 
mixture was quenched with TEA and concentrated in vacuo to afford a yellow oil. 
Purification of this oil by flash chromatography (35% EtOAc:hexanes, + 2% TEA) 
afforded 64 (4.7 g, 90%) as a pale yellow foam. The material was stored at -20 °C and 
under Ar, as it readily hydrolyzes to give an anomeric mixture of alcohols. Rf 0.74, (50% 
EtOAc:hexanes). [α]D24 = +12.0 (c = 0.5, CH2Cl2); IR (thin film on NaCl):  υ = 3422, 
2956, 2991, 2361, 1731, 1676, 1616, 1519, 1452, 1373, 1271, 1177, 1147, 1094, 1070, 
1028 cm-1; 1H NMR (300 MHz, CDCl3): δ = 8.69 (s, 1H,  C=NH), 7.90 (m, 4H, ArH), 
7.51 (m, 2H, ArH), 7.42 – 7.26 (m, 4H, ArH), 7.00 (d, J = 8.9 Hz, 2H, C6H4OMe), 6.93 
(d, J = 5.4 Hz, 1H, NHTCA), 6.77 (d, J = 2.1 Hz, 1H, H-1 GalNAc), 6.68 (d, J = 8.9 Hz, 
2H,  C6H4OMe), 5.52 (dd, J = 8.7, 8.7 Hz, 1H, H-3 GlcA), 5.45 (dd, J = 8.7, 8.7 Hz, 1H, 
H-2 GlcA), 5.27 (d, J = 7.8 Hz, 1H, H-1 GalNAc), 5.17 (s, 1H, MeOPhCH), 4.62 (m, 2H, 
H-4 GalNAc, H-4 GlcA), 4.49 (m, 1H, H-3 GalNAc), 4.31 (m, 2H, H-2 GalNAc, H-6 
GalNAc), 4.18 (d, J = 9.0 Hz, 1H, H-5 GlcA), 4.00 (d, J = 12.6 Hz, 1H, H-6 GalNAc), 
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3.94 (s, 1H, H-5 GalNAc), 3.75 (s, 3H, PhOCH3), 3.74 (s, 3H, CO2CH3), 0.73 (s, 9H, 
(CH3)3CSi), -0.06 (s, 3H, CH3Si), -0.19 (s, 3H, CH3Si); 13C NMR (75 MHz, CDCl3): δ = 
168.1, 165.9, 165.6, 162.0, 160.4, 133.9, 133.6, 130.1, 129.9, 129.4, 128.7, 128.6, 127.6, 
113.6, 101.1, 98.4, 95.3, 77.2, 75.5, 74.4, 71.2, 70.9, 69.2, 69.0, 65.5, 55.6, 53.0, 50.5, 
46.5, 25.7, -4.0, -4.8. The material hydrolyzed too readily to obtain a mass spectrum. 
 
 Allyl (methyl 2,3-di-O-benzoyl-β-D-glucopyranosyluronate)-(1 →  3)-4,6-O-p-
methoxybenzylidene-2-deoxy-2-trichloroacetamido-β-D-galactopyranoside (65). To a 
solution of 61 (2.5 g, 2.5 mmol) in dry THF (40 mL) and pyridine (40 mL) cooled to 0 
°C, was added HF•pyridine (13 mL, 715 mmol). The reaction mixture was warmed to rt 
and stirred for 18 h. The mixture was then diluted with EtOAc and washed with 10% 
aqueous CuSO4. The aqueous phase was extracted with EtOAc (3x) and the combined 
organics washed with saturated aqueous NaHCO3 and dried over MgSO4. The solvent 
was removed in vacuo to afford a yellow oil. Purification of this oil by flash 
chromatography (30 → 60% EtOAc:hexanes) afforded 65 (1.9 g, 85%) as a white solid. 
Rf 0.35 (60% EtOAc:hexanes). [α]D25 = +32.8 (c = 1.0, CH2Cl2); IR (thin film on NaCl):  
υ = 3422, 1731, 1616, 1519, 1452, 1369, 1251, 1173, 1093, 1069 cm-1; 1H NMR (300 
MHz, CDCl3): δ  = 7.93 – 7.87 (m, 4H, ArH), 7.50 – 7.42 (m, 4H, ArH, C6H4OMe), 7.36 
– 7.26 (m, 4H, ArH), 7.01 (d, J = 6.6 Hz, 1H, NHTCA), 6.89 (d, J = 8.7 Hz, 2H, 
C6H4OMe), 5.89 – 5.77 (m, 1H, OCH2CH=CH2), 5.47 (m, 3H, MeOPhCH, H-2 GlcA, H-
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3 GlcA), 5.26 – 5.12 (m, 4H, OCH2CH=CH2, H-1 GalNAc, H-1 GlcA), 4.73 (dd, J = 3.6, 
11.4 Hz, 1H, H-3 GalNAc), 4.41 – 4.28 (m, 3H, OCH2CH=CH2, H-4 GalNAc, H-6 
GalNAc), 4.19 (m, 1H, H-4 GlcA), 4.12 – 4.02 (m, 3H, OCH2CH=CH2, H-5 GlcA, H-6 
GalNAc), 3.83 (s, 3H, PhOCH3), 3.81 (s, 3H, CO2CH3), 3.72 (m, 1H, H-2 GalNAc), 3.48 
(s, 1H, H-5 GalNAc), 3.45 (d, J = 3.3 Hz, 1H, OH); 13C NMR (75 MHz, CDCl3): δ = 
169.3, 166.6, 165.2, 162.3, 160.1, 133.8, 133.6, 133.5, 130.4, 130.1, 130.0, 129.2, 129.1, 
128.7, 128.6, 127.5, 118.2, 113.7, 100.8, 100.7, 97.7, 76.1, 75.4, 74.3, 74.1, 71.4, 70.7, 
69.3, 66.8, 55.7, 53.4; ESI MS: m/z: calcd for C40H39Cl3NO15; 880.1; found: 880.2 [M – 
H]-. 
 
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1 → 3)-(4,6-O-p-methoxybenzylidene-2-deoxy-2-
trichloroacetamido-β-D-galactopyranosyl)-(1 → 4)-(methyl 2,3-di-O-benzoyl-β-D-
glucopyranosyluronate)-(1 → 3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-
trichloroacetamido-β-D-galactopyranoside (37). 64 (0.10 g, 0.088 mmol) and 65 
(0.065 g, 0.074 mmol) were combined and azeotroped by co-evaporation with toluene 
(3x) and placed under high vacuum overnight to dry. The mixture was dissolved in 
CH2Cl2 (3.0 mL), 4Å powdered molecular sieves added. The mixture was stirred for 1 h 
at rt and then cooled to –78 °C. Trimethylsilyl trifluoromethanesulfonate (0.5 N solution 
in CH2Cl2, 0.0033 g, 30 µL, 0.015 mmol) was cooled to –78 °C and added dropwise to 
the reaction mixture. After 10 min, the reaction mixture was warmed to –20 °C, stirred 
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for 30 min and then quenched with TEA. The mixture was filtered and concentrated to 
afford a yellow oil. Purification of this oil by flash chromatography (30 → 40% 
EtOAc:hexanes containing 0.1% TEA) followed by preparative thin layer 
chromatography (10% EtOAc:CH2Cl2) afforded 37 (59 mg, 44%) as a white solid. For 
complete assignment of the 1H NMR spectra of this compound, 1H decoupling and 
TOCSY experiments were performed. Rf 0.43 (60% EtOAc:hexanes). [α]D25 = +13.4 (c = 
0.5, CH2Cl2); IR (thin film on NaCl):  υ = 3424, 2956, 2361, 1732, 1638, 1519, 1452, 
1368, 1251, 1173, 1093, 1173, 1093, 1070, 1028; 1H NMR (600 MHz, CDCl3): δ = 7.88 
– 7.80 (m, 8H, ArH), 7.49 – 7.45 (m, 4H, ArH), 7.38 – 7.28 (m, 8H, ArH), 7.22 – 7.20 
(m, 2H, ArH), 7.06 (d, J = 8.4 Hz, 2H, C6H4OMe), 6.93 (d, J = 8.4 Hz, 2H, C6H4OMe), 
6.85 (d, J = 6.6 Hz, 1H, NHTCA), 6.74 (d, J = 8.4 Hz, 2H, C6H4OMe), 6.66 (d, J = 7.2 
Hz, 1H, NHTCA), 5.87 – 5.81 (m, 1H, OCH2CH=CH2), 5.58 (dd, J = 7.8, 7.8 Hz, 1H, H-
3 GlcA), 5.49 (s, 1H, MeOPhCH), 5.44 (dd, J = 8.7, 8.7 Hz, 1H, H-3 GlcA), 5.35 (m, 2H, 
H-2 GlcA, H-2 GlcA), 5.23 (d, J = 18.0 Hz, 1H, OCH2CH=CH2), 5.20 (s, 1H, 
MeOPhCH), 5.15 – 5.12 (m, 2H, OCH2CH=CH2, H-1 GlcA), 5.11 (d, J = 7.8 Hz, 1H, H-
1 GalNAc), 5.03 (d, J = 7.2 Hz, 1H, H-1 GlcA), 5.00 (d, J = 8.4 Hz, 1H, H-1 GalNAc), 
4.68 (dd, J = 3.6, 10.8 Hz, 1H, H-3 GalNAc), 4.58 (dd, J = 9.0, 9.0 Hz, 1H, H-4 GlcA), 
4.39 – 4.30 (m, 5H, OCH2CH=CH2, H-3 GalNAc, H-4 GalNAc, H-4 GlcA, H-6 
GalNAc), 4.14 (m, 2H, H-4 GalNAc, H-5 GlcA), 4.06 –3.91 (m, 3H, OCH2CH=CH2, H-5 
GlcA, H-6 GalNAc), 3.83 (s, 3H, PhOCH3), 3.81 – 3.68 (m, 4H, H-2 GalNAc, H-2 
GalNAc, H-6 GalNAc, H-6 GalNAc), 3.80 (s, 3H, PhOCH3), 3.80 (s, 3H, CO2CH3), 3.79 
(s, 3H, CO2CH3), 3.48 (s, 1H, H-5 GalNAc), 3.10 (s, 1H, H-5 GalNAc), 0.72 (s, 9H, 
(CH3)3CSi), -0.09 (s, 3H, CH3Si), -0.24 (s, 3H, CH3Si); 13C NMR (75 MHz, CDCl3):  δ = 
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168.8, 168.4, 165.7, 165.4, 165.2, 165.1, 162.2, 161.9, 160.0, 159.8, 133.8, 133.4, 133.3, 
133.1, 130.5, 130.4, 130.2, 130.1, 130.0, 129.9, 129.6, 129.5, 129.2, 129.1, 128.6, 128.5, 
128.4, 127.9, 127.8, 118.2, 113.7, 113.4, 100.8, 100.5, 100.4, 100.2, 98.6, 97.7, 77.4, 
76.4, 75.9, 75.8, 75.3, 75.0, 74.2, 74.1, 73.5, 73.4, 72.1, 71.9, 70.8, 70.6, 69.3, 68.4, 66.9, 
55.7, 55.6, 54.8, 53.5, 52.8, 25.7, 18.1, -4.1, -4.8. ESI MS: m/z: calcd for 
C83H89Cl6N2O29Si: 1819.4; found 1819.5 [M + H]+. 
 
Allyl (methyl 2,3-di-O-benzoyl-β-D-glucopyranosyluronate)-(1 → 3)-(4,6-O-p-
methoxybenzylidene-2-deoxy-2-trichloroacetamido-β-D-galactopyranosyl)-(1 → 4)-
(methyl 2,3-di-O-benzoyl-β-D-glucopyranosyluronate)-(1 → 3)-4,6-O-p-
methoxybenzylidene-2-deoxy-2-trichloroacetamido-β-D-galactopyranoside (67). To a 
solution of 37 (0.10 g, 0.055 mmol) in dry THF (0.84 mL) and pyridine (0.84 mL) cooled 
to 0 ˚C, was added HF•pyridine (0.28 mL, 15 mmol). The reaction mixture was warmed 
to rt and stirred for 12 h. The mixture was then diluted with EtOAc and washed with 10% 
aqueous CuSO4. The aqueous phase was extracted with EtOAc (3x) and the combined 
organics washed with saturated aqueous NaHCO3 and dried over MgSO4. The solvent 
was removed in vacuo to afford a yellow oil. Purification of this oil by flash 
chromatography (40 → 60% EtOAc:hexanes) afforded 67 (60 mg, 64%) as a white solid. 
Rf  0.24 (60% EtOAc:hexanes). [α]D25 = +13.8 (c = 0.5, CH2Cl2); IR (thin film on NaCl):  
υ = 3528, 2361, 1731, 1616, 1519, 1452, 1368, 1251, 1173, 1094, 1070, 1028; 1H NMR 
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(600 MHz, CDCl3): δ = 7.92 (d, J = 7.8 Hz, 2H, ArH), 7.89 – 7.86 (m, 6H, ArH), 7.51 – 
7.47 (m, 5H, ArH), 7.39 – 7.32 (m, 7H, ArH), 7.22 – 7.19 (m, 2H, ArH), 7.11 (d, J = 8.4 
Hz, 2H, C6H4OMe), 6.91 (d, J = 8.4 Hz, 2H, C6H4OMe), 6.87 (d, J = 6.6 Hz, 1H, 
NHTCA), 6.87 (d, J = 7.2 Hz, 1H, NHTCA), 6.75 (d, J = 8.4 Hz, 2H, C6H4OMe), 5.87 – 
5.81 (m, 1H, OCH2CH=CH2), 5.60 (dd, J = 8.4, 7.8 Hz, 1H, H-3 GlcA), 5.49 (s, 1H, 
MeOPhCH), 5.42 – 5.34 (m, 3H, H-3 GlcA, H-2 GlcA, H-2 GlcA), 5.25 (s, 1H, 
MeOPhCH), 5.23 (d, J = 18.0 Hz, 1H, OCH2CH=CH2), 5.17 – 5.11 (m, 5H, 
OCH2CH=CH2, H-1 GlcA, H-1 GalNAc, H-1 GlcA, H-1 GalNAc), 4.70 (dd, J = 3.3, 
11.1 Hz, 1H, H-3 GalNAc), 4.61 (dd, J = 9.0, 8.4 Hz, 1H, H-4 GlcA), 4.44 (dd, J = 3.0, 
11.4 Hz, 1H, H-3 GalNAc), 4.37 – 4.30 (m, 4H, OCH2CH=CH2, H-4 GalNAc, H-4 GlcA, 
H-6 GalNAc), 4.25 (d, J = 3.0 Hz, 1H, H-4 GalNAc), 4.20 (m, 1H, H-2 GalNAc), 4.17 
(d, J = 9.0 Hz, 1H, H-5 GlcA), 4.08 – 4.03 (m, 3H, OCH2CH=CH2, H-5 GlcA, H-6 
GalNAc), 3.86 (s, 3H, PhOCH3), 3.80 (s, 3H, PhOCH3), 3.80 (s, 3H, CO2CH3), 3.79 (s, 
3H, CO2CH3), 3.74 – 3.65 (m, 3H, H-2 GalNAc, H-6 GalNAc, H-6 GalNAc), 3.48 (s, 
1H, H-5 GalNAc), 3.38 (d, J = 2.4 Hz, 1H, OH), 3.13 (s, 1H, H-5 GalNAc); 13C NMR 
(75 MHz, CDCl3) δ = 169.4, 168.4, 166.7, 165.5, 165.2, 162.3, 162.0, 160.0, 159.9, 
133.7, 133.6, 133.5, 133.1, 129.9, 128.6, 128.4, 127.7, 127.6, 118.2, 113.7, 113.4, 100.8, 
100.5, 100.2, 98.2, 97.7, 75.7, 75.6, 75.5, 74.8, 74.2, 74.1, 73.9, 73.4, 69.3, 68.6, 67.9, 
66.8, 55.7, 55.6, 55.1, 53.5, 53.3. ESI MS: m/z: calcd for C83H89Cl6N2O29Si: 1705.1; 
found 1705.2 [M + H]+.  
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Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1 → 3)-(4,6-O-p-methoxybenzylidene-2-deoxy-2-
trichloroacetamido-β-D-galactopyranosyl)-(1 → 4)-methyl 2,3-di-O-benzoyl-4-O-
tert-butyldimethylsilyl-β-D-glucopyranosyluronate)-(1 → 3)-(4,6-O-p-
methoxybenzylidene-2-deoxy-2-trichloroacetamido-β-D-galactopyranosyl)-(1 → 4)-
(methyl 2,3-di-O-benzoyl-β-D-glucopyranosyluronate)-(1 → 3)-4,6-O-p-
methoxybenzylidene-2-deoxy-2-trichloroacetamido-β-D-galactopyranoside (68). 64 
(0.073 g, 0.066 mmol) and 67 (0.094 g, 0.055 mmol) were combined, azeotroped by co-
evaporation with toluene (3x), and placed under high vacuum overnight to dry. The 
mixture was dissolved in CH2Cl2 (1.2 mL) and 4Å powdered molecular sieves added. 
After stirring for 1 h at rt, the reaction mixture was cooled to –15 ˚C. Trimethylsilyl 
trifluoromethanesulfonate (0.25 N in CH2Cl2, 60 µL, 0.011 mmol) was added, and the 
reaction was stirred at –15 ˚C for 30 min and quenched with TEA. The mixture was 
filtered and the solvent removed in vacuo to afford a yellow oil. Purification of this oil by 
flash chromatography (35 → 50% EtOAc:hexanes) afforded 68 (32 mg, 25%) as a white 
solid. Rf 0.56 (60% EtOAc:hexanes). For complete assignment of the 1H NMR spectra of 
this compound, 1H decoupling and TOCSY experiments were performed. [α]D25 = +5.7 (c 
= 1.0, CH2Cl2); IR (thin film on NaCl):  υ = 3424, 2928, 2360, 1732, 1617, 1519, 1452, 
1368, 1251, 1173, 1093, 1070; 1H NMR (600 MHz, CDCl3): δ = 7.89 – 7.84 (m, 8H, 
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ArH), 7.81 (d, J = 7.2 Hz, 2H, ArH), 7.48 – 7.26 (m, 18H, ArH), 7.22 – 7.17 (m, 6H, 
ArH), 7.05 (d, J = 8.4 Hz, 2H, C6H4OMe), 6.90 (d, J = 9.0 Hz, 2H, C6H4OMe), 6.86 (d, J 
= 7.2 Hz, 1H, NHTCA), 6.81 (d, J = 8.4 Hz, 2H, C6H4OMe), 6.72 (d, J = 8.4 Hz, 2H, 
C6H4OMe), 6.63 (d, J = 7.2 Hz, 1H, NHTCA), 6.60 (d, J = 7.2 Hz, 1H, NHTCA), 5.84 
(m, 1H, OCH2CH=CH2), 5.59 (dd, J = 8.1, 8.1 Hz, 1H H-3 GlcA), 5.52 (dd, J = 7.5, 7.5 
Hz, 1H, H-3 GlcA), 5.49 (s, 1H, MeOPhCH), 5.44 (dd, J = 8.4, 8.4 Hz, 1H H-3 GlcA), 
5.36 (m, 2H, H-2 GlcA, H-2 Glc-A), 5.27 (dd, J = 6.9, 6.9 Hz, 1H, H-2 GlcA), 5.24 (s, 
1H, MeOPhCH), 5.22 (s, 1H, OCH2CH=CH2), 5.15 (m, 3H, OCH2CH=CH2, H-1 GlcA, 
MeOPhCH), 5.11 (d, J = 7.8 Hz, 1H, H-1 GalNAc), 5.05 (m, 2H, H-1 GalNAc, H-1 
GlcA), 5.02 (d, J = 7.2 Hz, 1H, H-1 GlcA), 4.86 (d, J = 7.8 Hz, 1H, H-1 GalNAc), 4.69 
(dd, J = 3.3, 11.1 Hz, 1H, H-1 GlcA), 4.59 (dd, J = 9.0, 9.0 Hz, 1H, H-4 GlcA), 4.54 (dd, 
J = 9.0, 9.0 Hz, 1H, H-4 GlcA), 4.37 – 4.30 (m, 6H, H-4 GlcA, H-5 GalNAc, H-3 
GalNAc, OCH2CH=CH2, H-6 GalNAc, H-4 GalNAc), 4.16 – 4.03 (m, 7H, 
OCH2CH=CH2, H-6 GalNAc, H-5 GlcA, H-5 GlcA, H-4 GalNAc, H-5 GlcA, H-4 
GalNAc), 3.81 – 3.76 (m, 2H, H-6 GalNAc, H-6 GalNAc), 3.80 – 3.77 (6s, 18H, 
CO2CH3, PhOCH3), 3.73 – 3.61 (m, 5H, H-6 GalNAc, H-6 GalNAc, H-2 GalNAc, H-2 
GalNAc, H-2 GalNAc), 3.48 (s, 1H, H-5 GalNAc), 3.08 (s, 1H, H-5 GalNAc), 3.00 (s, 
1H, H-5 GalNAc), 0.72 (s, 9H, (CH3)3CSi), -0.10 (s, 3H, CH3Si), -0.25 (s, 3H, CH3Si); 
13C NMR (75 MHz, CDCl3): δ = 168.8, 168.5, 168.4, 165.7, 165.5, 165.4, 165.3, 165.1, 
165.0, 162.3, 161.9, 161.8, 160.0, 159.9, 159.8, 133.7, 133.4, 133.3, 133.1, 130.7, 130.5, 
130.4, 130.2, 130.1, 130.0, 129.9, 129.5, 129.4, 129.2, 129.1, 128.6, 128.5, 128.4, 128.0, 
127.8, 127.7, 118.2, 113.7, 113.4, 113.3, 102.9, 100.7, 100.6, 100.5, 100.1, 98.8, 98.4, 
97.7, 97.6, 92.5, 92.4, 92.3, 77.5, 76.4, 75.8, 75.7, 75.3, 75.2, 75.0, 74.3, 74.2, 74.1, 73.8, 
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73.6, 73.5, 73.4, 72.1, 71.9, 70.8, 70.6, 69.3, 68.6, 66.8, 55.6, 55.5, 54.9, 54.7, 53.5, 53.4, 
52.8, 30.1, 25.7, 18.1, -4.1, -4.8. ESI MS: m/z: calcd for C120H123Cl9N3O43Si: 2637.4; 
found 2637.5 [M + H]+. 
 
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1 →  3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-acetamido-
β-D-galactopyranoside (69). 69 was prepared using a procedure modified from Coutant 
et al.46 To a solution of 61 (250 mg, 0.251 mmol) in benzene (7.80 mL).  were added 
tributylstannane (305 µL, 1.51 mmol) and 2,2’-azobisisobutyronitrile (80.0 mg).  The 
reaction was stirred at rt for 45 min.  It was then heated to 80 °C and stirred an additional 
1.5 h.  The reaction was cooled to rt and concentrated to afford a white solid.  The 
product was purified by flash chromatography (50% EtOAc:hexanes) to afford 69 (190 
mg, 85%) as a white solid.  Rf 0.19 (50% EtOAc:hexanes).  1H NMR (300 MHz, CDCl3): 
δ = 7.89 – 7.86 (m, 4H, ArH), 7.51 – 7.42 (m, 4H, ArH), 7.37 – 7.31 (m, 4H, ArH), 6.88 
(d, J = 8.7 Hz, 2H, C6H4OMe), 5.91 – 5.75 (m, 1H, OCH2CH=CH2), 5.55 (dd, J = 8.9, 
8.9 Hz, 1H, H-3’), 5.46 (s, 1H, MeOPhCH), 5.40 – 5.35 (m, 2H, NHAc, H-2 GlcA), 5.20 
(dd, J = 1.4, 17.3 Hz, 1H, OCH2CH=CH2), 5.14 – 5.11 (m, 2H, OCH2CH=CH2, H-1 
GalNAc), 4.97 (d, J = 7.5 Hz, 1H, H-1 GlcA), 4.77 (dd, J = 3.9, 11.1 Hz, 1H, H-3 
GalNAc), 4.37 – 4.25 (m, 4H, OCH2CH=CH2, H-4 GalNAc, H-4 GlcA, H-6 GalNAc), 
4.10 (d, J = 9.6 Hz, 1H, H-5 GlcA), 4.10 – 3.98 (m, 2H, OCH2CH=CH2, H-6 GalNAc), 
3.81 (s, 3H, CO2CH3), 3.78 (s, 3H, PhOCH3), 3.47 (s, 1H, H-5 GalNAc), 3.34 – 3.26 (m, 
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1H, H-2 GalNAc), 1.53 (s, 3H, HNC(O)CH3), 0.72 (s, 9H, (CH3)3CSi), -0.07 (s, 3H, 
CH3Si), -0.23 (s, 3H, CH3Si); 13C NMR (75 MHz, CDCl3):  δ = 171.4, 168.7, 165.8, 
165.0, 160.0, 134.1, 133.5, 133.4, 130.7, 129.9, 129.8, 129.6, 129.5, 128.6, 128.5, 127.8, 
118.0, 113.6, 101.6, 100.8, 98.0, 76.3, 76.1, 75.6, 72.4, 70.9, 70.4, 69.4, 66.7, 55.6, 55.1, 
52.9, 25.8, 23.6, 18.1, -4.0, -4.7; ESI MS: m/z: calcd for C46H57NNaO15Si: 914.3, found 
914.4 [M + Na]+. 
 
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1   3)-6-O-p-methoxybenzyl-2-deoxy-2-acetamido-β-D-
galactopyranoside (70). To 69 (144 mg, 0.162 mmol) dissolved in CH2Cl2 (2.8 mL) was 
added sodium cyanoborohydride (102 mg, 1.62 mmol) in THF (1.8 mL) and 4 Å 
powdered molecular sieves, and the reaction stirred at rt for 1 h.  Trifluoroacetic acid 
(250 µL, 3.23 mmol) was then added dropwise, and the reaction was stirred overnight.  It 
was then filtered through Celite, diluted with CH2Cl2, and washed with saturated aqueous 
NaHCO3.  The aqueous layer was extracted with CH2Cl2 (3x).  The combined organic 
layers was washed with brine, dried over MgSO4, filtered, and concentrated to afford a 
colorless syrup.  The product was purified by flash chromatography (60% 
EtOAc:hexanes) to yield 70 (118 mg, 82%) as a white solid.  Rf 0.17 (60% 
EtOAc:hexanes).  1H NMR (300 MHz, CDCl3): δ = 7.88 (d, J = 7.5 Hz, 4H, ArH), 7.50 – 
7.44 (m, 2H, ArH), 7.57 – 7.30 (m, 4H, ArH), 7.24 (d, J = 8.7 Hz, 2H, C6H4OMe), 6.86 
(d, J = 8.7 Hz, 2H, C6H4OMe), 5.85 – 5.72 (m, 1H, OCH2CH=CH2), 5.58 (dd, J = 9.2, 
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9.2 Hz, 1H, H-3 GlcA), 5.47 (d, J = 6.6 Hz, 1H, NHAc), 5.38 (dd, J = 7.8, 8.4 Hz, 1H, H-
2 GlcA), 5.17 (dd, J = 1.4, 17.3 Hz, 1H, OCH2CH=CH2), 5.09 (d, J = 10.5 Hz, 1H, 
OCH2CH=CH2), 4.99 (d, J = 9.0 Hz, 1H, H-1 GalNAc), 4.89 (d, J = 7.5 Hz, 1H, H-1 
GlcA), 4.63 (dd, J = 3.0, 10.5 Hz, 1H, H-3 GalNAc), 4.51 (d, J = 11.7 Hz, 1H, 
MeOPhCH), 4.46 (d, J = 11.4 Hz, 1H, MeOPhCH), 4.33 – 4.22 (m, 2H, H-4 GlcA, 
OCH2CH=CH2), 4.11 – 4.05 (m, 2H, H-5 GlcA, OCH2CH=CH2), 3.99 (dd, J = 6.3, 12.9 
Hz, 1H, H-5 GalNAc), 3.78 – 3.64 (m, 4H, H-2 GalNAc, H-4 GalNAc, H-6 GalNAc, H-6 
GalNAc), 3.78 (s, 3H, CO2CH3), 3.74 (s, 3H, PhOCH3), 2.67 (s, 1H, OH), 1.30 (s, 3H, 
HNC(O)CH3), 0.72 (s, 9H, (CH3)3CSi), -0.05 (s, 3H, CH3Si), -0.20 (s, 3H, CH3Si); 13C 
NMR (75 MHz, CDCl3):  δ = 171.2, 168.4, 165.7, 165.1, 159.3, 134.1, 133.6, 133.4, 
130.4, 129.9, 129.9, 129.5, 129.5, 129.2, 128.7, 128.6, 117.8, 114.0, 102.1, 98.1, 78.7, 
76.5, 75.1, 73.4, 73.2, 72.2, 70.9, 70.2, 69.2, 68.5, 55.6, 55.1, 53.0, 25.8, 23.3, 18.1, -4.0, 
-4.7; HR-FAB MS:  m/z:  calcd for C46H60NO15Si:  894.3732; found:  894.3696 [M + H]+. 
 
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1   3)-6-O-p-methoxybenzyl-4-O-sodium sulfonato-2-
deoxy-2-acetamido-β-D-galactopyranoside (71).  70 (0.40 g, 0.45 mmol) was dissolved 
in DMF (13.5 mL), SO3•TMA (1.9 g, 13.4 mmol) was added, and the reaction was 
stirred at 50 °C overnight.  The reaction was then quenched with MeOH, cooled to rt, and 
concentrated to afford a white solid.  The residue was purified on Sephadex LH-20 (50% 
CH2Cl2:MeOH, 30 mL resin, 1 cm x 30 cm column), followed by flash chromatography 
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(100% EtOAc) and Sephadex SP C25 (Na+) (10% H2O:MeOH, 50 mL resin, 1 cm x 40 
cm column) to afford 71 (0.34 g, 76%) as a white solid.  Rf 0.11 (60% EtOAc:hexanes).  
1H NMR (300 MHz, CD3OD): δ = 7.89 – 7.85 (m, 4H, ArH), 7.53 – 7.48 (m, 2H, ArH), 
7.38 – 7.27 (m, 6H, ArH), 6.87 (d, J = 8.7 Hz, 2H, ArH), 5.85 – 5.72 (m, 1H, 
OCH2CH=CH2), 5.64 (dd, J = 9.3, 9.3 Hz, 1H, H-3 GlcA), 5.46 (dd, J = 8.9, 8.9 Hz, 1H, 
H-2 GlcA), 5.17 (dd, J = 1.2, 17.4 Hz, 1H, OCH2CH=CH2), 5.09 – 5.04 (m, 2H, NHAc, 
H-1 GlcA), 4.91 – 4.87 (m, 2H, H-1 GalNAc, OCH2CH=CH2), 4.53 – 4.39 (m, 2H, H-3 
GalNAc, H-4 GalNAc), 4.20 (d, J = 9.3 Hz, 2H, MeOPhCH2), 4.03 – 3.97 (m, 2H, H-4 
GlcA, OCH2CH=CH2), 3.92 – 3.76 (m, 6H, H-5 GlcA, H-2 GalNAc, H-5 GalNAc, H-6 
GalNAc, H-6 GalNAc, OCH2CH=CH2), 3.77 (s, 3H, CO2CH3), 3.76 (s, 3H, PhOCH3), 
1.39 (s, 3H, HNC(O)CH3), 0.73 (s, 9H, (CH3)3CSi), -0.01 (s, 3H, CH3Si), -0.17 (s, 3H, 
CH3Si); 13C NMR (75 MHz, CD3OD):  δ = 172.2, 169.0, 165.9, 165.8, 159.5, 134.3, 
133.4, 130.5, 129.9, 129.6, 129.5, 129.3, 128.3, 128.2, 115.9, 113.5, 102.2, 100.7, 78.7, 
76.2, 75.6, 73.7, 72.9, 72.7, 70.8, 70.0, 69.6, 54.6, 52.2, 44.8, 25.0, 21.6, 17.7, -5.0, -5.6; 
ESI MS:  m/z:  calcd for C46H58NNa2O18SSi:  1018.4; found:  1019.1 [M + Na]+. 
 
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1 →  3)-2-deoxy-2-acetamido-β-D-galactopyranoside (74). 
To a solution of 69 (190 mg, 0.213 mmol) in CH2Cl2 (2.40 mL) and H2O (0.560 mL) was 
added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (73.0 mg, 0.320 mmol).  The reaction 
was stirred at rt for 3 h, quenched with MeOH, and concentrated to yield a red solid.  The 
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product was purified on Sephadex LH-20 (50% CH2Cl2:MeOH, 30 mL resin, 1 cm x 30 
cm column), followed by flash chromatography (100% EtOAc) to afford an orange solid 
containing the desired diol 74 (102 mg, 62%).  Rf 0.23 (100% EtOAc). 1H NMR (300 
MHz, CD3OD): δ = 7.90 – 7.86 (m, 4H, ArH), 7.49 – 7.44 (m, 2H, ArH), 7.37 – 7.29 (m, 
4H, ArH), 5.83 – 5.74 (m, 1H, OCH2CH=CH2), 5.61 (dd, J = 9.0, 8.7 Hz, 1H, H-3 GlcA), 
5.35 (dd, J = 8.1, 9.0 Hz, 1H, H-2 GlcA), 5.18 (dd, J = 1.7, 17.6 Hz, 1H, 
OCH2CH=CH2), 5.10 (d, J = 9.9 Hz, 1H, OCH2CH=CH2), 4.97 (d, J = 7.5 Hz, 1H, H-1 
GlcA), 4.90 (d, J = 7.5 Hz, 1H, H-1 GalNAc), 4.552 (m, 1H, NHAc), 4.29 – 4.17 (m, 3H, 
H-1 GalNAc, H-4 GalNAc, H-6 GalNAc), 4.03 – 3.93 (m, 4H, OCH2CH=CH2, H-3 
GalNAc, H-4 GlcA, H-6 GalNAc), 3.89 – 3.86 (m, 2H, OCH2CH=CH2, H-5 GalNAc, H-
5 GlcA), 3.65 (m, 1H, H-2 GalNAc), 3.78 (s, 3H, CO2CH3), 1.26 (s, 3H, HNC(O)CH3), 
0.73 (s, 9H, (CH3)3CSi), -0.07 (s, 3H, CH3Si), -0.20 (s, 3H, CH3Si); ESI MS: m/z: calcd 
for C38H52NO14Si 774.9; found 774.2 [M + H]+. 
 
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1   3)-4,6-O-disodium sulfonato-2-deoxy-2-acetamido-β-
D-galactopyranoside (72).  To 71 (300 mg, 0.301 mmol) dissolved in CH2Cl2 (3.4 mL) 
and H2O (0.80 mL) was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (103 mg, 
0.452 mmol).  The reaction was stirred at rt for 4 h at rt, quenched with MeOH, and 
concentrated to yield a red solid.  The product was purified on Sephadex LH-20 (50% 
CH2Cl2:MeOH, 30 mL resin, 1 cm x 30 cm column), followed by flash chromatography 
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(90% CH2Cl2:MeOH), and Sephadex SP C25 (Na+) (1:8 H2O:MeOH, 50 mL resin, 1 cm 
x 40 cm column) to afford an orange solid containing the desired alcohol.  Rf 0.77 
(EtOAc:pyr:H2O:AcOH, 8:5:2:1).   
 
The impure alcohol (303 mg) was dissolved in DMF (9 mL), and SO3•TMA (1.25 g, 
9.04 mmol) was added.  The reaction was stirred at 50 °C overnight and then cooled to rt, 
quenched with MeOH, and concentrated to afford a yellow solid.  This was purified on 
Sephadex LH-20 (50% CH2Cl2:MeOH, 30 mL resin, 1 cm x 30 cm column), followed by 
flash chromatography (100% EtOAc  8:3:1:0.5 EtOAc:pyr:H2O:AcOH), and Sephadex 
SP C25 (Na+) (H2O:MeOH, 1:1, 50 mL, resin 1 cm x 40 cm column).  The product was 
lyophilized to afford 72 (177 mg, 60% from 71) as a white solid.  Rf 0.49 
(EtOAc:pyr:H2O:AcOH, 8:5:3:1).   
 
72 was prepared by an alternative method. The sulfation of 74 was performed using a 
procedure modified from Tamura et al.22  The crude diol 74 (102 mg, 0.132 mmol) was 
dissolved in DMF (5 mL), and SO3•TMA (0.550 g, 3.96 mmol) was then added.  The 
reaction was stirred at 50 °C overnight.  It was cooled to rt, quenched with MeOH, and 
concentrated to afford a yellow solid.  The product was purified on Sephadex LH-20 
(50% CH2Cl2:MeOH, 30 mL resin, 1 cm x 30 cm column), followed by flash 
chromatography (10% → 20% MeOH:CH2Cl2), to afford 72 (115 mg, 93%) as a white 
solid.  Rf 0.125 (15% MeOH:CH2Cl2).  1H NMR (300 MHz, CD3OD): δ = 7.88 – 7.85 
(m, 4H, ArH), 7.54 – 7.47 (m, 2H, ArH), 7.38 – 7.32 (m, 4H, ArH), 5.86 – 5.73 (m, 1H, 
OCH2CH=CH2), 5.67 (dd, J = 9.3, 9.3 Hz, 1H, H-3 GlcA), 5.48 (dd, J = 8.1, 9.2 Hz, 1H, 
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H-2 GlcA), 5.18 (dd, J = 1.7, 17.6 Hz, 1H, OCH2CH=CH2), 5.11 (d, J = 7.5 Hz, 1H, H-1 
GlcA), 5.05 (dd, J = 1.8, 10.5 Hz, 1H, OCH2CH=CH2), 4.96 (s, 1H, H-4 GalNAc), 4.44 – 
4.35 (m, 3H, H-1 GalNAc, H-3 GalNAc, H-4 GlcA), 4.30 – 4.22 (m, 3H, OCH2CH=CH2, 
H-5 GlcA, H-6 GalNAc), 4.09 – 3.98 (m, 2H, OCH2CH=CH2, H-6 GalNAc), 3.95 – 3.91 
(m, 2H, H-2 GalNAc, H-5 GalNAc), 3.86 (s, 3H, CO2CH3), 1.30 (s, 3H, HNC(O)CH3), 
0.74 (s, 9H, (CH3)3CSi), -0.02 (s, 3H, CH3Si), -0.18 (s, 3H, CH3Si); 13C NMR (75 MHz, 
CD3OD):  δ = 172.3, 170.0, 166.2, 165.8, 134.1, 133.5, 133.4, 130.0, 129.5, 129.4, 129.0, 
128.3, 128.2, 115.9, 102.5, 100.8, 79.2, 76.3, 75.9, 75.4, 72.8, 72.6, 70.9, 69.7, 67.6, 54.2, 
52.6, 25.0, 21.4, 17.6, -4.9, -5.6; HR-FAB MS:  m/z:  calcd for C38H49NNa3O20S2Si:  
1000.175; found:  1000.175 [M + Na]+. 
 
Allyl (sodium β-D-glucopyranosyluronate)-(1 →  3)-4,6-di-O-sodium sulfonato-2-
deoxy-2-acetamido-β-D-galactopyranoside (73). 72 (115 mg, 0.123 mmol) was 
dissolved in pyridine (1.7 mL) and THF (1.7 mL).  The reaction was cooled to 0 °C, 
HF•pyridine (0.60 mL, 33 mmol) was added, and it slowly warmed to rt overnight.  
After 12 h, the mixture was flowed through a Sephadex LH-20 column (50% 
CH2Cl2:MeOH, 30 mL resin, 1 cm x 30 cm column) and the concentrated residue was 
purified by flash chromatography (10% → 20% MeOH:CH2Cl2) to afford a white solid 
(90.0 mg).  Rf 0.50 (EtOAc:pyr:H2O:AcOH, 8:5:3:1).   
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The crude alcohol (90 mg, 0.11 mmol) was dissolved in THF (1.8 mL) and H2O (1.8 mL) 
and to this was added 2 M NaOH (0.72 mL, 1.4 mmol). After 12 h at rt, the reaction was 
neutralized with Amberlyst IR-120 resin, filtered, and lyophilized to afford an orange 
solid. The product was purified by gel filtration chromatography using Sephadex G-10 
UF, a resin for compounds with a molecular weight of 700 or less, (100% H2O, 25 mL 
resin, 1 cm x 20 cm) and Sephadex SP C25 (Na+) (100% H2O, 25 mL resin, 1 cm x 20 
cm), to sharpen the peaks in the 1H NMR spectrum. The fractions were lyophilized to 
afford 73 (45 mg, 55%, 2 steps) as a white solid.  Rf 0.12 (EtOAc:pyr:H2O:AcOH, 
8:5:3:1).  1H NMR (300 MHz, D2O): δ = 5.95 – 5.81 (m, 1H, OCH2CH=CH2), 5.32 – 
5.22 (m, 2H, OCH2CH=CH2), 4.80 (s, 1H, H-4 GalNAc), 4.57 – 4.54 (m, 1H, H-1 
GalNAc), 4.46 (d, J = 7.8 Hz, 1H, H-1 GlcA), 4.31 – 4.25 (m, 2H, OCH2CH=CH2, H-3 
GalNAc), 4.20 – 4.13 (m, 2H, OCH2CH=CH2, H-2 GalNAc), 4.05 – 4.02 (m, 3H, H-6 
GalNAc, H-6 GalNAc, H-5 GalNAc), 3.68 (d, J = 9.3, 1H, H-5 GlcA), 3.51 – 3.44 (m, 
2H, H-3 GlcA, H-4 GlcA), 3.33 (dd, J = 8.1, 8.1 Hz, 1H, H-2 GlcA), 1.99 (s, 3H, 
HNC(O)CH3); 13C NMR (75 MHz, D2O):  δ = 118.7, 103.4, 100.0, 175.6, 174.8, 133.2, 
76.4, 75.2, 75.1, 72.6, 72.4, 71.9, 70.8, 68.0, 51.8, 22.5; HR-FAB MS:  m/z:  calcd for 
C17H24NNa2O18S2:  640.0230; found:  640.0202 [M - Na]-. 
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Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1 →  3)-(4,6-O-p-methoxybenzylidene-2-deoxy-2-
acetamido-β-D-galactopyranosyl)-(1 →  4)-(methyl 2,3-di-O-benzoyl-β-D-
glucopyranosyluronate)-(1 →  3)-4,6-O-p-methoxybenzylidene-2-deoxy-2-acetamido-
β-D-galactopyranoside (75). 75 was prepared using a procedure modified from Karst et 
al.24 To a solution of 37 (98 mg, 0.054 mmol) in benzene (1.7 mL) and N,N-
dimethylacetamide (0.43 mL) were added tributylstannane (0.20 mL, 0.97 mmol) and 
2,2’-azobisisobutyronitrile (5.2 mg). The reaction was stirred at rt for 30 min and then 
was heated at 80 °C for 5 h. It was cooled to rt, concentrated to afford a yellow-white 
solid, and purified by flash chromatography (80% → 100% EtOAc:hexanes) to yield the 
product as a white solid (80 mg, 92%). Rf 0.69 (100% EtOAc). 1H NMR (300 MHz, 
CDCl3): δ = 7.95 – 7.84 (m, 8H, ArH), 7.52 – 7.43 (m, 6H, ArH), 7.38 – 7.27 (m, 8H, 
ArH), 7.21 (d, J = 9.0 Hz, 2H, C6H4OMe), 6.86 (d, J = 8.7 Hz, 2H, C6H4OMe), 6.80 (d, J 
= 9.0 Hz, 2H, Ph C6H4OMe), 5.89 – 5.76 (m, 1H, OCH2CH=CH2), 5.61 (dd, J = 7.2, 8.1 
Hz, 1H, H-3 GlcA), 5.51 (s, 1H, MeOPhCH), 5.44 (dd, J = 8.7, 9.0 Hz, 1H, H-3 GlcA), 
5.42 (d, J = 6.6 Hz, 1H, NHAc), 5.31 (dd, J = 6.6, 7.2 Hz, 1H, H-2 GlcA), 5.28 (dd, J = 
7.2, 8.7 Hz, 1H, H-2 GlcA), 5.20 (dd, J = 0.9, 17.3 Hz, 1H, OCH2CH=CH2), 5.18 (s, 1H, 
MeOPhCH), 5.13 (d, J = 11.4 Hz, 1H, OCH2CH=CH2), 5.11 (d, J = 8.1 Hz, 1H, H-1 
GlcA), 5.05 (d, J = 7.2 Hz, 1H, H-1 GalNAc), 4.98 (d, J = 6.6 Hz, 1H, NHAc), 4.89 (d, J 
= 7.5 Hz, 1H, H-1 GalNAc), 4.86 (d, J = 9.0 Hz, 1H, H-1GlcA), 4.75 (dd, J = 3.3, 10.8 
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Hz, 1H, H-3 GalNAc), 4.51 (dd, J = 8.1, 9.3 Hz, 1H, H-4 GlcA), 4.37 – 4.25 (m, 5H, 
OCH2CH=CH2, H-3 GalNAc, H-4 GalNAc, H-4 GlcA, H-6 GalNAc), 4.16 (d, J = 9.3 
Hz, 1H, H-5 GlcA), 4.06 – 3.98 (m, 4H, OCH2CH=CH2, H-4 GalNAc, H-5 GlcA, H-6 
GalNAc), 3.77 – 3.73 (m, 1H, H-6 GalNAc), 3.80 (s, 3H, PhOCH3), 3.79 (s, 3H, 
PhOCH3), 3.73 (s, 3H, CO2CH3), 3.70 (s, 3H, CO2CH3), 3.56 – 3.52 (m, 1H, H-6 
GalNAc), 3.46 (s, 1H, H-5 GalNAc), 3.35 – 3.26 (m, 2H, H-2 GalNAc, H-2 GalNAc), 
2.84 (s, 1H, H-5 GalNAc), 1.54 (s, 3H, HNC(O)CH3), 1.50 (s, 3H, HNC(O)CH3), 0.70 (s, 
9H, (CH3)3CSi), -0.10 (s, 3H, CH3Si), -0.25 (s, 3H, CH3Si). ESI MS: m/z: calcd for 
C83H94N2O29Si: 1645.5; found 1645.4 [M + Cl]-. 
 
 
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D-
glucopyranosyluronate)-(1 → 3)-(2-deoxy-2-acetamido-β-D-galactopyranosyl)-(1 → 
4)-(methyl 2,3-di-O-benzoyl-β-D-glucopyranosyluronate)-(1 → 3)-2-deoxy-2-
acetamido-β-D-galactopyranoside (76). 75 (42 mg, 0.026 mmol) was dissolved in 
CH3CN (840 µL) and H2O (90 µL) and the reaction was covered with aluminum foil and 
stirred in the dark. 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (24 mg, 0.10 mmol) was 
added and the reaction stirred for 2 h at rt. The reaction mixture was subjected to 
Sephadex LH-20 (50% CH2Cl2:MeOH, 30 mL resin, 1 cm x 30 cm column) to afford 76 
as a pale pink solid (34 mg, 93%). Rf 0.2 (100% EtOAc). 1H NMR (300 MHz, CD3OD): 
δ = 7.85 – 7.76 (m, 8H, ArH), 7.47 – 7.42 (m, 4H, ArH), 7.36 – 7.27 (m, 8H, ArH), 5.79 
O
HO
O O
AcHNOBz
MeO2C
BzO
O
OAll
O
HO
O
AcHN
O
BzO
MeO2C
BzO
TBSO
OH
OH
76
 123 
– 5.66 (m, 1H, OCH2CH=CH2), 5.52 (dd, J = 8.4, 8.4 Hz, 1H, H-3 GlcA), 5.51 (dd, J = 
8.4, 9.9 Hz, 1H, H-3 GlcA), 5.27 – 5.19 (m, 3H), 5.12 (dd, J = 1.6 Hz, 17.3 Hz, 1H, 
OCH2CH=CH2), 5.00 – 4.96 (m, 4H), 4.43 – 4.42 (m, 1H), 4.32 – 4.26 (m, 2H), 4.20 – 
4.10 (m, 5H), 4.00 (d, J = 2.4 Hz, 1H), 3.96 – 3.88 (m, 3H), 3.70 (s, 3H, CO2CH3), 3.69 
(s, 3H, CO2CH3), 3.41 – 3.35 (m, 2H), 3.17 – 3.10 (m, 3H), 3.04 – 3.00 (m, 1H), 1.20 (s, 
3H, HNC(O)CH3), 1.18 (s, 3H, HNC(O)CH3), 0.66 (s, 9H, (CH3)3CSi), -0.10 (s, 3H, 
CH3Si), -0.26 (s, 3H, CH3Si). ESI MS: m/z: calcd for C67H82N2NaO27Si: 1397.5; found 
1397.6 [M + Na]+. 
 
Allyl (methyl 2,3-di-O-benzoyl-4-O-tert-butyldimethylsilyl-β-D- 
glucopyranosyluronate)-(1 →  3)-(4,6-di-O-sodium sulfonato-2-deoxy-2-acetamido-
β-D-galactopyranosyl)-(1 →  4)-(methyl 2,3-di-O-benzoyl-β-D-
glucopyranosyluronate)-(1 → 3)-4,6-di-O-sodium sulfonato-2-deoxy-2-acetamido-β-
D-galactopyranoside  (77). To a solution of 76 (23 mg, 0.017 mmol) in DMF (600 µL)  
was added SO3•TMA (90 mg, 0.64 mmol). The reaction was stirred at 50 °C for 2 d, at 
which time additional SO3•TMA (50 mg, 0.36 mmol) was added, and the reaction 
continued at 50 °C for 1 d. The reaction pH was carefully monitored to ensure it did not 
drop below pH 5.0. It was quenched with MeOH, concentrated to afford a yellow solid, 
and purified on Sephadex LH-20 (50% CH2Cl2:MeOH, 30 mL resin, 1 cm x 30 cm 
column). The resulting crude product was purified by flash chromatography (6:2:1 
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EtOAc:MeOH:H2O) to afford 77 as a white solid (24 mg, 84%). Rf 0.51 (6:2:1 
EtOAc:MeOH:H2O). 1H NMR (300 MHz, CD3OD): δ = 7.92 – 7.81 (m, 8H, ArH), 7.55 – 
7.45 (m, 4H, ArH), 7.43 – 7.33 (m, 8H, ArH), 5.87 – 5.73 (m, 1H, OCH2CH=CH2), 5.67 
(dd, J = 9.0, 9.0 Hz, 1H, H-3 GlcA), 5.61 (dd, J = 9.3, 9.3 Hz, 1H, H-3 GlcA), 5.42 – 
5.32 (m, 3H), 5.19 (dd, J = 1.6, 17.3 Hz, 1H, OCH2CH=CH2), 4.93 – 4.79 (m, 4H, H-4 
GalNAc, H-4 GalNAc), 4.54 – 4.52 (m, 1H), 4.49 (dd, J = 9.0, 9.6 Hz, 1H, H-4 GlcA), 
4.40 – 4.33 (m, 5H), 4.28 – 4.22 (m, 3H), 4.18 (d, J = 9.3 Hz, 1H, H-5 GlcA), 4.08 – 3.98 
(m, 4H), 3.90 – 3.89 (m, 1H), 3.87 (s, 3H, CO2CH3), 3.86 – 3.85 (m, 2H), 3.83 (s, 3H, 
CO2CH3), 1.20 (s, 3H, HNC(O)CH3), 1.18 (s, 3H, HNC(O)CH3), 0.73 (s, 9H, 
(CH3)3CSi), -0.03 (s, 3H, CH3Si), -0.19 (s, 3H, CH3Si). ESI MS: m/z: calcd for 
C67H78N2Na3O39S4Si: 1759.3; found 1759.8 [M - Na]-. 
 
Allyl (methyl 2,3-di-O-benzoyl-β-D-glucopyranosyluronate)-(1 → 3)-(4,6-di-O-
sodium sulfonato-2-deoxy-2-acetamido-β-D-galactopyranosyl)-(1 →  4)-(methyl 2,3-
di-O-benzoyl-β-D-glucopyranosyluronate)-(1 →  3)-4,6-di-O-sodium sulfonato-2-
deoxy-2-acetamido-β-D-galactopyranoside (78). 77 (32 mg, 0.019 mmol) in a plastic 
centrifuge tube was dissolved in pyridine (585 µL) and THF (585 µL). The reaction was 
cooled to 0 °C and to this was added HF•pyridine (94 µL, 5.2 mmol). After stirring at 0 
°C for 1 h and at rt overnight, the reaction mixture was loaded onto a Sephadex LH-20 
column (50% CH2Cl2:MeOH, 30 mL resin, 1 cm x 30 cm column). The product was 
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concentrated, taken up in H2O, and lyophilized to afford a white solid (45 mg, 91%) that 
was immediately used in the next reaction. Rf 0.36 (6:2:1 EtOAc:MeOH:H2O). ESI MS: 
m/z: calcd for C61H67N2O39S4: 1579.2; found 1579.4 [M - H]-. 
 
 Allyl (sodium β-D-glucopyranosyluronate)-(1 → 3)-(4,6-di-O-sodium sulfonato-2-
deoxy-2-acetamido-β-D-galactopyranosyl)-(1 → 4)-(sodium β-D-
glucopyranosyluronate)-(1 → 3)-4,6-di-O-sodium sulfonato-2-deoxy-2-acetamido-β-
D-galactopyranoside (79: CS-E). 78 was deprotected in a manner similar to a procedure 
from Lucas and coworkers.51 78 (45 mg, 0.028 mmol) was dissolved in THF (2.3 mL) 
and H2O (1.7 mL) and cooled to 0 °C. To this were added 1 M aq. LiOH (330 µL. 0.33 
mmol) and 30% H2O2 (170 µL, 0.0015 mmol). The reaction was stirred at 0 °C for 1 h 
and at rt for 12 h. At this time, 4 M NaOH (230 µL, 0.46 mmol) and MeOH (1.7 mL) 
were added and the reaction stirred for another 12 h. It was then neutralized with 
Amberlyst IR-120 resin, filtered, and lyophilized to afford an orange solid. The product 
was purified by Sephadex G-25 UF, a resin for compounds with a molecular weight of 
700 or more, (0.9 % NaCl in H2O, 30 mL resin, 1 cm x 20 cm column) and desalted with 
Sephadex G-25 UF (100% H2O, 30 mL resin, 1 cm x 20 cm column) to afford 79: CS-E 
as a white solid upon lyophilization (23 mg, 70%). For complete assignment of the 1H 
NMR spectra of this compound, 1H decoupling experiments were performed. 1H NMR 
(600 MHz, D2O): δ = 5.94 – 5.88 (m, 1H, OCH2CH=CH2), 5.33 (dd, J = 1.5, 17.1 Hz, 
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1H, OCH2CH=CH2), 5.27 (d, J = 10.2 Hz, 1H, OCH2CH=CH2), 4.85 (s, 1H, H-4 
GalNAc), 4.79 (d, J = 1.2 Hz, 1H, H-4 GalNAc), 4.61 (dd, J = 3.9, 7.8 Hz, 1H, H-1 
GalNAc), 4.59 (d, J = 7.8 Hz, 1H, H-1 GalNAc), 4.49 (d, J = 7.8 Hz, 1H, H-1 GlcA), 
4.47 (d, J = 7.8 Hz, 1H, H-1 GlcA), 4.35 (dd, J = 5.4, 13.2 Hz, 1H, OCH2CH=CH2), 4.29 
(dd, J = 3.0, 11.4 Hz, 2H, H-6 GalNAc), 4.24 – 4.18 (m, 4H, OCH2CH=CH2, H-2 
GalNAc, H-5 GalNAc), 4.13 (dd, J = 2.7, 8.7 Hz, 1H, H-3 GalNAc), 4.09 – 4.05 (m, 4H, 
H-6 GalNAc, H-2 GalNAc, H-3 GalNAc), 3.77 (dd, J = 9.6, 9.6 Hz, 1H, H-4 GlcA), 3.69 
(d, J = 9.6 Hz, 1H, H-5 GlcA), 3.67 (d, J = 9.6 Hz, 1H, H-5 GlcA), 3.61 (dd, J = 9.0, 9.6 
Hz, 1H, H-3 GlcA), 3.52 (dd, J = 9.0, 9.0 Hz, 1H, H-4 GlcA), 3.47 (dd, J = 9.0, 9.6 Hz, 
1H, H-3 GlcA), 3.41 (dd, J = 8.4, 9.0 Hz, 1H, H-2 GlcA), 3.34 (dd, J = 7.8, 9.0 Hz, 1H, 
H-2 GlcA), 2.04 (s, 3H, HNC(O)CH3), 2.01 (s, 3H, HNC(O)CH3). ESI MS: m/z: calcd for 
C31H42N2Na5O35S4: 1245.0; found 1245.0 [M - Na]-. 
 
Allyl (sodium β-D-glucopyranosyluronate)-(1 → 3)-(2-deoxy-2-acetamido-β-D-
galactopyranosyl)-(1 → 4)-(sodium β-D-glucopyranosyluronate)-(1 → 3)-2-deoxy-2-
acetamido-β-D-galactopyranoside (81). 76 (8.5 mg, 0.0062 mmol) was dissolved in 
pyridine (110 µL) and THF (110 µL). The reaction was cooled to 0 °C and to this was 
added HF•pyridine (30 µL, 1.7 mmol). After stirring at 0 °C for 1 h and at rt overnight, 
the mixture was loaded onto a Sephadex LH-20 column (50% CH2Cl2:MeOH, 30 mL 
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resin, 1 cm x 30 cm column), and the product was a yellow solid (5.3 mg) that was 
immediately used in the next reaction. Rf 0.75 (6:2:1 EtOAc:MeOH:H2O). 
 
The alcohol 80 (5.3 mg, 0.0042 mmol) was dissolved in THF (120 µL) and H2O (60 µL) 
and cooled to 0 °C. To this were added 1 M aq. LiOH (47 µL, 0.047 mmol) and 30% 
H2O2 (23 µL, 0.20 mmol). The reaction was stirred at 0 °C for 1 h and at rt for 12 h. At 
this time, 4 M NaOH (35 µL, 0.070 mmol) and MeOH (173 µL) were added and the 
reaction stirred for another 12 h. It was neutralized with Amberlyst IR-120 resin, filtered, 
and lyophilized to afford an orange solid. The product was purified by Sephadex G-25 
UF (100% H2O, 30 mL resin, 1 cm x 20 cm column) and lyophilized to afford 81 as a 
white solid (2.6 mg, 52% from 76). For complete assignment of the 1H NMR spectra of 
this compound, 1H decoupling experiments were performed. 1H NMR (600 MHz, D2O): 
δ = 5.91 – 5.84 (m, 1H, OCH2CH=CH2), 5.28 (d, J = 17.4 Hz, 1H, OCH2CH=CH2), 5.23 
(d, J = 10.2 Hz, 1H, OCH2CH=CH2), 4.51 – 4.45 (m, 4H), 4.31 (dd, J = 4.8, 12.9 Hz, 1H, 
OCH2CH=CH2), 4.16 – 4.09 (m, 3H), 4.01 – 3.96 (m, 2H), 3.78 – 3.71 (m, 5H), 3.67 – 
3.64 (m, 5H), 3.55 (dd, J = 9.0, 9.0 Hz, 1H, H-3 GlcA), 3.48 – 3.42 (m, 3H), 3.34 (dd, J = 
8.4, 9.0 Hz, 1H, H-2 GlcA), 3.29 (dd, J =7.2, 8.4 Hz, 1H, H-2 GlcA), 1.99 (s, 3H, 
HNC(O)CH3), 1.98 (s, 3H, HNC(O)CH3). ESI MS: m/z: calcd for C31H47N2O23: 815.7; 
found 815.4 [M - H]-. 
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